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A n Update on the Carotid Endarterectomy
Study
Michael D. Cusimano, MD, FRCSC
Fellow in cranial base surgery, Department o f Neurological Surgery, University o f Pittsburgh
School o f Medicine, Pittsburgh, Penn.

nly 3 years ago I wrote in this
column1 that the uncertainty
of the literature on carotid endar
terectomy had led Canadian neuro
scientists to propose a randomized
prospective trial assessing the bene
fits of this operative procedure and
the best medical therapy against the
best medical therapy alone. The
primary question of the trial was:
“Among symptomatic patients with
high-grade carotid stenosis (70% to
99%) does carotid endarterectomy,
despite perioperative risk of stroke
or death from any cause, reduce the
overall risk of fatal and nonfatal
ipsilateral stroke?”
At that time I urged surgeons to
enter the trial in an effort to evalu
ate critically what we do daily as
surgeons. I saw the trial as the best
way to obtain an unequivocal an
swer to the question being posed.
As could be seen by the data 1
provided 3 years ago, the rate at
which carotid endarterectomy was
being performed in Ontario was
declining sharply, and, although the
operation made sense to me, it
seemed as though the eloquence of
our medical colleagues in extolling
the benefits of medical therapy over
surgical therapy was going to lead
to the death of the procedure before
I completed my residency.
The goal of the trial was to enter
3000 patients over a 2-year trial
and follow them for 5 years. Not
surprisingly study organizers were
not able to meet their accrual tar

O
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gets on time and had to extend the
trial. The trial has been conducted
at 50 United States and Canadian
centres, all of which had document
ed surgical and neurologic exper
tise.
In April 1991 the investigators of
this trial issued a clinical alert,
notifying physicians that random
ization into the group of patients
with high-grade stenosis (295 pa
tients in the medical group and 300
in the surgical group had been
entered into the trial) had been
stopped after an average follow-up
of 18 months.2 They reported that,
including perioperative morbidity
and mortality (5% in the surgical
group) or its equivalent in the medi
cal group (approximately 3%), over
24% of medical patients but only
7% of surgical patients had experi
enced fatal or nonfatal ipsilateral
stroke at 18 months. This translat
ed into an absolute risk reduction
of 17% (p < 0.001). As well, they
indicated that carotid endarterecto
my was beneficial in preventing
stroke of any severity, and the
degree of relative risk reduction
correlated with the degree of steno
sis. The benefit to surgical patients
was seen within 3 months and con
tinued to increase for at least 30
months. The investigators stressed
the need to continue to study pa
tients with moderate-grade stenosis
(30% to 69%) and patients who
were asymptomatic and that there
was a high level of expertise among

the surgeons involved in the trial.
Patients, physicians and those
who pay for the procedure must
find it gratifying that there is now
an unequivocal answer to the ques
tion of whether carotid endarterec
tomy is truly beneficial, at least in
those with symptomatic high-grade
stenosis of the internal carotid ar
tery. The findings are particularly
gratifying not only in their conclu
sions but also in their demonstra
tion that we surgeons can answer
questions about whether what we
do has any benefit with as much
scientific rigour as our medical col
leagues have been applying to medi
cal therapy for years. With this trial
and others it appears that Canadian
surgeons have taken a leading role
in the surgical world by posing and
answering critical questions about
their daily practices. We must con
tinue to demand critical appraisal of
surgical activities and instil this
sense of constructive criticism with
in all surgical trainees under our
guidance. It is only with a truly
critical approach that we will be
able to advance our field.

References
1. C usimano MD: The carotid endarterecto
my study. Can J S urg 1988; 31: 3 -4
2. NASCET Investigators: Benefit o f Carotid
Endarterectomy fo r Patients w ith H ighGrade Stenosis o f the Internal Carotid
Artery, Clinical Alert of the National

Institute of Neurological Disorders and
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W aiting for Weight Loss
D.M. Grace, MD, DPhil, FRCSC, FACS
Department o f Surgery, University o f Western Ontario, London, Ont. Member, Editorial Board,

Canadian Journal of Surgery

surgery so that obese
D elaying
patients may lose weight is
often recommended but is rarely
successful. Excessive fat prolongs
operations, makes anatomy difficult
to define, increases the likelihood of
wound infection, decreases postop
erative mobility and makes recogni
tion of complications difficult. Se
vere obesity may cause diabetes,
cardiovascular disease, hyperten
sion, respiratory insufficiency and
other problems, which make anes
thesia and operation hazardous.
These factors may explain why sur
geons dislike obesity. It is likely,
however, that our attitude is similar
to that of other physicians1 and of
society in general. Obese patients
are stereotyped as lazy and lacking
in discipline. As surgeons we pay
little attention to the importance of
heredity and metabolism in obesity.
Affluence makes us ignore the role
of social class in the development of
obesity.2 We lecture, scold and ridi
cule our obese patients without
attempting to understand or help
them.
Obesity is not a popular topic
unless you happen to be obese or
run a weight-loss program. Re
search funding is difficult to obtain,
yet billions of dollars are spent
yearly on commercial weight-loss
clinics, and the cost of obesity relat
ed disease is comparable.3 Obesity
does not receive the same attention
as transplantation or open-heart
416
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surgery, but it does affect more
than 30% of the adult population of
Canada.4 Severe obesity is a particu
lar hazard to health. The effects of
massive obesity on cardiac function,
and the improvements resulting
from weight loss are documented by
Herrera and Deitel in this issue
(pages 431 to 434). There are good
reasons to lose weight, but effective
methods to achieve this goal and to
maintain weight loss are not yet
available.
As a profession we lack knowl
edge of nutrition, although medical
school curricula are changing to
rectify this situation. Patience, in
volvement of the whole family, di
etary advice and long-term follow
up are necessary to achieve good
results. Snacking on high-energy
foods, inactivity due to television
and unemployment, and eating in
response to stress and boredom are
difficult habits to correct. Support
from weight-loss clubs may be ben
eficial. Commercial clinics are popu
lar and offer short-term weight loss
at high cost, but the drop-out rate
is high, and evidence of long-term
effectiveness is lacking. Exploita
tion of patients by aggressive adver
tising and anecdotal reports is com
mon. Very low calorie diets under
close medical supervision combined
with behaviour modification and ex
ercise training may be effective for
severely obese people, but these
programs are also expensive, and

there is often late weight gain.
Although weight loss is beneficial
repeated cycles of weight gain and
loss may be more dangerous to
health than persistent obesity.5-6
Marked variation in weight is now
thought to contribute to cardiovas
cular disease and increased mortali
ty. If this is true, and further data
are needed, then much closer super
vision of dieting and weight-loss
programs is essential.
The most extreme and controver
sial method of weight loss is gastro
plasty for severe obesity. Wide
spread enthusiasm for jejunoileal
bypass in the 1970s was followed
by the late recognition of multiple
complications. Gastroplasty opera
tions have been safer, but a large
number of procedures have been
developed, revised, adopted and dis
carded. Horizontal gastroplasty,
used in the late 1970s and early
1980s, proved ineffective and even
dangerous in the long term.7 In
recent years gastric bypass8 and
vertical banded gastroplasty9 have
proven relatively safe and effective
in the surgical treatment of severe
obesity. Although some late weight
gain does occur, 5-year results are
encouraging, but close and long
term follow-up is essential, and revi
sion procedures may be necessary.10
This is not a field for the occasional
surgeon. A special interest in obesi
ty and availability of a multidiscipli
nary treatment team are essential.

WEIGHT LOSS

The frustration of patient noncom
pliance, medicolegal concerns and
poor late results may explain why
fewer surgeons are performing gas
troplasties in the 1990s.
In March 1991 a National Insti
tutes of Health Consensus Develop
ment Conference on gastrointestinal
surgery for severe obesity was held
before a panel of experts from a
variety of medical and scientific
fields.11 The limited success of diet
and drug therapy was noted. Verti
cal banded gastroplasty and gastric
bypass were recommended for pa
tients who met weight and other
criteria. Multidisciplinary care and
long-term follow-up were empha
sized. The need for more controlled
and long-term trials was noted,
such as the Swedish Obesity Sub
jects (SOS) trial now under way.12
Two thousand severely obese con
trol patients will be compared for
mortality and morbidity with 2000
patients randomized to gastric
banding, gastric bypass or vertical
banded gastroplasty. Data from the
same country13 have shown the
cost-effectiveness in terms of health
and productivity achieved by gastro
plasty and dramatic weight loss.
What do we do with all this
information? We should recognize
obesity as a medical, not cosmetic,
problem. We should also recognize
the need for more research and for
more multidisciplinary treatment.
We need to encourage programs to
prevent obesity in families and chil
dren and to correct social condi
tions that contribute to obesity. We
need to control the commercial ex
ploitation of obese people and en
courage medical supervision during
weight loss. We should accept the
fact that gastroplasty and gastric
bypass may have a role in the
treatment of severe obesity, but we
should encourage multidisciplinary
clinics, accumulation of scientific
data and long-term follow-up.
Above all, we should demonstrate a

sympathetic attitude toward obese
patients until more effective meth
ods of prevention and treatment are
available.
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QUILL ON SCALPEL

T h e Natural History of Suspected
Scaphoid Fractures
J.P. Waddell, MD, FRCSC
Surgeon-in-chief, St. Michael's Hospital, Toronto. Ont. Member. Editorial Board. The Canadian
Journal of Surgery

F

ractures of the carpal scaphoid
continue to pose diagnostic dif
ficulty. As reported by Zarnett and
associates in the August issue
(pages 334 to 337), the lack of
specific diagnosis by routine roent
genography frequently results in
overtreatment of soft-tissue injury
of the wrist or delay in treatment of
the nonvisualized scaphoid fracture.
The importance of prompt recog
nition in treatment of scaphoid frac
tures is based on our belief that the
most potent cause of nonunion of
carpal scaphoid fractures is lack of
appropriate immobilization. Once
nonunion has become” established,
surgical treatment is required to
secure union. When nonunion per

sists, eventual osteoarthritis of the
wrist appears to be inevitable.
Therefore, to minimize the need for
surgery to correct delayed union
and nonunion as well as to prevent
degenerative arthritis of the wrist,
prompt recognition and treatment
of scaphoid fractures are essential.
The authors provide some com
fort for the practising surgeon by
stating that patients with suspected
scaphoid fracture whose x-ray films
show no abnormality do not have
scaphoid fractures; furthermore, pa
tients with equivocal x-ray films can
be investigated further by techne
tium bone scanning.
Zarnett and associates discovered
that an extremely high percentage

of their patients with equivocal or
nondiagnostic x-ray films had
scaphoid fractures, which were evi
dent radiographically 6 weeks after
injury.
It would seem a sensible recom
mendation, therefore, that patients
with clinical symptoms suggesting
scaphoid fracture whose x-ray films
show no abnormalities be observed
only; in patients with equivocal
x-ray films and positive physical
findings the balance of probabilities
suggests the presence of a scaphoid
fracture, and these patients should
be treated appropriately. If there is
any doubt about the diagnosis, con
firmation can be obtained with nu
clear imaging.*

SESAP VI Question
Question SESAP VI
Item 30
For patients with colon cancer,
(A) a blood carcinoembryonic antigen (CEA) assay has sufficient sensitivity and specificity to function as
a cancer-screening test
(B) poorly differentiated tumors produce greater quantities of CEA than do well-differentiated tumors
(C) preoperative CEA levels may provide prognostic information
(D) an elevated plasma CEA titer will return to normal within 10 days if the malignancy is completely
removed
(E) high postoperative CEA titers are more predictive of recurrence than steadily rising CEA titers.
For the incomplete statement above select the one completion that is best of the five given.
For the critique of Item 30 see page 483.
(Reproduced by permission from SESAP VI Syllabus; Surgical Education and Self-Assessment Program No. 6.
For enrolment in the Surgical Education and Self-Assessment No. 6, please apply to the American College of
Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Laparoscopic Cholecystectomy
To the editors. I read, with some
amusement, the recent discussion in
the April issue of the journal (pages
103 to 106) and the previous edit
orials on laparoscopic cholecystec
tomy. I believe that the community
surgeon is being short-changed
when others imply that there may
be a lack of judgement on their
parts as to whether to carry out
relatively new procedures.
Laparoscopic cholecystectomy,
although new in approach, is still a
cholecystectomy with all its inher
ent complications. However, with
the introduction of fiberoptics and
indirect visualization, these proce
dures initially require somewhat
more concentration and hand-eye
coordination. It is only with practice
that performance improves. Unfor
tunately, as for new procedures in
any sphere, experience is not gained
until theory is put into practice in
real-life situations.
As a surgeon practising in a rural
community, 1 agree with Dr. Nagy’s
comments about the importance of
training, not only in the operative
techniques but also in the physical
and psychological approach to
these procedures, which initially
can be frustrating and physically
exhausting.
To follow Dr. Lomax’s advice
about maintaining the “status quo”
would be to deny the community
surgeon the opportunity to become
involved in what will surely be a
revolution in our specialty. My first
exposure to laparoscopic cholecys
tectomy (canine model) was in
March 1989. Subsequently, laser
laparoscopic cholecystectomy and a
wide range of other laser proce
424
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dures are being carried out routine
ly in our community hospital.
It behoves the community sur
geon, who is the backbone of surgi
cal practice in this country, to be
come familiar with these emerging
techniques and procedures. The
general public is already aware of
the possible benefits, and demand is
increasing rapidly. The community
surgeon who cannot provide these
services ultimately may be relegated
to the surgical backwaters in the
wake of public demand.
J. Morrison, MD, FRCSC, FICS, FACS
Department of Surgery
James Paton Memorial Hospital
Gander, NF
A1V 1P1

nal pain, obstipation, weakness, diz
ziness and lightheadedness. He stat
ed that he had flown in from Am
sterdam 72 hours earlier and was
reluctant to give any detailed histo
ry. He appeared healthy, and, ex
cept for an orange coating on his
oral mucosa, there were no abnor
mal findings. Blood work yielded
normal results; urine testing for
amphetamines, cocaine and ben
zodiazepines was negative, whereas
that for barbiturates was positive.
Three views of the abdomen (Fig. 1)
showed multiple foreign bodies in
the stomach, duodenum and small
bowel.
When I was asked to see this
patient he reiterated his previous
history but volunteered that origi
nally he had come from Ghana and
had been in Amsterdam for 12
years. During questioning about the

The Case of a Reluctant Mule
To the editors. After years of look
ing south of the border at the
explosion of illicit drug use with its
associated violence, Canadians must
now realize that we are living in
that same milieu, in both large and
small cities. We describe the case of
a body packing man who presented
to the emergency department of a
large peripheral hospital in metro
politan Toronto. We will discuss
not only the medicolegal aspect of
this problem but also whether such
cases should be treated medically or
surgically.

Case Report
A 32-year-old black man present
ed to the emergency department of
our hospital complaining of abdomi

FIG. 1. X-ray film of abdomen showing
multiple foreign bodies in stomach,
duodenum and intestine.

CORRESPONDENCE

foreign bodies seen on the x-ray
film the patient was adamant that
they were there as a result of a
tribal ritual in which he swallowed
“packets of herbs.” I suggested to
the patient that the packets might
be narcotics and that a leakage or
rupture might have fatal results;
however, the patient stuck to his
story. Although he was then told
that we could do nothing for him
and that he could leave, about 1
hour later he was still lying on a
stretcher, appearing somewhat anx
ious and reluctant to leave.
An intravenous drip was started,
and I considered my medicolegal
obligation in this case. The police
were called. Two undercover mem
bers of the narcotics squad were
very impressed with the x-ray find
ings.
A few hours later the patient
became delirious and confused; he
had pinpoint pupils with an irregu
lar heart rate varying from 40 to 97
beats/min and a blood pressure of
200/100 mm Hg. He was given
three ampoules intravenously of na
loxone hydrochloride, a narcotic an
tagonist, which quickly reversed the
abnormal findings.
When the police interrogated the
patient, he admitted to swallowing
multiple packets of heroin within
the last 72 hours. He produced a
new Dutch passport, which bore a
single stamp of entry at Pearson
International Airport in Toronto,
and two new 100-guilder bills. He
stated that he was to receive
$10 000 for his trouble. The police
had gone to the residential address
the patient had given, but whoever
had been in the house had fled.
The patient was reminded of the
danger he was in, and he reluctant
ly agreed to surgery; however, he
would not sign a consent form. All
this information was heard and re
corded by only a nurse and me. An
hour later the patient again became
drowsy, and his heart rate was

fluctuating; he was therefore given
another vial of naloxone intrave
nously.
An enterotomy was done through
an upper-midline incision, and four
packets were removed from the pa
tient’s small bowel; through a gastrotomy another 28 packets were
removed. All the packets were made
from the ends of surgical gloves
and tied with string. Some of them
were also wrapped in plastic electri
cians’ tape. Some of the packets
had ruptured (Fig. 2). What was
also interesting was the bright yel
low discoloration of the small bow
el, a result of the patient’s chewing
Betel nuts (the orange astringent
seed of an East Indian palm tree),
which also explained the orange
coloration of his oral mucosa.
Apart from a small wound ab
scess the patient made a smooth
recovery. He was convicted of im
porting $250 000 worth of heroin
and was given a 12-year sentence.

to be imported this way. Cocaine,
which is prepared from the Erythroxylon coca bush of Peru and
Bolivia, is smuggled mainly into
North American cities. It is known
on the street as C, coke, flake,
snow or stardust. In combination
with heroin it is called dynamite,
speedball or whizbang. Cocaine hy
drochloride is most often inhaled
(“snorted”) into the nose after
being arranged into thin strips
called “lines.” It can be converted
into a free base and then smoked
after being heated in a free-base
pipe. Adding baking soda to a solu
tion of cocaine hydrochloride pro
duces crack or rock, which is sold
in small clumps and also smoked in
a free-base pipe.
The second drug, heroin, also
called diamorphine or diacetyl mor
phine, is semisynthetic and is pro
duced through a chemical modifica
tion of the natural alkaloid mor
phine. Morphine is extracted from
the plant Papaver omniferum; the
main source of natural illicit mor
phine is the “Golden Triangle” —
Burma, Thailand and Indonesia. Be
cause of the potency of its euphoric

Discussion
Two main drugs have been found
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FIG 2. Packets of heroin removed from patient. Packets were made from ends of
surgical gloves and tied with string. Some were wrapped in plastic electricians’
tape.
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and analgesic affect heroin has the
greatest potential of any of the
common narcotic analgesics for
producing dependency. In North
America it is either snorted or in
jected subcutaneously (“skin pop
ping”), but the main preference is
to inject it intravenously (“main
lining”). The content of heroin in a
typical “street bag” is usually dilut
ed to 5% to 10% of the total weight.
Because of repeated intravenous in
jections and shared needles, teta
nus, viral hepatitis and, in the last
few years, acquired immunodefi
ciency syndrome are common com
plications of the use of this illicit
drug. Long-term users of heroin
become extremely dependent, but
less frequent or intermittent users
(i.e., on weekends, referred to as
“chipping”) do not become depen
dent. During the Vietnam war many
servicemen were major users, yet
after the war up to 90% were not
dependent on the drug.
The use of body packers, or
“ mules,” to transport narcotics was
first reported in 1975; up to 1981
in half of the reported cases the
patients died.1 At ports of entry in
Europe suspect people, especially
those who have swallowed the nar
cotic, have a highly positive result
of urine enzyme aminoassay test
ing; in those in whom the drug has
been inserted into the rectum or
vagina the rate of positivity is less.2
Subsequent plain x-ray films of the
abdomen confirm the suspicion.
When encountering a case of nar
cotic pack ingestion the decision
must be made whether to treat the
patient medically or surgically. A
packet does not have to break open
to cause death from acute cocaine
toxicity. With experience the ability
to pack and insulate these drugs
adequately has improved dramati
cally; unless there are symptoms of
toxicity or mechanical obstruction
the patient may be treated conserva
tively. This was true in two reported
426
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studies — one of 47 patients3 and
the other of 75 patients4 in which
patients who had ingested cocaine
packets were treated conservatively;
fewer than 5% required emergency
surgery.
It is obvious that more cases like
the one we have reported will be
seen in Canada, and we must be
diligent in determining the best way
to treat such a case. As in Europe,
the Canadian Customs and Immi
gration Department must be more
aware of “mules.”
Robert B. Stitt, MD, FRCSC
Attending surgeon
Kim E. Turner, BSc(Pharm), MD, FRCPC
Attending anesthetist
Annie Ngan, BSc(Pharm)
Pharmacist
Scarborough General Hospital
3050 Lawrence Ave. E
Scarborough, ON
M1P2V5
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Spontaneous Bacterial
Peritonitis in a Healthy Male
Caused by Streptococcus
viridans
To the editors. It is generally ac
cepted that spontaneous bacterial
peritonitis occurs in patients with
impaired immune defence mecha
nisms caused by either disease or
treatment with steroids or antimi
totic drugs. It is likely to occur in

patients with ascites, especially
when associated with cirrhosis.1 Its
origin is not well understood, but it
is generally assumed to be from
bowel organisms, either bloodborne or by direct migration
through the bowel wall. Positive
cultures of the ascitic fluid usually
show that Escherichia coli is the
most frequently found organism
(34%), the next most common being
Klebsiella (22%), pneumococci
(14%) and streptococci: a-hemolytic, /3-hemolytic, Streptococcus bovis
and an anaerobic peptostreptococcus (14%).*
We report the case of a
48-year-old white man who was
admitted to our hospital with sus
pected acute appendicitis. His medi
cal history included a second repair
of a right inguinal hernia 6 years
earlier and nonactive chronic pro
statitis. The day before his admis
sion he had experienced right lower
abdominal pain and nausea, and he
had vomited twice. Abdominal ex
amination revealed maximal tender
ness in the right iliac fossa with
defence and rebound. His oral tem
perature was 37.4°C and rectal
temperature 38.6°C. The pulse rate
was 110 beats/min, blood pressure
120/80 mm Hg and the leukocyte
count 13.4 X 109/L . Rectal exami
nation yielded normal results, and
both inguinal regions were free of
abnormalities. Plain abdominal and
chest x-ray films showed no abnor
malities.
Acute appendicitis was diag
nosed, and an operation was per
formed immediately. The abdomen
was found to contain about 200 mL
of cloudy, odourless fluid bathing
the intestines. The appendix and
bowel appeared normal. Swabs were
taken for aerobic and anaerobic
bacteriologic testing. Lavage of the
peritoneal cavity was carried out
with saline. Intravenous administra
tion of sodium was begun, but in
spite of this treatment the patient’s
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temperature remained 38.6°C. On
day 3, the swabs from the peritone
um gave a profuse, pure growth of
Streptococcus viridans (a-hemolytic
Streptococcus). Therefore, cephalothin was replaced with penicillin G
according to the sensitivity tests.
The patient’s temperature returned
to normal in the next few days. An
echocardiogram revealed no patho
logic abnormalities, and blood cul
tures taken on the first postopera
tive day were negative.
The patient had no obvious asci
tes, was not immunologically com
promised and took no drugs. From
our search of the literature this
appears to be the first case of
spontaneous bacterial peritonitis
caused by S. viridans reported in an
otherwise healthy man.
A.E. Benet, MD
S. Kyzer, MD
Ch. Chaimoff, MD
Department of Surgery
“ A” Hasharon Hospital
Golda Medical Center
Petah-Tiqva 49372
PO Box 121
Israel
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Diagnostic Peritoneal Lavage:
the Cook County Hospital
Experience
To the editors. Peritoneal lavage
has been the uncontested diagnostic
procedure for the evaluation of
blunt abdominal trauma since
Root’s landmark article in 1965.1
Before then blunt abdominal trau
ma was associated with a death rate
approaching 45.6% in some series.2
This was related to the 16% to 45%

inaccuracy rate of the initial physi
cal examination in detecting intra
abdominal injury.3 To increase the
accuracy of the initial examination
physicians began to use a fourquadrant paracentesis. A positive
result was a grossly positive aspi
rate. This still missed 17% to 36%
of injuries.45 In 1964, Root and
colleagues first used peritoneal la
vage for patients with negative pa
racentesis.1 This proved 98.5% ac
curate in detecting intra-abdominal
injury.6 The standard criteria for
positivity are as follows:7
• a red blood cell count >
100 000/m m 3 (0.1 X 1012/L ) in
the lavage fluid
• a leukocyte count of >
500/mm 3 (0.5 X 109/L ) in the
lavage fluid
• amylase > 200 Caraway
units/100 mL (370 U/L) in the
lavage fluid
• positive lavage fluid through
chest tube or Foley catheter
• presence of food particles,
stool, bile or bacteria.

Open Versus Closed Peritoneal
Lavage
When diagnostic peritoneal la
vage (DPL) was first introduced, it
was performed percutaneously with
an 18-gauge dialysis catheter.1 But
when Pachter and Hofsteller8 dem
onstrated a 98% accuracy and a 2%
complication rate with the open
technique compared with a 92%
accuracy and a 5% complication
rate with the closed technique, the
American College of Surgeons rec
ommended the open technique as
the standard one. Now, however,
the pendulum is beginning to swing
back in favour of the percutaneous
method. The retrospective study by
Sherman and colleagues9 of the
percutaneous method has the same
accuracy as in Pachter’s series but a

complication rate of 0.8%. Looking
at our experience with 177 cases of
closed lavage over 6 months, we
found a 98% specificity, 100% sen
sitivity, 98% predictive value and
0.5% complication rate in cases of
blunt abdominal trauma.10 Two re
cent prospective randomized studies
by Wilson and associates11 and Cue
and associates12 showed that the
percutaneous method is preferred
over the open one in uncomplicated
cases, because of similar safety and
accuracy, and superior speed, pa
tient comfort and ease of perfor
mance. We use the open technique
only for patients with pelvic frac
tures, in advanced pregnancy and in
selected cases of previous abdomi
nal operations.

Leukocyte Count in DPL
At Cook County Hospital, we
have questioned the strict use of
the leukocyte count to mandate
laparotomy.13 We did a 5-year retro
spective review of 3503 peritoneal
lavages. Forty-eight patients with
blunt abdominal trauma had posi
tive lavage based solely on the
leukocyte count. Of this group,
42% (20 patients) were simply ob
served and then discharged without
further intervention or morbidity.
Fifty-eight percent (28 patients) un
derwent laparotomy. Of these lapa
rotomies 61% (17) were negative
and 39% (11) were positive, necessi
tating surgery. The positive predic
tive value of an isolated leukocyte
lavage count of more than
5 0 0 /mm3 as a predictor of abdomi
nal injury was 23% (11 of 48). Even
when the cutoff point was raised to
2000/m m 3, the positive predictive
value was still only 22%.13 This
strongly suggests that leukocyte
count alone is not an adequate
criterion for mandatory laparotomy
in trauma patients.
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DPL in Penetrating Trauma:
the Balance Between Missed
Injury and Negative
Laparotomy
It is accepted that patients with
penetrating abdominal trauma and
clear evidence of visceral injury re
quire laparotomy. Also, in most
trauma centres, all patients with
gunshot wounds with abdominal
penetration, even without evidence
of visceral injury, require explorato
ry surgery. This is based on the fact
that 96% to 98% of these gunshot
wounds produce serious injuries
that need to be approached opera
tively.1415 Although some authors
advocate laparotomy for a stab or
gunshot wound close to the abdom
inal cavity, this is not our approach.
The negative laparotomy for trauma
is not a benign procedure as shown
by Lowe and colleagues.16 In a
series of 254 patients who had a
negative laparotomy, with 6- to
9-month follow-up. 1.6% mortality
and 19% morbidity were reported.
Therefore, we advocate a reduction
in the number of unnecessary ex
plorations, and we use DPL to
accomplish this.

Stab Wounds to the Anterior
Abdominal Wall
Generally, however, experts dis
agree as to the management of
penetrating trauma and the role of
peritoneal lavage. For example, the
management of anterior abdominal
stab wounds may vary from manda
tory laparotomy, exploration for
penetration or selective laparotomy
for visceral injury. As previously
stated, the last option is the most
reasonable in our opinion because
only 50% of all the stab wounds will
penetrate the peritoneum, and only
half of these (25%) will inflict sig
nificant visceral injury.17
We did a retrospective study of
428

JCC, VOL. 34. N° 5. OCTOBRE 1991

333 consecutive patients with ante
rior abdominal stab wounds.18 They
were managed selectively with serial
abdominal observation; 165 under
went laparotomy when the initial
physical examination was consistent
with visceral injury, and 168 pa
tients were observed. Of the latter
group, 18 had abnormal findings on
further examination, mandating lap
arotomy after 8 to 13 hours of
observation. Four of these 18 had a
negative laparotomy. The remaining
150 patients were simply observed
and discharged after 2 days without
sequelae. Sensitivity, specificity,
and positive and negative predictive
values for initial clinical evaluation
were 91%, 85%, 92% and 83%,
respectively, with 87% accuracy.
We conclude that the most serious
stab wounds are detected at the
initial examination.
Other patients can be safely ob
served because there is no signifi
cant increase in morbidity or mor
tality due to the delay. In fact, in
the delayed group of 14 patients
who had a positive laparotomy, the
injuries discovered in 10 were of
minor significance. Four patients,
however, did have major injuries:
small-bowel and iliac artery and vein
injuries (spreading tenderness); co
lonic and inferior vena caval injuries
(delayed peritonitis); duodenal inju
ry (peritonitis); and hepatic and pan
creatic injuries (peritonitis). Never
theless, this delayed management
group with injuries had no in
creased complication rate compared
with the immediate management
group.18
Demetriades and Rabinowitz19
have also advocated observation for
asymptomatic anterior abdominal

stab wounds. We are currently in
vestigating the role of peritoneal
lavage in combination with serial
physical examinations for stab
wounds to the abdomen.

Difficult Penetrating Injury:
the Role of Peritoneal Lavage
Penetrating trauma to the thora
coabdominal region and to the flank
and back is difficult to manage. The
controversy still exists between
mandatory exploration and observa
tion. 18’2°-24 We use peritoneal lavage
to establish penetration and indica
tions for surgery in these situa
tions.
We conducted a retrospective re
view of 235 patients who under
went DPL for penetrating trauma to
the flank and back or to the thora
coabdominal area. Of these, 44 pa
tients had positive lavages defined
by a red blood cell count of
10 000/m m 3 or more, or the pres
ence of bile, feces or food particles.
Six (13.6%) of them had false-posi
tive lavage with negative laparoto
my. Two of 191 (1.0%) had false
negative lavage with missed injury.
The overall accuracy for a red blood
cell count of 10 000/mm3 or more
was 96.6%.
If we had changed our criteria for
positivity to a red blood cell count
of 100 000/m m 3 or more, there
would have been no negative lapa
rotomy, but we would have missed
injuries in 11.1% of the patients.25
We believe that a red blood cell
count of 10 000/mm3 or more
gives adequate sensitivity, specifici
ty and accuracy (Table I).
In specific reference to penetrat-

T a b le 1. C riteria o f P o s itivity
R e s u lt, n o ./to t a l n o . (% )
c o u n t, /m m 3

> 10 000
> 50 000
> 100 000

F a ls e p o s itiv e

6 /4 4 (1 3 .6 )
0 /2 0 (0)
0 /1 4 (0 )

F a ls e n e g a tiv e

2 /1 9 1 ( 1.0)
2 0 /2 1 5 ( 9.3)
2 6 /2 2 1 (11.1)

A c c u ra c y ,

%
96.6
91.5
88.9
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ing thoracoabdominal trauma, we
studied, prospectively, the accuracy
of a red blood cell count of
10 000/mm3. Forty-five consecu
tive patients underwent exploratory
laparotomy for thoracoabdominal
penetrating trauma. Eight of these
had standard indications for opera
tion and did not have DPL. The
remaining 37 underwent closed la
vage before surgery. Mandatory lap
arotomy was performed independ
ent of the lavage result. In analy
sing our results, using a red blood
cell count of 10 000/mm 3 or more,
there were 7 true-positive results, 1
false-positive result, 28 true-nega
tive results and 1 false-negative
result for 94.6% accuracy, 87.5%
sensitivity and 96.6% specificity, as
determined by laparotomy with a
confidence interval of ±16%. Al
though 35.6% of these patients
were found to have significant inju
ries, 64.4% had negative explora
tions. Of these 29 negative explora
tions, there were three complica
tions for an operative morbidity of
10.4%. The complications included
atelectasis, respiratory failure and
iatrogenic splenic injury requiring
splenectomy.26 Therefore, peritoneal
lavage is helpful in determining
penetration through the diaphragm
and in restricting the incidence of
negative laparotomy for thoracoab
dominal penetrating trauma.
We conclude that, even in the
modern era of computed tomogra
phy, there is a continuing role for
peritoneal lavage in the evaluation
of the patient with abdominal trau
ma. Closed peritoneal lavage is pre
ferred over the open technique be
cause of safety, accuracy, expedien
cy, patient comfort and ease of
performance in the majority of
cases of blunt trauma. In regard to
Root’s original criterion we con
clude that the leukocyte count is
not an adequate single criterion for
mandatory laparotomy. Peritoneal

lavage is a useful adjunct in reduc
ing the number of unnecessary ex
plorations in penetrating trauma. In
fact, a red blood cell count of
10 000/mm 3 or more gives sensi
tive, specific and accurate criteria
for necessary operative intervention
in injuries with difficult localization.
Peritoneal lavage continues to be an
accurate, safe, simple, rapid and
inexpensive test.
Roxanne Roberts, MD
Marcel Martin, MD
Linda Farkas, MD
Juan Bonilla, MD
John Barrett, MD
Division of Trauma
Department of Surgery
Cook County Hospital
1835 W Harrison St.
Chicago, IL
60612-9985
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Cardiac Function in Massively Obese
Patients and the Effect of Weight Loss
Miguel F. Herrera, MD; Mervyn Deitel, MD, FRCSC
Massively obese patients are at increased risk for heart disease. Blood volume and
capillary flow are increased to supply the excess body mass, and there is a
concomitant increase in preload and, often, afterload. The heart compensates for the
expanded blood volume by increasing stroke volume and cardiac work to provide
increased cardiac output. The result is left ventricular dilatation followed by
eccentric left ventricular hypertrophy. Cardiac compensatory reserve is limited,
leading, at times, to overt congestive failure. After reduction of the excess body fat,
most of the cardiovascular derangements appear to reverse. The authors review the
effect of massive obesity on the heart and the cardiovascular consequences of weight
reduction.

Les patients tres obeses courrent un risque accru de cardiopathies. Le volume
sanguin et le debit capillaire sont augmentes pour irriguer cette masse corporelle
excessive, et il y a une augmentation concomitante de la precharge et, souvent, de la
postcharge. Le coeur compense pour l’augmentation du volume sanguin en
augmentant le debit systolique et le travail cardiaque pour fournir un debit
cardiaque augmente. II en resulte une dilatation ventriculaire gauche suivie d’une
hypertrophie excentrique du ventricule gauche. La reserve compensatoire cardiaque
est limitee, entrainant parfois une insuffisance cardiaque manifeste. Apres reduction
de l’exces de tissu adipeux, la plupart des dereglements cardiovasculaires semble
s’inverser. Cet article passe en revue les effets de l’obesite massive sur le coeur et
les consequences cardiovasculaires d’une reduction de poids.

he influence of excess weight
on the heart has been evaluat
ed extensively in the last 30 years.
Several studies have shown that the
death rate in obese patients is in
creased because of diabetes, cardio
vascular disease and cancer.1 Car
diovascular disease has been report
ed as the most frequent cause of
death in middle-aged obese men.2 In
this paper we review the effect of
obesity on the heart, analysing the
influence of cardiovascular function

T

on morbidity and the effects of loss
of the excess weight.

Overweight and Obesity as
Risk Factors
Massive obesity is deleterious to
the vascular apparatus. However,
the precise degree of risk of cardio
vascular disease in patients with
moderate obesity is not well de
fined. Life-insurance studies have
found a stepwise association be
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tween obesity and heart disease,3
but the validity of these studies has
been widely criticized.45 Analysing
most published studies, we can find
discrepant results, including no as
sociation, a U-shaped relation and a
positive relation of obesity to coro
nary artery disease.67 Increased risk
of cardiovascular disease in over
weight patients has been shown to
be related primarily to an adverse
risk-factor profile.8 It has been pro
posed9 that obesity alone does not
contribute to future coronary artery
disease, whereas male sex, smoking
and increasing age, blood pressure
and serum cholesterol levels are
significant factors. However, the
Framingham study,10 which was a
large general-population-based
study with a long follow-up, dis
closed an increasing risk of angina
pectoris and sudden death with in
creasing levels of obesity, independ
ent of the other standard risk fac
tors. Other studies11^13 have also
shown a direct relation of extreme
obesity to myocardial infarction,
coronary insufficiency and sudden
death. Recent studies1415 indicate
that an android distribution of fat
(truncal obesity) may be a better
predictor of coronary artery disease
than the degree of obesity.

Cardiac Function in Obese
Patients
Pathologic Changes
Smith and Willius16 showed that
heart weight increases as body
weight does, but without a linear
relationship. Originally, patholoCJS. VOL. 34, NO. 5, OCTOBER 1991
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gists believed that the increased
heart weight was due to excess
epicardial fat,16 but subsequently it
was found17 that, although excess
epicardial fat and fatty infiltration
of the myocardium are more com
mon in obese patients than in “ideal
weight” subjects, they are not of
sufficient degree to explain the
marked increase in heart weight.
Rather, this increased cardiac
weight is due to an increase in left
ventricular (LV) weight, resulting
from eccentric wall hypertrophy17
(Table I). Eccentric LV hypertrophy
is not only the most important
abnormality in the hearts of morbid
ly obese patients but also the most
common, occurring in almost 100%
of cases,18 in contrast to fatty infil
tration, which is found in 3% at
autopsy.19
Hemodynamic Derangements

The massively obese state is al
ways accompanied by marked he
modynamic abnormalities. The total
blood volume increases as a re
sponse to an increase in the size of
the vascular bed, mainly in the
excess adipose tissue. The splanch
nic blood flow is only slightly in
creased, and the cerebral and renal
blood flow are near that of “ ideal
weight.” Because adipose tissue is
metabolically very active, cardiac
output (CO) increases proportional
ly to the excess in oxygen con
sumption. It has been calculated
from indirect measurements of adi
pose tissue blood flow, that the
blood volume and CO of a person

weighing 170 kg are roughly twice
those of a subject weighing 70
kg.20 When we take into account
the fact that oxygen transport to
adipose tissue is less than that to
parenchymal organs in the resting
state, we find that blood volume,
CO and oxygen consumption ex
pressed as units per kilogram of
body weight are less in obese pa
tients than in subjects of “ideal
weight.” However, cardiac index
(CO per unit body surface area)
tends to be in the normal range.
There is only slight increase in the
resting heart rate, so that the
stroke volume is increased to han
dle the increased blood flow. In
order to accommodate the increased
CO, systemic vascular resistance
(SVR) is reduced in normotensive
obese patients and is normal in
those with systemic arterial hyper
tension (SAH).21
The response to exercise of mild
ly obese patients is comparable to
that of subjects at “ideal weight.”
However, morbidly obese subjects,
even in the absence of SAH, may
have pulmonary hypertension, ex
pressed by elevated LV diastolic or
pulmonary wedge pressures at rest
or during exercise.22 Excessive obe
sity results in higher LV preload
and, often, afterload, with mainte
nance of a high output state at the
expense of elevated LV and, some
times, right ventricular filling pres
sures. It has been postulated that
the increase in circulating blood
volume, and the resultant increase
in LV volume, precede LV hypertro
phy in these patients, because the

T a b le 1. C a rd io v a s c u la r D e ra n g e m e n ts S e c o n d a ry to M o rb id O b e sity and N o rm a l M e c h a n is m s o f
C a rd ia c C o m p e n s a tio n
H e m o d y n a m ic and m o rp h o lo g ic
d e ran g em en ts
In c re a s e d b o d y fat
In c re a s e d b lo o d vo lu m e
In c re a s e d c a p illa ry flo w
In c re a s e d le ft v e n tric u la r
p re lo a d and a fte rlo a d
S y s te m ic a rte ria l h y p e rte n s io n
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M e c h a n is m s of c a rd ia c
c o m p e n s a tio n
Increased ca rd ia c o u tp u t
E cce n tric le ft v e n tric u la r
h y p e rtro p h y
Increased s tro k e v o lu m e
Increased ca rd ia c w o rk

increase in wall tension increases
the afterload. Thus, LV hypertro
phy evolves in response to the in
crease in afterload. By contrast,
SVR varies directly with the blood
pressure and inversely with the CO,
and provides only a fraction of the
potential afterload.23
Severe SAH occurs in 5% to 10%
of grossly obese patients, moderate
hypertension in about 50% and normotension in the remainder.24 The
cardiovascular consequences of in
creased body weight are different,
but as powerful a stimulus as SAH
in normal weight. In obesity, the
cardiac adaptation consists of LV
dilatation and eccentric hypertro
phy, while SAH produces solely
concentric LV hypertrophy. Both
increase LV stroke work, although
through different mechanisms, and
their presence in the same patient
will increase the long-term risk of
congestive heart failure (CHF).25
Evaluation of LV performance by
echocardiographic methods has
provided further insight into the
mechanisms of heart disease in obe
sity. On the basis of ventricular
function, it is possible to differenti
ate two groups of patients.21 One
has normal LV systolic function,
increased wall thickness and cham
ber radius but normal wall stress. In
these patients sufficient LV hyper
trophy develops to normalize wall
stress, as a response to the chroni
cally increased preload, that is, a
compensated heart failure. The
other group has depression of ven
tricular systolic function, increased
chamber radius out of proportion to
wall thickness and abnormally ele
vated wall stress. In this group,
chamber dilatation is accompanied
by marked LV hypertrophy, result
ing in elevated wall stress, which
predisposes to myocardial decom
pensation and overt CHF. Thus, in
the grossly obese patient, ventricu
lar function may be adequate or
inadequate, and, in most cases, the

CARDIAC FUNCTION IN OBESITY

degree of impairment is related to
the degree of obesity and its dura
tion.
Alaud-din and colleagues,26 for
example, studied cardiac function in
morbidly obese patients using
echocardiography, radionucleotide
angiography scanning and SwanGanz right-heart catheterization.
They found that, with exercise, pa
tients increased their CO by an
increase in heart rate without an
increase in stroke volume. The rela
tion of the pulmonary wedge pres
sure and the LV stroke work and
index was abnormal in 48% and
depressed in 20%. After being chal
lenged by the intravenous infusion
of 1000 mL of fluid, 33% of these
patients experienced depression in
LV stroke work and index.
Recently, exercise-induced wallmotion abnormalities mimicking
coronary disease have been report
ed, even in the presence of a nor
mal, resting, LV end-diastolic frac
tion.27 This pattern is consistent
with functional ischemia, as has
been found in the absence of angio
graphic coronary disease; a reduced
coronary vasodilator reserve may be
the explanation.
Fatty infiltration of the atrioven
tricular node and infranodal con
duction system has been proposed
as the mechanism for the occur
rence of sinus bradycardia, atrial
fibrillation and sudden death in sev
eral case reports.28’29 More recently,
it has also been found that obese
patients with eccentric LV hypertro
phy are more prone to premature
ventricular contractions than either
obese patients without LV hypertro
phy or slender persons.30
Severe obesity can result in im
pairment of respiratory function.
Respiratory insufficiency related to
obesity has been termed the obesity
hypoventilation syndrome (OHS).
This syndrome is recognized when
a resting patient suffers from hy
poxemia and hypercarbia while

breathing room air, frequently re
sulting in somnolence. Its causes
include such diverse factors as re
strictive pulmonary disease and at
tenuated hypercarbic and hypoxic
central ventilatory responsiveness.31
Chronic hypoxemia causes pul
monary artery vasoconstriction and
severe pulmonary hypertension that
can produce CHF or cor pulmonale.
Pulmonary hypertension appears to
be related, in addition to arterial
vasoconstriction, to LV dysfunc
tion.32 Sugerman and associates33
found pulmonary hypertension in
88% of 26 obese patients with OHS
and identified three hemodynamic
patterns. Approximately one-third
of their patients had elevated pul
monary arterial pressure entirely
secondary to LV dysfunction, onethird had pulmonary hypertension
secondary to pulmonary vasocon
striction and the remainder had
both LV dysfunction and pulmonary
vasoconstriction. The proposed
causes of LV dysfunction in pa
tients with OHS are the same as in
the obese patients with heart failure
but without OHS. However, anoth
er theoretical cause for the LV
dysfunction could be the hypoxemia
itself, since the oxygen extraction
during the passage of blood
through the coronary circulation
when the Pa02 is extremely low
might be insufficient for proper LV
function.
Perioperative Hemodynamic
Changes

In 1982 Agarwal and colleagues34
who used right heart cathetherization, reported a study comparing 10
patients who underwent gastric par
tition and an equal group of normal
weight patients who underwent di
verse abdominal operations. They
found impaired cardiac performance
in obese patients owing to LV dys
function during the surgical proce
dure and early postoperative phase.
Maximum impairment occurred

after intubation and in the immedi
ate postoperative period. Thus, the
LV function of morbidly obese pa
tients is also compromised by the
stresses of surgery and anesthesia.

Effect of Weight Reduction on
Cardiac Function
Alexander and Peterson35 found
that morbidly obese patients, after
losing 24% to 55% of their total
weight by caloric restriction, had an
improvement in blood volume, CO
and SAH, but their LV compliance
problem persisted. Reisin and col
leagues36 noted a reduction in pa
tients’ arterial pressure after an
average weight loss of 10 kg. MacMahon, Wilcken and Macdonald,37
in 1986, showed reduced thickness
of the interventricular septum and
posterior wall as well as the LV
mass, after an average weight re
duction of 8.3 kg, independent of
changes in blood pressure.
Recent reports have described the
reversibility of LV dysfunction with
weight loss after surgical treatment
of obesity: by echocardiography, a
decrease in the LV hypertrophy,2638
increase in the mean LV fractional
shortening,38 and normalization of
LV hypertrophy26 have been found;
by radionucleotide scanning, an in
crease in stroke volume has also
been shown;2639 by right heart cath
eterization followed by exercise and
fluid infusion challenges, reduction
in filling pressures, increase in
stroke volume and increase in LV
stroke work and index were ob
served,26 although these changes
were not statistically significant in
the case of fluid challenge. Weight
reduction has also been shown to
benefit pulmonary function, result
ing in significant improvements in
Pao2, PaC02, pulmonary arterial
pressure and pulmonary artery oc
clusion pressure.32
The studies cited above show
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that the cardiopulmonary derange
ments associated with extreme obe
sity can be reversed by weight re
duction. Further studies are needed
to confirm the salutary effects of
weight reduction on the long-term
cardiac prognosis of morbidly obese
patients. In this regard Mason40
reported a fivefold decrease in the
risk of death from obesity after
surgically induced weight reduc
tion. Additional questions remain,
such as the time needed for restora
tion of normal cardiopulmonary
function after weight loss induced
by bariatric surgery and the per
centage of excess body weight that
must be lost to achieve such im
provement.
We thank Dr. George S.M. Cowan Jr.,
professor of surgery, University of Ten
nessee at Memphis, Dr. Boyd E. Terry,
associate professor of surgery, Universi
ty of Missouri Medical School, Colum
bia, Mo., and Dr. Eoghan R.T.C. Owen,
senior surgical registrar, Hammersmith
Hospital, London, UK, for valuable sug
gestions with this review.
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A Therapeutic Window for Carotid
Endarterectomy in Patients With
Asymptomatic Carotid Stenosis
C.Z. Zhu, MD; J.W. Norris, MD, FRCPC
The natural history of asymptomatic carotid stenosis was prospectively and
systematically studied in 500 patients by clinical observation and carotid Doppler
ultrasonography. In the 40% of carotid arteries (398) with an initial stenosis of over
35%, there were apparently two separate populations, with a cutoff point of 85%
stenosis. There were 79 ischemic cerebral events (54 transient ischemic attacks and
25 strokes) among the 500 patients during 60 months of follow-up, predominantly
in the severe-stenosis (more than 75%) group, with few events occurring in the nearor total-occlusion (95% to 100% stenosis) group; the highest incidence was in
patients whose arteries had 75% to 90% stenosis. These observations indicate a
critical degree of carotid stenosis at which stroke risk becomes maximal, declining
as the artery becomes occluded.
These findings suggest that there may be a “window” for carotid endarterectomy
in patients with asymptomatic carotid stenosis, when the stroke risk may be high
enough (5.5%/year) to warrant surgery.

L’histoire naturelle de la stenose carotidienne asymptomatique a ete etudiee de facon
prospective et systematique chez 500 patients au moyen d’examens cliniques et
d’echographies carotidiennes de Doppler. Parmi les 40 % d’arteres carotidiennes
(398) presentant une stenose initiale superieure a 35 %, il semblait exister deux
populations separees par un point critique a 85 % de stenose. Soixante-dix-neuf
evenements ischemiques cerebraux (54 acces ischemiques transitoires et 25
accidents vasculaires cerebraux) sont survenus chez les 500 patients pendant la
periode de surveillance de 60 mois, principalement chez ceux qui souffraient de
stenose severe (plus de 75 %), alors que peu d’evenements survenaient chez ceux qui
avaient avaient une occlusion quasi-totale ou totale (95 % a 100 % de stenose; la plus
forte incidence fut retrouvee chez les patients dont les arteres etaient stenosees de
75 % a 90 %. ces observations indiquent qu’il existe un degre critique de stenose
carotidienne oil le risque d’accident vasculaire cerebral devient maximal, et qui
diminue par la suite avec l’occlusion croissante de l’artere.
Ces resultats indiquent qu’il existe possiblement une fenetre pour l’endarterectomie carotidienne chez le patient ayant une stenose carotidienne asymptomatique,
quand le risque d’accident vasculaire cerebral est assez eleve (5,5 %/annee) pour
justifier la chirurgie.

From the Stroke Research Unit, Sunnybrook Health Science Centre, University o f Toronto,
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symptomatic neck bruits, often
discovered fortuitously during
routine physical examination, sug
gest underlying arterial disease and
are generally assumed to be risk
factors of stroke.1"3 Since the out
come data for such patients, includ
ing the risk of stroke, are still
scanty, the management of patients
with carotid stenosis remains con
troversial.2"4 Because of the paucity
of well-defined studies, information
on the natural history of asymptom
atic carotid stenosis is incomplete;
this has led to confusion rather
than clarification. The best prospec
tive data are obtained from such
community studies as the Evans
County5 and Framingham2 studies,
in which the overall stroke rates
were 2.3% and 1.7% per annum
respectively.6 In addition to in
creased stroke risk, the patients
had an increased cardiac risk and an
overall mortality from causes other
than stroke of approximately 4%
per annum.
The conclusion drawn from these
studies is that asymptomatic neck
bruits are a measure of systemic
vascular disease and not specifically
a risk factor for ipsilateral carotid
artery stroke. Some studies show
an apparent benefit from carotid
endarterectomy, and others prove
the opposite.7 In any case, the de
cline of carotid endarterectomy is
now evident. Whether we should
continue to perform this uncertain
operation depends on the balance
between the safety of endarterecto-
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my and the risk of spontaneous
stroke in patients with carotid ste
nosis. Established complication
rates (stroke and death) for this
procedure in skilled hands are
about 4%.8 Therefore, if the stroke
risk in patients with severe carotid
stenosis is above 4% per year, it
may be worthwhile for us to consid
er these patients as candidates for
carotid endarterectomy.
We performed a frequency distri
bution study of carotid artery steno
sis on the basis of prospective data
from 500 patients with an asymp
tomatic carotid bruit to determine
the relationship between the severi
ty of carotid stenosis and the inci
dence of ischemic cerebral events.

Patients and Methods
Over a 4-year period, consecutive
patients referred with asymptomatic
neck bruits to our laboratory for
carotid Doppler ultrasonography
were interviewed and examined clin
ically by the neurologist or the
stroke research fellow attending the
Doppler laboratory. Patients found
to have ischemic cerebral symptoms
(15%, 90 of 600 patients) before
their examination were not includ
ed. Patients under 45 years of age
were excluded because their neck
bruits were generally physiologic.
Those with a coexisting neurologic
disorder that could prevent detec
tion of subsequent symptoms of
stroke (e.g., dementia) or with a
terminal illness and those who re
fused to comply or refused to par
ticipate in the study were also ex
cluded. Five hundred patients (213
men, 287 women, mean age 64
years) were identified and were seen
at 6-month intervals for both clini
cal and Doppler assessment.
Patients were examined by con
tinuous-wave Doppler ultrasonogra
phy without B-mode scanning
(Model 1050; Carolina Medical Elec
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tronics Inc., King, NC), and estab
lished criteria were used to estimate
the percentage reduction in the
cross-sectional area of the internal
carotid artery lumen, without
knowledge of the ausculatory or
previous Doppler findings. Carotid
Doppler examination in our labora
tory has a sensitivity of 87% and a
specificity of 92% with stenoses
greater than 35% when compared
with conventional angiography.1
Ausculation was performed while
patients were seated. Periodic evalu
ations of these patients included
documentation of putative risk fac
tors, including the initial and subse
quent degree of arterial stenosis,
age, sex, the presence of hyperten
sion, diabetes, ischemic heart dis
ease and peripheral vascular dis
ease, a family history of stroke and
ingestion of antiplatelet agents and
smoking.
The study end-points were; tran
sient ischemic attack (TIA), defined
as an episode of focal cerebral dys
function due to presumed cerebral
or retinal ischemia, resolving within
24 hours, completed stroke of any
type or death. The mean follow-up
was 60 months (range from 3 to

109 months). Chi-squared tests and
analyses of variance were used in
statistical analysis.

Results
Among the 1000 arteries (500
patients), 398 (40%, 273 patients)
carotid arteries were abnormal as
detected by Doppler ultrasonogra
phy when the patients were entered
into the study. The status of the
initial carotid artery stenosis (exter
nal carotid artery stenosis was ex
cluded) is shown in Fig. 1. Two
apparently separate populations of
carotid stenosis were observed, with
the junction between the two
groups occurring at 15 KHz (about
85% stenosis). These findings were
independent of age and sex. The
percentage of arteries with stenosis
less than 85% was 95%, and of
arteries with stenosis greater than
85% was 5%.
During the follow-up, 77 patients
died; 46 died of cardiac events, 4 of
stroke, 6 of other vascular disease
such as aortic rupture and 21 of
nonvascular diseases (e.g., cancer).
The major cause of death was cardi-

FIG. 1. Frequency distribution of initial stenosis in 1000 carotid arteries.

CAROTID ENDARTERECTOMY

FIG. 2. Correlation of carotid stenosis ipsilateral to carotid events.

Table 1. D is trib u tio n o f C a ro tid Is c h e m ic E ve n ts and S e v e rity o f C a ro tid S te n o s is
Severity of stenosis, % (KHz)
< 50
(< 6)

Group

5 0 -7 5
(6 - 10)

75 - 90*
(1 1 -1 6 )

9 0 -1 0 0
(1 7 -2 0 )

S tro ke
T ra n s ie n t is c h e m ic
a tta c k
No e ve n t

10

2

4

2

12
712

12
158

14
28

9
37

T o ta l a rte ries

734

172

46

48

*p < 0.0 01

(a n a ly s is o f va ria n c e ).

ac rather than stroke, even in this
special group.
There were 80 cerebral events
(79 ischemic, 1 hemorrhagic): 54
TIAs and 25 ischemic strokes.
Fourteen were vertebrobasilar isch
emic events: in the 65 carotid cere
bral events there were 47 TIAs and
18 strokes. Signficantly, the high
est incidence of ischemic cerebral
events occurred at around 75% to
90% carotid stenosis (Fig. 2 and
Table I).
The mean initial stenosis at the
time of entry into the study and the
final stenosis were used to calculate
rate of progression (Fig. 3) as fol
lows: those with carotid events (TIA
and stroke); those with verte
brobasilar ischemic events; those
with cardiac ischem ic events
(whether or not fatal); normal con
trols.
There were 68 patients with ca
rotid events (68 arteries ipsilateral
to the event), 107 patients with
cardiac events, 14 patients with
vertebrobasilar events and 46 con
trols, age- and sex-matched, with
out any neurologic disease.
Differences in the mean initial
stenosis were significant (p <
0.025) in the carotid group com
pared with controls; this was not
due to age or sex differences. The
final mean stenosis in the carotid
group was again significantly (p <
0.05) different from th at of the
control group. Further, the rate of
progression of arterial stenosis in
the carotid group was significantly
increased compared with controls
(p < 0.05).

Discussion

FIG. 3. Progression of carotid stenosis in four groups. V-B = vertebrobasilar.

Our data allowed three major
conclusions. First, among patients
with asymptomatic neck bruits
there are apparently two separate
populations of severity of carotid
stenosis with a cutoff point at 85%
CJS, VOL. 34, NO. 5, OCTOBER 1991
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stenosis (or 15 KHz). Second, the
initial carotid stenosis plays an im
portant role in the disease progno
sis for these patients; the more
severe the initial carotid stenosis at
the time of entry into the study, the
greater is the risk of a cerebral
event. Third, the stenosis pro
gresses fastest in the severe-stenosis group, suggesting that these
patients may be a target group for
surgery.
The two separate frequency dis
tributions indicate that cerebral
ischemic events are related to the
presence, severity and progression
of carotid artery stenosis. Roederer
and colleagues,9 who studied 162
similar asymptomatic patients,
showed that those with greater
than 80% stenosis had a higher risk
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of TIA, stroke and occlusion than
those with less than 80% stenosis.
Further, although no spontaneous
strokes occurred in the low-risk
group, the incidence was 12.5% in
patients with carotid artery stenosis
of 80% to 90%. They suggested
that surgical treatment can be de
layed until the appearance of TIAs
or progression of the stenosis to
greater than 80%.
Our data indicate a relatively be
nign course for asymptomatic pa
tients with stenosis less than 75%,
which does not justify prophylactic
surgery. However, in patients with
carotid artery stenosis greater than
75%, symptoms are more likely, and
progression of the stenosis is great
er, so patients in this group might
require surgery. In patients with
over 90% stenosis, the threat to the
cerebral circulation rapidly lessens
because collaterals are established
from both the contralateral carotid
artery and the vertebrobasilar sys
tem. The risk becomes negligible
once the artery occludes,10 so the
therapeutic opportunity is lost, and
collateral blood supply has proven
itself adequate. The initial carotid
artery stenosis influences the pro
gression since the greater the de
gree of stenosis at onset, the faster
is the progression to complete oc
clusion.
The concept of a therapeutic win
dow (75% to 90% stenosis) in the
genesis of symptoms is supported
by data from Spencer and Reid.11
Stroke risk is minimal when the
stenosis is greater than 75%, after
which point there is a significant
risk of cerebral ischemia. This
could be a therapeutic opportunity
for surgical management. Once the
stenosis progresses to levels above
95% the hazard to the cerebral
circulation drops abruptly and is
minimal once the artery occludes.
These results confirm the relation
between carotid artery disease and
cerebral events, and indicate that

there is no linear relation between
the stroke risk and the severity of
carotid stenosis, so stenoses be
tween 75% and 90% may be the
therapeutic window for carotid en
darterectomy.
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Is Positive Diagnostic Peritoneal Lavage
an Absolute Indication for Laparotomy
in all Patients With Blunt Trauma? —
The Montreal General Hospital Experience
C. Barba, MD; D. Owen, MD, FRCSC; D. Fleiszer, MD, MSc, FRCSC; R.A. Brown, MD, FRCSC, FACS, MSc
The authors review the use of diagnostic peritoneal lavage (DPL) at The Montreal
General Hospital between 1982 and 1987. Fifty-two of 254 patients admitted with a
diagnosis of blunt abdominal trauma underwent DPL: results of the procedure were
negative in 23 and positive in 29 (grossly positive in 27). Twenty-one of the 23
patients with negative findings were managed nonoperatively; the other 2
underwent laparotomy, which revealed no abnormalities.
Nineteen of the 29 patients with positive findings were managed by immediate
laparotomy; the other 10 were managed conservatively. The mean (± standard
deviation) injury severity score (ISS) in the latter group was 13.1 ± 8.01. The
group managed by immediate laparotomy had an ISS of 25.91 ± 12.81 (p = 0.007).
The number of patients suffering from class I or class II shock in the group
managed nonoperatively was significantly (p = 0.045) larger than those in the
group managed by laparotomy.
The authors conclude that a positive result DPL is not a sine qua non for
immediate laparotomy in all patients with blunt abdominal trauma. A selective
approach can be taken in these patients, considering the severity of the associated
injuries and the patient’s hemodynamic status. Intensive-care monitoring must be
available.

Les auteurs commentent l’emploi du lavage peritoneal diagnostique (LPD) a
l’Hopital general de Montreal, entre 1982 et 1987. Cinquante-deux des 254 patients
reyus avec un diagnostic de traumatismes abdominaux fermes ont subi un LPD : les
resultats ont ete negatifs dans 23 cas et positifs dans 29 (nettement positifs dans
27). Vingt-et-un des 23 patients ayant des resultats negatifs ont ete traites de fa?on
conservatrice; les deux autres ont subi une laparotomie qui n’a revele aucune
anomalie.
Dix-neuf des 29 patients positifs ont subi une laparotomie immediate; les 10
autres ont ete traites de facon conservatrice. Dans ce dernier groupe, la moyenne (±
l’ecart type) de l’index de gravite lesionnelle (IGL) etait de 13.1 ± 8.01. Le groupe
soumis a une laparotomie immediate avait un IGL de 25.91 ± 12.81 (p = 0.007). Le
nombre de patients souffrant de chocs de classe I ou II etait significativement plus
eleve (p = 0.045) dans le groupe non opere par rapport au groupe qui subit une
laparotomie.
Les auteurs concluent qu’un resultat de LPD positif n’est pas une condition
absolue pour proceder a une laparotomie immediate chez les patients souffrant de
traumatismes abdominaux fermes. Une approche selective peut otre prise envers ces
patients, en fonction de la gravite des blessures associees et de l’etat hemodynamique du patient. Des soins de surveillance intensive doivent etre disponibles.
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any reports in the literature
have shown that diagnostic
peritoneal lavage (DPL) is a useful
tool in the management of patients
with blunt abdominal trauma.1-4
Since the introduction of this proce
dure in the 1960s the number of
negative laparotomies performed on
these patients has decreased subs
tantially. It has also contributed to
the early diagnosis and treatment of
serious intra-abdominal injuries.
Standard criteria have been used
by many physicians to diagnose
intra-abdominal disorders in blunt
abdominal trauma, with an accuracy
of approximately 95%.4 However,
these criteria are controversial, and
some reports have recommended
modifications, allowing more la
vages to be considered as positive.2'3
A positive result, when assessing
a patient with blunt trauma, is
considered by a majority of trauma
centres to be a clear indication for
performing an exploratory laparoto
my.1-5 In recent years procedures
such as computed tomography and
ultrasonography have been used to
complement DPL, and some, when
being used alone to assess patients
with blunt abdominal injury, have
given results similar to those of
DPL.6-8
In this study we review the expe
rience of The Montreal General
Hospital, over the last 5 years, with
DPL used for the assessment of
blunt abdominal trauma.

M

Patients and Methods
We studied, retrospectively, 254

DIAGNOSTIC PERITONEAL LAVAGE

patients admitted to the surgical
intensive care unit between 1982
and 1987 with blunt abdominal
trauma as part of the initial diagno
sis. Of these, 52 patients had DPL
and they constitute the study
group.
The condition of all patients was
assessed in the emergency depart
ment by two senior residents in
general surgery and at the surgical
intensive care unit by a junior sur
gical resident. The open technique
was utilized in all DPLs.
For each patient studied, the fol
lowing data were recorded: age,
sex, mechanism of injury, associat
ed injuries, grade of shock before
peritoneal lavage (shock was de
fined as class I, II, III or IV, accord
ing to the American College of
Surgeons’ classification), the injury
severity score (ISS), the time DPL
was performed and its result. The
time of surgery was recorded for all
patients having a laparotomy, and
the operative report was reviewed.
For the purpose of the study, a
laparotomy was considered as posi
tive when its findings indicated that
significant intraoperative therapy
was necessary. These findings in
cluded the following: perforation of
a hollow viscus, diaphragmatic
tears, spleen or liver lacerations
that were bleeding at the time of
laparotomy and required therapy
(packing, suturing, splenectomy,
partial hepatectomy) to stop the
bleeding and mesenteric injuries. A
negative laparotomy included:
Table 1. Results in 52 Patients Who
Underwent Diagnostic Peritoneal Lavage
(DPL)
Result
DPL negative
Standard criteria
Qualitative method (no cell
count)
DPL positive
Gross examination
Erythrocyte count >
100 00 0/m m 3

spleen or liver laceration not bleed
ing at the time of laparotomy,
small-bowel, large-bowel and mes
enteric contusions, and hematomas
not requiring exploration or evacua
tion.
We used the standard criteria to
interpret a DPL: positive — aspira
tion of gross blood, discharge of
lavage fluid through Foley catheter
or chest tube, grossly bloody lavage
return, erythrocytes more than
100 000/mm 3 (0.1 X 1012/L ), leu
kocytes more than 500/m m 3 (0.5
X 109/L); negative — erythrocytes
less than 100 000/m m 3, leukocytes
less than 500/mm3.9
The hospital course of the pa
tients was followed in all cases.
Differences between groups were
compared by means of Student’s
t-test.

Findings
The male-to-female ratio was 3:1.
Most of our patients were under 35
years of age (mean ± standard
error, 33.15 ± 2.06).
Fifty of the patients had been
involved in motor-vehicle accidents.
The lavage was performed in the
emergency department in 39 pa
tients, in the surgical intensive care
unit in 12 and in the operating

Table II. Associated Injuries (% of Patients)
Thoracic

Head and neck

Pelvis and
extremity

DPL negative
DPL positive

61
76

52
41

39
31

Total

69

46

35

Group

Table III. Hemodynamic Status of Patients

Number
23
11
12
29
27
2

room, preceding a craniotomy, in
one patient.
The indications for this proce
dure followed the recommendations
of the American College of Sur
geons: altered sensorium (52%),
equivocal abdominal signs (38%)
and major thoracic injuries (30%).
Only one complication with the
technique was reported: a blood
transfusion was accidentally infused
into the peritoneal cavity.
Our results are summarized in
Table I. Twenty-three patients had a
negative DPL. In 12 of these pa
tients no cell count was reported on
the chart. Twenty-seven of the la
vages were considered as grossly
positive (5 to 10 mL of blood on
aspiration) with only two being con
sidered positive as a result of the
blood cell count.
Thoracic injuries were present in
69%, head and neck injuries in 46%
and pelvic and extremity injuries in
35% of the patients (Table II). The
difference in the frequency of these
associated injuries, between positive
and negative lavages, was not sig
nificant.
With respect to hemodynamic
status at the time of the DPL, there
was no statistical difference in the
positive and negative lavage groups
when comparing patients having
class I to class IV shock (Table III).

Shock class*

DPL positive

DPL negative

I
II
III
IV

10
8
5
6

10
6
4
3

29

23

Total
‘ American College of Surgeons’ classification.
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organs more frequently affected
(Table IV). Only one patient was
considered to have a negative celi
otomy when a small retroperitoneal
hematoma was found without other
intra-abdominal injury. Twelve of
the patients having laparotomy had
a good outcome and 7 died. Five of
these deaths were directly related to
the severity of the abdominal injury,
one was secondary to severe brain
injury and the other to bilateral
necrotizing pneumonia.
Ten patients with a positive DPL
were initially managed non-operatively. Six of them underwent addi
tional diagnostic procedures: four
had ultrasonography; three had
computed tomography of the abdo
men; two had liver-spleen scan
ning; and one had intravenous pye
lography. These procedures con
firmed an intra-abdominal injury in
four patients — liver contusion,
kidney contusion, spleen laceration
and diaphragmatic rupture. The pa
tient with diaphragmatic rupture
had an elective laparotomy 14 days
after trauma to repair the tear.
Two of the patients who were
managed without laparotomy died:
one secondary to aspiration pneu
monia and the other as a result of
pulmonary embolism. The other pa
tients recovered from their injuries
without incident.
Table V compares the ISS and
shock classification of the patients
with positive DPL managed by im
mediate laparotomy with those ma

The ISS was 16.78 ± 2.15 for
patients having a negative lavage
compared with 21.9 ± 2.31 for
patients a positive lavage (p =
0.119).
Of the 23 patients who had a
negative DPL, 21 were managed
nonoperatively and 2 had a negative
laparotomy. Both presented with
severe head and thoracic injuries
and were classified as having class
IV hemorrhagic shock. One of these
patients had a contused colon and
small bowel with a few seromuscu
lar tears; the other presented with a
large retroperitoneal hematoma.
Nineteen patients with negative la
vage had a favourable outcome.
Three patients without laparotomy
died: two patients died secondary to
head injuries and the other died of
hypovolemic shock as a result of
traumatic rupture of the thoracic
aorta. One patient, in the group
managed by laparotomy, died sec
ondary to acute respiratory distress
syndrome.
Of the 29 patients who had a
positive DPL, 19 (66%) had immedi
ate exploratory laparotomy. As ex
pected the liver and spleen were the
Table IV. Laparotomy Findings in DPL*
Number

Injury
Liver
Spleen
Major vessels
Small bowel
Large bowel

10
7
3
2
2

*18 patients.

Table V. Data in Patients With Positive DPL: 19 Patients Who Underwent Laparotomy and 10
Treated Conservatively
Treatment
Shock class
1
II
III
IV
Mean injury severity score
Standard deviation

Laparotomy

Conservative

4*
5*
4
6

6*
3*
1
0

2 5 .9 5 t
12.51

13.10t
8.01

*p = 0.045.
t p = 0.007.
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naged initially with nonoperative
treatment. The difference in the ISS
was statistically significant (p =
0.007). Class I or class II shock was
found in 90% of the patients treated
conservatively and in 47% of the
patients who had surgery (p =
0.045). Only one (10%) patient ma
naged without immediate laparoto
my was classified as having class III
shock; however, 52% of the pa
tients who underwent laparotomy
had class III or class IV shock.

Discussion
Diagnostic peritoneal lavage is
used in approximately 20% of the
patients admitted to our surgical
intensive care unit with severe blunt
abdominal trauma. This rate is con
siderably lower than that in other
hospitals (approximately 60%).3
Most of the trauma literature
recommends immediate exploratory
laparotomy when a positive perito
neal lavage is found after abdominal
blunt trauma. It is surprising that
the management of 10 of our pa
tients who had grossly positive peri
toneal lavage did not include imme
diate surgery. Our results indicate
that the management of a patient
with a positive lavage does not
necessarily include laparotomy.
Eight of these 10 patients recovered
in spite of a positive lavage. The
other two died of causes unrelated
to their intra-abdominal injuries.
These patients were analysed
carefully, and no complication due
to the DPL or infusion of blood into
the peritoneal cavity was found.
The indications for doing the proce
dure were similar for the patients
treated conservatively and the pa
tients who underwent laparotomy.
Pelvic fractures, an important cause
of false-positive lavage,9 were dis
tributed equally between the groups
treated nonoperatively and with im
mediate laparotomy.

DIAGNOSTIC PERITONEAL LAVAGE

Additional diagnostic procedures
seem to be helpful, as indicated by
our results. The patient who had a
delayed laparotomy for diaphrag
matic tear was identified by one of
these procedures.
Patients with a positive lavage
managed initially without a laparot
omy were significantly more stable
(p = 0.045, when comparing those
in shock classes I and II) and had a
significantly (p = 0.007) lower ISS
score than those who had immedi
ate surgery. If the hemodynamic
status is relatively stable and there
are no other systems requiring op
eration, these results support an
initial nonoperative approach to cer
tain patients who sustain blunt ab
dominal trauma but have a positive
DPL.
Most of the literature advocating
immediate surgery after a positive
peritoneal lavage comes from cen
tres that manage a great volume of
trauma cases, where it would not be
possible to observe many of the
patients who are found to be stable
after initial resuscitation. However,
initial nonoperative management of
patients suffering blunt abdominal
trauma has recently been reported10
and compared to immediate laparot
omy, with no difference in the out
come in spite of a positive peritone
al lavage.
The Montreal General Hospital is

considered a tertiary care centre;
however, the volume of trauma
seen at our hospital is much lower
than the volume seen at centres
that have been producing most of
the trauma literature. This smaller
volume of trauma, which is com
mon to many hospitals in North
America, allows for more time and
facilities to accommodate selective
conservative management of the
trauma patient.
Our data suggest that a positive
peritoneal lavage should not be con
sidered a sine qua non for laparoto
my in every patient with blunt trau
ma, especially if the patient is hemodynamically stable with no major
injury to other systems. The use of
additional diagnostic tools should
be part of the initial assessment of
these patients. If conservative man
agement is chosen it should be
done in the intensive care unit.
Diagnostic peritoneal lavage is
still one of the most useful diagnos
tic procedures for the management
of the patient with blunt abdominal
trauma. The results can be selec
tively interpreted and treatment in
dividualized, so that not all patients
with a positive peritoneal tap are
necessarily subjected to laparotomy.
This must be done cautiously, and
the factors that allow this individu
alization should be studied prospec
tively.
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Long-Term Results After Omental Patch
Repair in Patients With Perforated
Duodenal Ulcers: a 5- to 10-Year
Follow-up Study
Ralph L. George, MD; Ian F. Smith, MD, FRCSC
Ninety-two patients with perforated duodenal ulcers were treated at two hospitals in
St. John’s. Five patients were managed conservatively, and the remainder received
omental patch closure. All were prescribed histamine receptor antagonists. No
patient had a definitive ulcer operation.
Seventy-five patients were followed up for 5 to 10 years. Fourteen patients who
had been taking ulcerogenic medications had a low recurrence rate (7%); the other
61 patients who had not been taking ulcerogenic medications had a high recurrence
rate (77%).
Use of an omental patch is effective treatment for perforated duodenal ulcers and
provides long-term benefit for patients whose perforations are associated with
ulcerogenic medications. Selected patients who have not been taking ulcerogenic
medication are better treated by definitive ulcer surgery at the time of perforation.

Quatre-vingt-douze patients souffrant d’ulcere duodenal perfore ont ete traites dans
deux hopitaux de St-Jean. Cinq patients furent traites de fa$on conservatrice, les
autres faisant uniquement l’objet d’une fermeture par plaque epiploi'que. Tous les
patients re^urent une ordonnance d’antagonistes des recepteurs histaminiques.
Aucun patient ne subit une operation classique pour ulcere.
Soixante-quinze patients furent suivis pendant 5 a 10 ans. Quatorze patients
qui avaient re?u des medicaments ulcerogenes ont presente un faible taux de
recidives (7 %). Les 61 autres patients qui n’avaient pas pris de medicaments
ulcerogenes ont eu un taux eleve (77 %) de recidives.
L’emploi d’une plaque epiploi'que constitue un traitement efficace de l’ulcere
duodenal perfore et il offre des resultats de longue duree aux patients dont la
perforation est reliee a la prise de medicaments ulcerogenes. Pour certains patients
qui n’ont pas pris de medicaments ulcerogenes, il est preferable de traiter par
chirurgie definitive de l’ulcere, au moment ou survient la perforation.
ith the advent of histamine
receptor antagonists and,
more recently, proton pump inhibi
tors, the role of surgery in duodenal
ulcer disease has changed marked

W

ly. Gustavsson and Nyren1 recently
documented the declining incidence
of elective surgery for duodenal
ulcer disease. However, Bardham
and colleagues2 in 1989 were un
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able to demonstrate a correspond
ing decrease in the complications
(perforation and hemorrhage) of du
odenal ulceration, and Christensen,
Bousfield and Christiansen3 found
no change in the rate of emergency
operations for gastroduodenal dis
ease. The last two studies show that
perforated duodenal ulcers are still
a serious problem.
Although the perforation rates
remain static, the demographics
have changed. Once seen predomi
nantly in younger men, perforations
are seen increasingly in older peo
ple, with the malerfemale ratio ap
proaching unity in some series.1-4
This change has been linked to the
increased use of ulcerogenic antiarthritic medications in the elder
ly.3-4
The optimal management of a
perforated duodenal ulcer is contro
versial. Crofts and colleagues5 have
advocated a trial of nonoperative
treatment and careful observation in
people under 70 years of age. Berne
and Donovan6 favoured a similar
approach in selected patients, and
Bornman and colleagues7 recently
supported simple patch closure.
Definitive ulcer operations also
have their proponents, with Jordon
and Morrow8 and Boey and associ
ates9 suggesting patch closure and
parietal cell vagotomy.
Because of these advances in
management and the options in
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treatment, we undertook a 5- to
10-year follow-up review of patients
treated for a perforated duodenal
ulcer at two hospitals in St. John’s
to assess the efficacy of omental
patching in terms of operative mor
tality, reoperation rate and ongoing
symptoms in those who were taking
ulcerogenic medications at the time
of perforation and those who were
not.

Patients and Methods
By reviewing medical record
codes for peptic ulcer disease we
identified 92 patients who, between
1977 and 1985, suffered a perforat
ed duodenal ulcer. These patients
were treated at Grace General Hos
pital and The General Hospital in
St. John’s. Each perforation had
been confirmed at laparotomy or by
radiographic contrast study. The
charts of these 92 patients were
reviewed, and the variables of age,
operation, complications, mortality,
hospital stay and use of ulcerogenic
drugs were recorded. All patients
were released on histamine receptor
antagonists.
Patients were contacted by phone
5 to 10 years postoperatively and
were asked four questions requiring
a yes or no response:
• Have you had an ulcer opera
tion since the original perforation?
• Have you been hospitalized
for complications of duodenal ulcer
since the original perforation?
• Have you undergone subse
quent radiographic or endoscopic
follow-up?
• Are you now taking prescrip
tion antiulcer medications to con
trol your symptoms?
Analysis of differences found was
performed with the Epistat statisti
cal software package (Tracy Gustafsson, Round Rock, Tex.) and
included descriptive statistics, Fish
er’s exact test and Student’s f-test.
448

JCC, VOL. 34, N ° 5, OCTOBRE 1991

Results
The original 92 patients had an
average age of 52 years (range from
16 to 94 years). Eighty-seven were
treated by omental patch closure.
Five patients with a delayed presen
tation or a late diagnosis were ma
naged without an operation.
The death rate overall was 8.7%
(eight patients) and the mean age of
the patients who died was 87 years.
Of the 75 survivors, in whom fol
low-up was complete, 14 patients
were on ulcerogenic medications at
the time of perforation (group 1),
and 61 patients were not (group 2).
The responses of these patients to
the telephone interview are shown
in Table 1, and analysis of the
differences is shown in Table II.
Patients in group 1 were found
to be significantly (p = 0.0001,
Student’s f-test) older than those
in group 2. Likewise, the death rate
was significantly (p = 0.036, Fish
er’s exact test) higher for those in
group 1. In contrast, no patients in
group 1 required reoperation for
recurrence, but 16 (26%) patients in
group 2 required reoperation; there

was a significant (p = 0.000046,
Fisher’s exact test) difference be
tween those in group 1 and those in
group 2 with respect to ongoing
disease requiring reoperation, hos
pital admission for bleeding or
other complications, or still requir
ing prescription medical therapy —
7.1% for group 1 patients and 77%
for group 2 patients. Only one
patient in group 1 had ongoing
problems.

Discussion
Patients who suffered an acute
perforation of the duodenum in
conjunction with the use of ulcero
genic medications fared extremely
well with a simple omental patch
closure. It proved quick and effec
tive in this group of patients, who
were older and higher operative
risks.
The 77% recurrence rate among
those not on ulcerogenic medica
tions (group 2) after 5- to 10-year
follow-up suggests that these pa
tients have a virulent ulcer disease.
A definitive ulcer operation at the

Table 1. Response to Telephone Interview of 75 Patients 5 to 10 Years After Treatment of a
Perforated Duodenal Ulcer by Omental Patching
Response
Required reoperation
Required rehospitalization
without reoperation
Underwent radiography or endoscopy
Now on prescription antiulcer
medication

Group 1*
(n = 14)

Group 2 t
(n= 6 1 )

0

16

1
1

7
27

1

31

’ Patients who were taking ulcerogenic medications at the time of perforation.
tPatients who were not taking ulcerogenic medications at the tim e of perforation.

Table II. Differences Between Patients Who Were Taking Ulcerogenic Medications at the Time of
Perforation and Those Who Were Not
Group 1
(r» = 1 4 )
Mean age, yr
Mortality, %
Reoperation, %
Ongoing disease, %
(5 -1 0 -y r follow -up)

72
29
0
7.1

Group 2
(n = 61)

/rvalue

47
6.3
26

0.0001
0.036

77

0.00046

OMENTAL PATCH FOR PERFORATED ULCERS

NOTICES
AVIS
Quebec Association of Urologists

time of laparotomy for perforation
is preferable for them, providing it
can be performed with no increase
in death rate, with minimal side
effects and with a low recurrence
rate.
Irvin,10 Ball, Thomas and Evan11
and Svanes and associates12 have
identified delayed presentation,
shock, concurrent illnesses and ad
vanced age as risk factors for post
operative death in perforated duode
nal ulcer patients. Low-risk patients
can be selected, and in the experi
ence of Boey and colleagues,1314 as
well as in a randomized trial of 162
patients by Hay and colleagues,15
definitive ulcer surgery can be per
formed for a perforated duodenal
ulcer without increasing the death
rate and with minimal side effects.
Our data show that 77% of pa
tients who suffer perforation of a
duodenal ulcer and who are not on
ulcerogenic medications experience
continued or recurrent symptoms
after omental patching. We sug
gest, therefore, that such patients
should undergo definitive surgery,
provided that they are under 70
years old, have no intercurrent dis
ease, have no shock on presentation
and that there is no major contami
nation at the time of laparotomy.
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Hepatic and Biliary Disease
The 2nd annual symposium on hepatic
and biliary disease will be held at the
Rush-Presbyterian-St. Luke’s Medical
Center, Chicago on Nov. 1, 1991. The
discussion and presentation format will
focus on current issues in the manage
ment and treatment of patients with
liver disease. CME credit applied for.
Registration fee: $150 (US). For further
information contact: Suzanne Buss,
Physician relations coordinator, Rush
Liver Transplant Program, Rush-Presbyterian-St. Luke’s Medical Center,
1653 W Congress Parkway, Chicago,
IL 60612; phone (312) 942-6242.

Management of Cranial Base Dis
eases
The Multidisciplinary Panel on Skull
Base Diseases, University of California
School of Medicine, San Francisco, Ca
lif., is presenting a postgraduate course
on the management of cranial base
diseases on Nov. 10, 1991, at the
Ritz-Carlton Hotel, San Francisco, Ca
lif. This course will provide a compre
hensive review of contemporary man
agement of cranial base diseases for
neurosurgeons, otolaryngologists, radi
ation oncologists and reconstructive
surgeons. Course directors are Drs.
P.H. Gutin, R.K. Jackler and L.H. Pitts.
For further information contact: Ex
tended Programs in Medical Education,
Rm. LS-105, University of California
School of Medicine, San Francisco, CA
94143-0742; phone (415) 476-4 2 5 1 .
continued on page 476
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Abdominal Wall Actinomycosis
Associated With Use of an Intrauterine
Device: a Case Report
Gary Groot, MD, FRCSC; Leonard Rivers, MD, FACS, FRCSC; Thirza Smith, MD, FRCSC;
Peter Urbanski, MD; Carol Boyle, MD
The association between pelvic actinomycosis and the use of intrauterine devices is
well established. However, abdominal wall actinomycosis without clinical
involvement of the pelvic organs has been reported only once in the literature. The
authors present a second case, which occurred in a 24-year-old woman who was
using a copper 7 intrauterine device.

L’association entre l’actinomycose pelvienne et Tutilisation du sterilet est maintenant bien reconnu. Cependant, une actinomycose de la paroi abdominale sans
atteinte des organes pelviens n’a ete signalee qu’une seule fois dans la litterature.
Les auteurs decrivent un second cas qui fut observe chez une femme de 24 ans qui
utilisait un sterilet Copper 7.

he association between pelvic
actinomycosis and the use of
intrauterine devices is now well es
tablished.1"9 The majority of pa
tients have colonization only, but a
small number will have invasive
disease. Only a few cases of primary
abdominal wall actinomycosis10"14
and only one case of isolated ab
dominal wall actinomycosis associ
ated with an intrauterine device
have been reported.1 We report a
second such case.

T

Case Report
A 24-year-old white woman, para
2 -0 -0 -2 , was seen complaining of
lower abdominal pain and some dysuria, urgency and frequency. No

other complaints were elicited. A
large tender mass was palpable in
the left lower quadrant, but there
was no guarding or rebound. On
pelvic examination the mass ap
peared to be separate from the
uterus and left ovary.
She had undergone treatment for
a right salpingitis, diagnosed by
laparoscopy, in 1982. This had re
solved, and in 1983 she had had an
intrauterine device inserted. Be
cause of bleeding and cramping, the
intrauterine device was removed
after 2 months. Between 1983 and
1985 she had had two children,
each delivered by cesarean section.
After the second delivery she again
had an intrauterine device (a copper
7) inserted, which remained in place
until this admission. She had been
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well until just before the time of
presentation.
She was afebrile when admitted
to hospital and had a leukocyte
count of 8.9 X 109/L . Ultrasonog
raphy showed a complex mass,
measuring 7 X 2.5 X 6.2 cm in the
left lower quadrant of the abdomen
and some free fluid in the pelvis.
The mass was separate from the
uterus and from the left ovary and
tube. The right ovary and tube were
not well seen.
Before any further investigations
could be carried out, diffuse abdom
inal pain with guarding and re
bound tenderness developed, and
her temperature spiked to 39.1°C.
At laparotomy the patient was
found to have an anterior abdomi
nal wall abscess, and there was free
pus within the abdomen. The omen
tum was adherent to the anterior
abdominal wall, to the left of the
midline and just cephalad to the
bladder. Cultures were taken and
the involved omentum was resected.
The inflamed omentum had been
loosely adherent to the sigmoid co
lon, but no communication with the
bowel was identified. The uterus,
ovaries and tubes were not involved
with the inflammatory process and
appeared normal. The appendix
contained a fecolith but was not
inflamed, nor was it involved in the
abscess.
Since there was no obvious
source for the infection, the abdo
men was irrigated, an appendecto
my performed and the wound

ACTINOMYCOSIS AND INTRAUTERINE DEVICE

closed. The patient was placed on
ampicillin, gentamicin and met
ronidazole postoperatively. The cul
tures taken intraoperatively grew
Staphylococcus haemolyticus and
Streptococcus, bovis-group. Histo
logic examination of the omentum
demonstrated a sulfur granule, the
typical actinomycetic picture of
gram-positive filamentous bacteria
within the mass and club-like exten
sions beyond the periphery of the
mass. The intrauterine device was
removed, and she was started on
penicillin G. All cultures failed to
grow Actinomyces.

Discussion
The association between the use
of intrauterine devices and pelvic
actinomycosis was demonstrated by
Brenner and Gehring in 196715 and
Henderson3 who, in 1973, reported
a tubo-ovarian abscess due to Acti
nomyces bovis in a 38-year-old
woman using an intrauterine device.
In 1976 Gupta, Hollander and
Frost16 identified, for the first time,
actinomycosis in cervicovaginal
smears of 17 women wearing an
intrauterine device. This was later
confirmed in a 1978 study8 of 350
pancervicovaginal smears in in
trauterine-device users. Since then
numerous reports in the literature
have confirmed this association.17-22
In 1981 Pine and associates,23
using the fluorescent antibody tech
nique, detected Actinomyces in the
vaginal flora of a woman not using
an intrauterine device. In their
study it is unclear whether the
patient had previously worn an in
trauterine device or had a history of
any other foreign body. Their ob
servations have not been confirmed,
and most investigators believe that
the organism becomes a part of the
vaginal or cervical flora only in the
presence of a foreign body, usually
an intrauterine device.1'26816

Most cases of actinomycosis as
sociated with use of the intrauterine
device are of simple colonization.8
Endometritis or salpingitis may
occur and present with abdominal
pain.68 Less commonly, a tuboovarian abscess associated with ac
tinomycosis has been reported.2-4'6"9
A few cases of pelvic and abdominal
wall abscesses have also been re
ported.2'5 However, only one other
case of isolated abdominal wall ab
scess and intrauterine device use
has been reported.1 In 1985 Adachi
and associates1 described a
39-year-old para 4 -0 -1 -4 woman
who had an isolated anterior ab
dominal wall abscess caused by Ac
tinomyces. She had worn an intra
uterine device for 7 years. Coloniza
tion of the endometrium with Acti
nomyces was documented in an
endometrial curettage. At laparoto
my the patient was noted to have
grossly normal fallopian tubes, ova
ries, appendix, omentum, and small
and large intestines.
Although it is unclear exactly
how the Actinomyces gained access
to the anterior abdominal wall in
our patient, it may be associated
with the use of the intrauterine
device. It is proven1’9 that pelvic
infections caused by Actinomyces
occur after colonization of the geni
tal tract of women who use intra
uterine devices. The gastrointestinal
tract is not likely the source of the
Actinomyces in this patient, be
cause no disease of the small or
large intestines was identified at
laparotomy. Since histopathologic
examination of the appendix re
vealed no inflammation, that also
was unlikely to have been the
source of the Actinomyces.
Actinomycosis is caused by a
gram-positive filamentous bacteria
and appears to be a cooperative
disease of Actinomyces and a mixed
flora of other bacteria. These or
ganisms live a parasitic existence as
nonpathogens in the mucous mem

branes of the oral cavity and ali
mentary tract, but outside these
sites they are pathologic and result
in chronic indolent infections.
The generally accepted treatment
for actinomycosis is long-term (12
to 18 months) treatment with oral
penicillin (2 to 15 million units
daily) after an initial period of intra
venous penicillin G therapy. When
abscess is present, it is necessary to
treat the usual associated mixed
infection.24
This case illustrates that abdomi
nal wall actinomycosis may occur in
intrauterine device users without
the pelvic organs being clinically
involved. Although obviously a rare
event, this possibility needs to be
considered when treating intra
abdominal abscesses in young intra
uterine device users when no other
identifiable cause is evident.
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Postoperative Heterotopic Ossification
in Children: a Comparison of Children
With Spina Bifida and With Cerebral Palsy
Jacques Bouchard, MD, FRCSC;* Jacques D’Astous, MD, FRCSCt
The authors reviewed 250 consecutive myotomies and tenotomies performed on the
hips of 186 children. Two groups were studied: 162 children with cerebral palsy and
24 children with spina bifida. In total 19 children were found to have heterotopic
ossification postoperatively. The incidence of heterotopic ossification was 21% in the
spina bifida group and 8.6% in the cerebral palsy group. The most severe cases were
in children with thoracic myelomeningocele. Only one child with lumbar
myelomeningocele had ossification, and it was mild. This difference was statistically
significant. Two children with thoracic spina bifida had severe ossification and
abduction contractures requiring resection of the bony mass. Recurrence was
successfully prevented by a course of radiotherapy.

Les auteurs ont etudie 250 myotomies et tenotomies consecutives, pratiquees sur les
hanches de 186 enfants. Deux groupes furent etudies: 162 enfants souffrant de
paralysie cerebrale et 24'enfants ayant un spina bifida. Au total, on a decouvert une
ossification heterotopique postoperatoire chez 19 enfants. L’incidence des ossifica
tions heterotopiques a ete de 21 %dans le groupe spina bifida et de 8,6 %dans le
groupe paralysie cerebrale. Les cas les plus graves ont ete observes chez les enfants
souffrant de myelomeningocele thoracique. Seulement un enfant porteur d’un
myelomeningocele lombaire a souffert d’ossification, et celle-ci etait benigne. La
difference observee est statistiquement significative. Deux enfants avec un spina
bifida thoracique ont eu une ossification grave avec contractures d’abduction
necessitant la resection de la masse osseuse. La recidive a pu etre evitee grace a la
radiotherapie.

eriarticular soft-tissue calcifica
tion can be classified into two
causes: systemic factors and local
factors. It has been shown that
burns,12 neurologic insults, such as
polio,3 head injuries,4-7 and trau
matic paraplegia,8-11 as well as nu

P

merous rheumatologic conditions
may result in an increased incidence
of soft-tissue ossification. Local tis
sue damage during total hip re
placement,12-15 open reduction and
internal fixation of acetabular frac
tures, and open reduction of con
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genitally dislocated hips16 have re
sulted in heterotopic ossification.
To our knowledge, this problem has
not been described following softtissue procedures around the hip in
children with nonprogressive neuro
logic diseases.
The purpose of this study was to
analyse cerebral palsy and spina
bifida patients with respect to the
following: the incidence of postop
erative heterotopic ossification after
tenotomy and myotomy around the
hip; the clinical relevance of hetero
topic ossification; and the associat
ed factors.

Patients and Methods
Charts, radiographs and range of
motion data on 250 consecutive
myotomies and tenotomies of the
hips performed at the Children’s
Hospital of Eastern Ontario in Otta
wa between 1977 and 1986 were
reviewed. There was sufficient doc
umentation on 186 children for
them to be included in the study.
All the children were followed up at
the hospital and at the children’s
treatment centre at regular intervals
by therapists, pediatricians and or
thopedic surgeons. The range of
motion of all joints in the lower
limb was recorded by the surgeons
at every visit. Radiographs were
obtained at 3- to 6-month intervals
pre- and postoperatively.
Statistical analysis was performed

POSTOPERATIVE HETEROTOPIC OSSIFICATION

by independent consultants from
the University of Ottawa, Depart
ment of Epidemiology.
Cerebral palsy was the most com
mon diagnosis (162 children) fol
lowed by spina bifida (24 children).
Ten children were excluded because
of their neurologic diagnosis (cere
bral dysgenesis in 3, MerzbacherPerlizaeus disease in 2. and spinal
muscular atrophy, congenital ky
phosis and paraplegia, poliomyelitis,
tetrasomy 21 and intraventricular
teratoma in 1 each).
Indications for surgery were par
alytic hip subluxation or dislocation
in 114 cases, correction of contrac
tures in 53 and improvement of gait
in 19.

Results
Heterotopic ossification was
found in 19 patients postoperatively
— in 21% of children with spina
bifida and in 8.6% of children with
cerebral palsy (p < 0.053, relative
risk 2.52 [range from 1.00 to
6.33]). This difference was not sta
tistically different because of the
small number of children in the
spina bifida group.
The three most severe cases of
heterotopic ossification were in chil
dren who had a thoracic myelo
meningocele, and only one child

FIG. 1. Anteroposterior view of hips of
11-year-old girl with thoracic spina
bifida 4 years after myotomies and
tenotomies. She required resection of
bony mass and radiotherapy to prevent
recurrence.

who had a lumbar myelomenin
gocele was so affected. This differ
ence was highly significant (p <
0.005). Two children with thoracic
spina bifida suffered severe ossifica
tion and abduction contractures re
quiring resection of the bony mass
(Figs. 1 and 2). Histologically, welltrabeculated woven bone was seen
within the soft tissues. Recurrence
was successfully prevented by a
course of radiotherapy.
The radiographic appearance var
ied from faint calcification around
the hip capsule to marked diffuse
ankylosis of the joint. Five patterns
of calcification emerged: psoas
sheath (eight children); rectus femoris (two children); gluteal region
(two children); hip capsule (two
children); and diffuse (three chil
dren). Psoas sheath calcifications
(Fig. 3) were the most common; in
all these cases the psoas had been
released close to its insertion on the
lesser trochanter. Children with ce
rebral palsy generally had Brooker
class I or II ossification,12 whereas

FIG. 2. Anteroposterior view of hip of
10-year-old boy with low thoracic
spina bifida 2 years after myotomies of
psoas, abductor and proximal ham
string muscles and anterior capsule.
Severe ossification and abduction con
tractures necessitated resection of
bony mass.

children with spina bifida were more
likely to show a higher ossification
grade (Fig. 4).
The clinical course in 60% of the
children with heterotopic ossifica
tion was uncomplicated. Four chil
dren had prolonged pain, two had
slow return to their preoperative
level of function, two had decreas
ing range of motion postoperatively
and two required resection of hete
rotopic bone. Excessive pain and
slow return of function were subjec
tive observations that could not be
correlated directly to the presence
of heterotopic ossification. Howev
er, no other causes were found to
explain these observations.

Discussion
The occurrence of postoperative
heterotopic ossification in children
with cerebral palsy does not have

FIG. 3. (Top) Anteroposterior view
showing bilateral ossification in psoas
region in 2-year-old boy with severe
spastic quadriplegia 6 months after hip
flexor, abductor and proximal ham
string releases. (Bottom) Anteropost
erior view 16 months postoperatively.
Child was clinically asymptomatic.
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significant clinical implications. Its
presence in about 9% of patients is
a radiologic finding and does not
influence the results of the myoto
mies and tenotomies. The incidence
is similar to that in the study of
Garland, Blum and Waters4 on
head-injured adults in which 11% of
patients had periarticular heterotop
ic ossification. Similar reports on
children are sparse. There is no
comparable group of patients. Koragjozi16 reported a 24% incidence
of heterotopic ossification after
open reduction of congenitally dis
located hips; however, the children
in that study were neurologically
normal.
Children with spina bifida do not
fare as well after myotomies and
tenotomies of the hip. Those partic
ularly at risk are children with high
or thoracic spina bifida. The majori
ty of them have severe ossification,
which leads to ankylosis of the hip.
This produces unacceptable results
and exposes the child to the need
for further corrective surgery and
radiotherapy. The reasons for this
group being at higher risk are un
clear. Associated factors may be a
more extensive soft-tissue proce
dure required, nonambulatory sed
entary patients or urinary tract bacteriuria. These factors need to be

addressed specifically in further
studies.
Two patients who required surgi
cal resection of heterotopic bone
had recurrence prevented by a
course of low-dose radiotherapy (10
Gy). The use of radiotherapy in
these cases is effective but should
be used with discretion because the
long-term effect of low-dose radio
therapy is unknown. Although not
used in our patients, an effective,
safe and readily available alternative
is to use a prostaglandin inhibitor
such as indomethacin perioperatively in high-risk children.
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Liver Transplantation With Calcific
Sclerosis of the Portal Vein
Mark A. Hoffman, MS, MD, FRCSC;*t Lisa A. Planeta, MD;* Richard J. Rohrer, MD, FACS*
Thrombosis or phlebosclerosis of the portal vein is an infrequent finding during the
preoperative evaluation of a potential liver transplant recipient. Occasionally the
process extends proximally into the superior mesenteric vein. This precludes
conventional methods of portal venous reconstruction, necessitating reconstitution
of portal venous inflow during liver transplantation through a venous conduit. The
authors present a case of calcific phlebosclerosis of the portal and distal superior
mesenteric veins that was delineated during preoperative imaging. This case
emphasizes the importance of visualizing both the portal and superior mesenteric
veins during the preoperative assessment, when patency of the portal vein is
questionable. When the obliterative process extends into the distal superior
mesenteric vein the authors recommend construction of the venous conduit from the
proximal superior mesenteric vein as a pre-emptive manoeuvre before dissection of
the recipient’s liver and hilar structures. The venous conduit is then ready for
immediate use during engraftment, thereby maintaining the shortest possible
anhepatic time.
La thrombose ou la phlebosclerose de la veine porte est une observation rare de
l’evalution preoperatoire en vue d’une transplantation hepatique. Parfois, l’anomalie
s’etend de fa^on proximale dans la veine mesenterique superieure, empechant les
methodes classiques de reconstruction de la veine porte et necessitant la reconstitu
tion d’un apport veineux durant la greffe hepatique, a l’aide d’un conduit veineux.
Les auteurs decrivent un cas de phlebosclerose calcifiante de la veine porte et de la
mesenterique superieure qui fut decouvert aux examens de visualisation preoperatoires. Ce cas met en evidence l’importance de visualiser aussi bien la veine porte,
que la mesenterique superieure au cours de 1’evaluation preoperatoire, lorsqu’on
doute de la permeabilite de la veine porte. Quand l’obliteration s’etend jusque dans
la partie distale de la mesenterique superieure, les auteurs recommandent la
construction d’un conduit veineux a partir du bout proximal de la mesenterique
superieure comme manoeuvre preparatoire a la dissection du foie et des structures
hilaires du receveur. Le conduit veineux est alors pret pour usage immediat lors de
la pose de la greffe, reduisant ainsi au minimum la periode d’absence de fonction
hepatique.

he status of the portal vein is a
central consideration in the
preoperative assessment of patients
with advanced liver disease for pos
sible liver transplantation. Phlebos
clerosis, calcification and frank

T

thrombosis of the portal vein, al
though not absolute contraindica
tions to liver replacement, portend a
difficult and technically challenging
operation and necessitate innovative
manoeuvres to establish adequate
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portal venous inflow. Although
tracking of the recipient portal vein
back to the confluence of the sple
nic and superior mesenteric veins
beneath the superior aspect of the
pancreas is usually successful, this
manoeuvre does not always yield a
recipient vessel suitable for an anas
tomosis. In that case a vascular
conduit must be used from a more
proximal portion of the recipient’s
superior mesenteric vein to the
donor portal vein. Sclerosis of the
portal vein is frequently discovered
during the anhepatic phase, when
the portal structures are divided to
facilitate dissection of the portal
vein toward the pancreas.
We present a patient with ad
vanced alcoholic cirrhosis, hepa
torenal syndrome and marked cal
cific phlebosclerosis of the portal
vein extending into the distal seg
ment of the superior mesenteric
vein. Effective preoperative venous
visualization was accomplished with
Doppler ultrasonography, computed
tomography (CT) and magnetic res
onance imaging (MRI). Diminished
renal function precluded arteriogra
phy. Our operative approach to this
patient emphasizes the importance
of visualizing the superior mesen
teric and portal veins during preop
erative assessment, when the paten
cy or suitability of the recipient’s
portal vein is in doubt.

Case Report
This 62-year-old man drank heav
ily until 1982. Over the ensuing 6
years, his liver function gradually
deteriorated despite abstinence from
CJS, VOL. 34. NO. 5, OCTOBER 1991
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FIG. 1. Computed tomography scan without contrast demonstrating calcification of
portal vein wall (arrowhead) beneath head of pancreas.

FIG. 2. Magnetic resonance imaging with enhancement showing patency of
superior mesenteric vein (arrow).
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alcohol, and at the time of referral
for liver transplantation, he had
profound nutritional wasting,
marked ascites and nonoliguric
renal failure. Coagulation parame
ters were normal. Doppler ul
trasonography of the portal vein
revealed a vessel 5 mm in diameter
with hepatofugal blood flow. Com
puted tomography (Fig. 1) con
firmed the Doppler findings and
further delineated calcification of
the portal vein wall, extending into
the distal segment of the superior
mesenteric vein. Magnetic reso
nance imaging with enhancement
demonstrated that the proximal
wall of the superior mesenteric vein
was of good quality, with a diame
ter of 1 cm (Fig. 2). The portal vein
was 5 mm in diameter and heavily
calcified but broadened to 1 cm in
diameter just proximal its conflu
ence with the splenic vein. Severe
renal dysfunction precluded angiog
raphy.
Liver transplantation was per
formed on Nov. 21, 1989. Donor
vascular anatomy was normal. At
the time of liver procurement, long
segments of both iliac veins were
removed for portal venous recon
struction. These were joined on the
back table using 6-0 Prolene su
ture, and all side branches were
secured, yielding a venous graft 10
cm long.
The recipient operation began
with isolation of the superior mes
enteric vein at the ro,ot of the
transverse mesocolon in the in
fracolic abdominal compartment
(Fig. 3). Enough vein length and
circumference were exposed to
allow placement of a partially oc
cluding vascular clamp. The vascu
lar conduit was spatulated, and an
end-to-side venovenous anastomosis
was performed with running 6-0
Prolene suture (Fig. 4). A vascular
bulldog clamp was next placed
across the venous conduit, and the
superior mesenteric vein clamp was
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Discussion

removed. The distal end of the
venous graft was tunnelled through
the lesser sac over the pancreas and
under the pylorus to the subhepatic
area (Fig. 5).
Donor hepatectomy proceeded
smoothly, with single-limb venovenous bypass from the femoral to the
axillary vein. The area of the portal
vein was found to be thickened and
fibrous, and no attempt was made
to dissect this area. The portal vein
and surrounding tissues were ligat
ed en masse after the hepatic artery
and common bile duct were freed.
Liver engraftment was performed
by the sequential anastomosis of
the suprahepatic and infrahepatic
vena caval cuffs, followed by the
portal venous anastomosis to the
vein graft. Reperfusion was excel
lent. The arterial and bile-duct anas
tomoses were then completed. Total
anhepatic time (recipient hepatic ar
tery ligation to reperfusion of the
liver graft) was 87 minutes. The
warm ischemic time for the liver
was 45 minutes. The liver graft
demonstrated excellent postopera
tive function. Brisk flow was seen
within the portal vein on postopera
tive Doppler ultrasonography. The
patient was discharged from the
hospital 6 weeks postoperatively
with normal liver function and re
mained well 6 months after trans
plantation.

Marked phlebosclerosis and frank
thrombosis of the portal vein were
once considered contraindications
to liver transplantation.1 Usually,
however, these changes are con
fined to the portal vein itself, and
adequate venous inflow can be es
tablished either by portal-vein
thrombectomy or by an anastomosis
between the donor portal vein and
the confluence of the recipient su
perior mesenteric and splenic veins
just beneath the superior aspect of
the pancreas.2 This may require the
use of a short segment of inter
posed donor iliac vein to bridge the
gap.3
Sclerosis of the portal vein ex
tending into the superior mesenter
ic vein is rare. This is usually
discovered during the anhepatic
phase after the portal structures
have been divided to facilitate dis
section of the portal vein beneath
the pancreas for inspection of the
confluence of the splenic and supe
rior mesenteric veins. A vascular
conduit from a more proximal por
tion of the superior mesenteric vein
must then be constructed,4-5 with
commensurate extension of the an
hepatic period and increased blood
loss.
In the case presented, recognition
of the sclerosis preoperatively al

lowed construction of the venous
conduit pre-emptively before dissec
tion of the recipient liver. This
permitted dissection of the superior
mesenteric vein and fashioning of
the venous conduit in a more re
laxed manner, the patient remaining
physiologically intact without the
threat of marked extension of the
anhepatic phase. In a recent report
Kirsch and associates6 described six
cases of problematic portal venous
disease requiring extra-anatomic re
construction of portal venous in
flow with end-to-side donor iliac
vein conduits from the recipient’s
superior mesenteric vein to the liver
graft portal vein. Their technique
differs from the one we describe in
that they recommend anastomosis
of the iliac vein conduit to the liver
graft portal vein on the “back ta
ble” and subsequently perform the
arterial anastomosis before the con
duit reconstruction of portal venous
inflow. We suggest that our tech
nique offers two theoretical advan
tages: (a) the more difficult of the
venous conduit anastomoses is per
formed with the liver graft protect
ed in the cold ischemic phase of the
procedure, with the native liver still
in-situ. This situation takes full
advantage of whatever hepatic re
serve is present in the recipient’s
liver: (b) once the conduit is fash
ioned and tunnelled into the su-

FIG. 3. Dissection of superior mesen
teric vein (arrow) at root of transverse
mesocolon in infracolic compartment of
abdomen.

FIG. 4. Anastomoses between superior
mesenteric vein and venous conduit
(open arrow) and two segments of
donor iliac vein (closed arrow).

FIG. 5. Completed venous conduit
(closed arrow) traversing tunnel made
through transverse mesocolon (open
arrow).
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INSTAT*

Collagen Absorbable
Hemostat
DESCRIPTION:
INSTAT* Collagen Absorbable Hemostat is a
purified and lyophilized bovine dermal collagen.
The material, prepared as a sponge-like pad, is
lightly cross-linked, sterile, nonpyrogenic, and
absorbable. Hemostatic activity, which is an
inherent property of collagen, is largely dependent
on the basic helical structure of this protein. The
helical structure of native collagen is preserved
during the manufacture of INSTAT Absorbable
Hemostat. When collagen comes into contact with
blood, platelets aggregate on the collagen and
release coagulation factors which, together with
plasma factors, result in the formation of fibrin, and
finally in the formation of a clot.

INDICATIONS:
INSTAT Absorbable Hemostat is indicated in
surgical procedures (other than in neurosurgical,
urological and ophthalmological surgery) for use as
an adjunct to hemostasis when control of bleeding
by ligature or other conventional methods is
ineffective or impractical.

CONTRAINDICATIONS:
INSTAT Absorbable Hemostat should not be used in
the closure of skin incisions as it may interfere with
the healing of skin edges. This interference is due
to simple mechanical interposition of dry collagen
and not due to any intrinsic interference with wound
healing. It has been reported with another
absorbable collagen hemostat that, in filling
porosities of cancellous bone, collagen may reduce
the bonding strength of methylmethacrylate.
Therefore. INSTAT Absorbable Hemostat should not
be applied on bone surfaces to which prosthetic
materials are to be attached with
methylmethacrylate adhesives.

WARNINGS:
INSTAT Absorbable Hemostat is inactivated by
autoclaving. It should not be resterilized. As with
any foreign substance, use in contaminated wounds
may enhance infection.
INSTAT Absorbable Hemostat should not be used in
instances of pumping arterial hemorrhage.
INSTAT Absorbable Hemostat should not be used
where blood or other fluids have pooled or in cases
where the point of hemorrhage is submerged.
INSTAT Absorbable Hemostat will not act as a
tampon or plug in a bleeding site, nor will it close off
an area of blood collecting behind a tampon.
Only the amount of INSTAT Absorbable Hemostat
necessary to provide hemostasis should be used.
The long-term effects of leaving INSTAT Absorbable
Hemostat in situ are unknown. Opened, unused
INSTAT Absorbable Hemostat should be discarded
because it cannot be resterilized.

ADVERSE REACTIONS:
INSTAT Absorbable Hemostat is a collagen product.
Although several types of postoperative
complications were observed in INSTAT Absorbable
Hemostat-treated patients, none were attributed to
INSTAT Absorbable Hemostat except one case of
fibrotic reaction where INSTAT Absorbable
Hemostat involvement could not be ruled out.
Adverse reactions reported for other collagen
hemostats include hematoma, potentiation of
infection, wound dehiscence, inflammation and
edema. Other reported adverse reactions that may
be related to the use of collagen hemostats include
adhesion formation, allergic reaction, foreign body
reaction and subgaleal seroma (in a single case).
The use of microfibrillar collagen in dental extraction
sockets has been reported to increase the incidence
of alveolalgia. The possibility that all of the above
reactions may occur with INSTAT Absorbable
Hemostat cannot be excluded.

ADMINISTRATION:
INSTAT Absorbable Hemostat is applied directly to
the bleeding surface with pressure. INSTAT
Absorbable Hemostat can be cut to size. The
amount needed and the period of time necessary to
apply pressure will vary with the type and amount of
bleeding to be controlled. Hemostasis time depends
upon the type of surgery and degree of pretreatment
bleeding. It usually occurs between 2 to 5 minutes
with INSTAT Absorbable Hemostat.
INSTAT Absorbable Hemostat maintains its integrity
in the presence of blood and is not dispersed when
wet. It is easily removed from the site following
hemostasis. It is most effective when used dry.
INSTAT Absorbable Hemostat may be left in situ
whenever necessary. However, the surgeon, at his
discretion, should remove any excess of INSTAT
Absorbable Hemostat prior to wound closure.
Animal implant studies have demonstrated that
absorption and tissue reaction to INSTAT
Absorbable Hemostat are similar to those observed
with another absorbable collagen hemostatic agent.
In these studies, on visual examination, most of
INSTAT Absorbable Hemostat was found to be
absorbed within 8 to 10 weeks after implantation.

CLINICAL STUDIES:
The safety, effectiveness and handling
characteristics of INSTAT Absorbable Hemostat
were evaluated in a variety of surgical procedures.
The median time to hemostasis for INSTAT
Absorbable Hemostat was 3 minutes. Passive
Hemagglutination Assay (PHA) and Enzyme-Linked
Immunoabsorbent Assay (ELISA) methods have
been used to evaluate the immunologic potential for
INSTAT Absorbable Hemostat to produce
antibodies in patients. These assays revealed mild
elevation of antibody titers in both INSTAT
Absorbable Hemostat-treated patients and patients
treated with a collagen control hemostat, confirming
that INSTAT Absorbable Hemostat, like other
collagen hemostats, is a weak antigen.

PRECAUTIONS:
As with other hemostatic agents, it is not
recommended that INSTAT Absorbable Hemostat
be left in an infected or contaminated space, nor is it
recommended for use in persons known to be
sensitive to materials of bovine origin. When placed
into cavities or closed spaces, care should be
exercised to avoid overpacking INSTAT Absorbable
Hemostat as it may absorb fluid and expand and
press against neighbouring structures.
Safety of this product has not been established in
children and pregnant women. Therefore, INSTAT
Absorbable Hemostat should only be used when
benefit to risk clearly warrants its use.
INSTAT Absorbable Hemostat is not intended to be
used to treat systemic coagulation disorders.

HOW SUPPLIED:
INSTAT Absorbable Hemostat is supplied in a
sponge-like form in peelable plastic envelopes in the
following sizes:
2.5 cm x 5.0 cm (1 in. x 2 in.)
7.5 cm x 10.0 cm (3 in. x 4 in.)
The sterility of the product is guaranteed unless the
individual envelope is damaged or opened.
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pracolic compartment, all anasto
moses can proceed rapidly in rou
tine order. If there is any difficulty
with the arterial anastomosis, it can
be remedied with portal venous in
flow already established.
We conclude that adequate visu
alization of the portal and superior
mesenteric veins is of paramount
importance during the preoperative
assessment of liver transplant recip
ients when the status of the portal
vein is in question. Magnetic reso
nance imaging with enhancement is
extremely useful for this purpose ,7
particularly when arteriography is
contraindicated. If the confluence of
the superior mesenteric and splenic
veins appears unsuitable for anasto
mosis to the donor portal vein, the
venous conduit should be con
structed before any dissection of
the recipient liver or hilar struc
tures to avoid prolonging the anhepatic phase and to utilize the
patient’s small hepatic reserve to
the greatest advantage.
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Inflammatory Pseudotumours
of the Lung: Two Cases and a Review
F.A. Daudi, MD; G.M. Lees, MD, FRCSC; T.E. Higa, MD, FRCPC
A discrete pulmonary mass lesion has different implications in children and in
adults. Although infectious, congenital and metastatic etiologies are part of the
differential diagnosis, inflammatory pseudotumour of the lung, or plasma cell
granuloma, has emerged as the most common entity. The authors describe two
patients with this poorly understood lesion and review the current state of
knowledge. Both patients were young (4 and 5 years) and had recurrent lower
respiratory tract infections; one patient was asthmatic. Both had persistent cough,
and discrete lung lesions were apparent radiologically. Both children were treated
by thoracotomy and excision of the tumour. There were no operative complications,
and the convalescent period was uncomplicated. There were no signs of recurrence
at follow-up 1 and 2 years postoperatively. This lesion is almost always benign, but
aggressive behaviour has been documented. The authors recommend prompt
conservative surgical excision.

Selon qu’il s’agisse d’un enfant ou d’un adulte, la decouverte d’une masse
pulmonaire discrete a des implications differentes. Bien que les etiologies infectieuses, congenitales ou metastatiques fassent partie du diagnostic differentiel, les
pseudotumeurs inflammatoires du poumon, ou granulomes a cellules plasmatiques,
sont ressorties comme etant l’entite la plus frequemment rencontree. Les auteurs
decrivent deux patients souffrant de cette lesion mal connue et ils passent en revue
l’etat des connaissances actuelles sur le sujet. Les deux patients etaient jeunes (4 et
5 ans) et ils souffraient d'infections des voies respiratoires basses a repetition; un
des patients etait asthmatique. Les deux avaient une toux persistante et presentaient
a la radiographie, une lesion pulmonaire discrete. Les deux enfants furent traites
par thoracotomie et excision de la tumeur. II n’y eut aucune complication operatoire
et la convalescence fut sans histoire. Aux examens de controle, 1 et 2 ans plus tard,
il n’y avait aucun signe de recidive. Cette lesion est presque toujours benigne mais
on a rapporte qu’elle pouvait se comporter de facon agressive. Les auteurs
recommandent de proceder promptement a une excision chirurgicale conservatrice.
nflammatory pseudotumour of
the lung is recognized as a reac
tive local process simulating a neo
plasm. Umiker and Iverson1 were
among the first to recognize this
entity and suggested the name

I

“postinflammatory tumours of the
lung.” Depending on the predomi
nant histologic features, other au
thors have suggested different
names: plasma cell granuloma,2
xanthom atous postinflammatory
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pseudotumour3 and fibrous histi
ocytoma.4
Approximately 50 pediatric cases
have been reported in the English
literature. Most have been charac
terized by an antecedent respiratory
tract infection, minimal symptoms
and a radiopaque nodule on the
chest x-ray film. In this article we
describe two cases of inflammatory
pseudotumour, review the histopa
thologic features and discuss the
optimum management.

Patients and Methods
A retrospective chart review,
spanning the years 1970 to 1988,
was conducted at the University of
Alberta Hospitals. Six cases of non
specific granulomas of the lung in
children were noted. The clinical
presentation, laboratory data, histopathological features and the lit
erature were reviewed. Two o f these
six cases met the accepted histolog
ic criteria. The patients were fol
lowed up by clinic visits and chest
radiography.

Case Reports
Case 1
A 5-year-old boy was referred to
the University of Alberta Hospitals
for the investigation of a radi
opaque mass in the right lung. Six
weeks before admission the boy was
seen at a peripheral hospital with a
CJS, VOL. 34, NO. 5, O CTO BER 1991
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persistent cough and radiographic
evidence of pneumonia. The chest
x-ray film revealed a solitary lesion
in the right lung. The pneumonia
cleared with antibiotic therapy;
however, a nonproductive cough
persisted.
Asthma had been diagnosed
when the boy was 6 months of age,
and current control was with a
salbutamol inhaler. Asthmatic exac
erbations had required frequent
hospitalizations (three to four times
a year). On no occasion was the boy
intubated.
The patient was afebrile with nor
mal vital signs. The only abnormali
ty on physical examination was a
few scattered wheezes bilaterally.
The chest x-ray film (Fig. 1) and
computed tomography (CT) scan
(Fig. 2) showed the right-sided le
sion. Abdominal ultrasonography
was carried out to exclude metastat
ic disease. It showed normal intra
abdominal viscera except for moder
ate splenomegaly. Laboratory inves
tigations gave the following results:
hemoglobin level 143 g/L ; platelet
count 429 X 109/L ; and leukocyte
count 11.8 X 109/ L (67% neutro
phils, 22% lymphocytes, 4% mono
cytes, 5% eosinophils, 1% basophils,
1% band cells). The SMA-12 bio
chemical analysis and results of
urinalysis were normal.
Through a right thoracotomy a
hard nodule was removed by wedge
resection. The postoperative course
was uncomplicated. Frozen and per
manent sections yielded a diagnosis
of plasma cell granuloma (Fig. 3).

chest radiography because of recur
rent respiratory tract infections, and
a mass was demonstrated in the left
lung. A follow-up x-ray film 3 days
before admission showed an in
crease in the size of the mass.
The patient’s history was unre
markable except for frequent upper
respiratory tract infections and oti
tis media. There was no history of
atopy or allergy.
The child was afebrile with nor
mal vital signs. Physical examina
tion of the pulmonary system was
normal. A grade II/VI systolic mur
mur was assessed as a functional
murmur.
A chest x-ray film (Fig. 4) and CT
scan (Fig. 5) showed the lesion in
the left lung. Laboratory investiga
tions gave the following results:
hemoglobin level 125 g/L; platelet
count 357 X 109/L ; and leukocyte
count 8.2 X 109/ E (36% neutro
phils, 50% lymphocytes, 4% mono
cytes, 7% eosinophils, 1% basophils,
2% band cells). Serum electrolyte
levels and results of urinalysis were
normal.
Through a left thoracotomy lingulectomy was performed. The
boy’s postoperative course was un
complicated. Histologically, the di
agnosis of plasma cell granuloma
was confirmed (Fig. 3).

Discussion
Both of these young children
presented with recurrent respiratory
tract infections. The child with
asthma also had a persistent cough.
The findings on physical examina
tion and results of blood work were
noncontributory. In both cases CT
scans of the chest confirmed the
location and character of the lesion.
Although preoperatively the diagno
sis of pseudotumour of the lung
was entertained, definitive confirma
tion was realized only after exci
sion.
Pseudotumours of the lung are
rare, but in the clinical setting of a
discrete lung lesion exclusive of
infections, neoplasms or congenital
abnormalities they merit consider
ation. In the pediatric population a
pseudotumour is probably the most
common cause of an unexplained
pulmonary nodule.5 By no means is
this tumour limited to children;
peaks of incidence are noted in the
fourth and seventh decades of life.6
Pseudotumours have been de
scribed in diverse ethnic groups7
and races,6 and also inflammatory
pseudotumours have been reported
in the breast, heart, stomach and
pleura.7' 10
The pathogenesis of inflammato
ry pseudotumour of the lung re
mains unknown. The inflammatory
and reactive characteristics of this

Case 2

A 4-year-old boy was admitted for
excision of an enlarging nodule in
the left lung. Eighteen months be
fore admission the child had been
hospitalized for pneumonia that re
solved with intravenously adminis
tered antibiotics. Then, 8 months
before admission, he had undergone
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FIG. 1. Case 1. Preoperative posteroanterior chest radiograph shows
right-sided lesion (arrows).

FIG. 2. Case 1. Preoperative computed
tomography scan localizes lesion to
right lung field (arrow).

INFLAMMATORY PSEUDOTUMOURS

lesion have been well elaborated.2-46
The relation of chronic inflamma
tion to the development of neo
plasia is well documented in many
sites of the body,4 but the etiologic
mechanisms remain unclear. Matsubara and colleagues11 have pro
posed a gradual progression from
an interstitial pneumonia to an or

ganizing pneumonia to fibrous his
tiocytoma and finally to plasma cell
granuloma. Antecedent respiratory
tract infections were evident in both
of our patients, and, in case 1,
asthma represented an additional
inflammatory insult. Matsubara and
colleagues11 suggested that a spec
trum of overlapping histologic find

ings in plasma cell granuloma con
notes an evolutionary process. They
described organizing pneumonia, fibrohistiocytic and lymphoplasmacytic subgroups. In our files,
four other children had localized
necrotizing lesions rimmed by a
fibrohistiocytic cellular proliferation
with occasional multinucleate cells.
There was no vasculitis, and no
organisms could be identified histo
logically or by culture. It is possible
that these cases would have evolved
into the more classic findings of
plasma cell granuloma or its vari
ants. In five cases in the series of
Matsubara and colleagues11 and in
three in the series of Bahodori and
Liebow2 foci of necrosis were found.
The pathological findings in
these two cases conformed to clas-

FIG. 4. Case 2. Preoperative posteroanterior chest radiograph showing
left-sided lesion (arrows).

FIG. 3. Typical histologic features of inflammatory pseudotumour of lung. (Top)
Entrapped bronchiole (arrow) is shown with collagen proliferation and inflammato
ry cell infiltrate (hematoxylin-eosin, original magnification X 100). (Bottom)
Inflammatory cell infiltrate is made up predominantly of plasma cells (hematoxylineosin, original magnification X 400).

FIG. 5. Case 2. Preoperative computed
tomography scan localizes lesion to
left lung field (arrows).
CJS. VOL. 34. NO. 5. OCTOBER 1991
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sic descriptions in the literature.2
Both lesions were characterized by
an abundance of lymphocytes and
plasma cells. There was also a pro
liferation of irregular fascicles of
collagen. Cellular atypia and mitotic
activity were notably absent, al
though hints of vascular invasion
were identifiable in both cases (Fig.
3). Malignant fibrohistiocytic le
sions are rare in childhood, al
though Yousem and Hochholzer12
included a 19-year-old patient in
their series, and Juettner and col
leagues13 referred to a 14-year-old
boy reported by Cardesi and associ
ates.14 Significant atypia or mitotic
activity in the spindle cells of a
pseudotumour should alert the phy
sician to the possibility of a malig
nant tumour. Although malignant
fibrous histiocytoma is a possibility,
other malignant tumours, such as
rhabdomyosarcoma, should be con
sidered.
In most large series almost all
patients have been asymptomatic;
the most common symptoms have
been nonproductive cough and fe
ver. Less common symptoms were
hemoptysis, shortness of breath and
malaise. There have been isolated
reports of clubbing.15 Although ele
vated sedimentation rates and raised
immunoglobulin levels15 are occa
sionally noted, laboratory findings
are usually nonspecific.
Bronchoscopy is rarely helpful
except when the tumour has an
endobronchial component or when
there is lobar or segmental collapse.
Most tumours are parenchymal, and
a CT scan of the chest is the best
radiographic technique for further
localizing the tumour. Computed
tomography scans may also show
other conditions such as bronchiec
tasis. In a recent report Cohen and
colleagues16 stated that magnetic
resonance imaging may be superior
to CT for inflammatory lung disor
ders.
The tumour usually is associated
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with minimal symptoms and is a
benign reactive mass of inflammato
ry tissue. However, there have been
reports of invasion17 and recurrence
with a metastatic nodule.18 Con
versely spontaneous regression has
been noted.8 These facts pose a
therapeutic dilemma. Most workers
favour a very conservative segmen
tal or wedge excision, preserving as
much normal lung as possible. In
our two patients the diagnosis was
evident intraoperatively by frozensection examination, and a segmen
tal resection was performed. There
was no evidence of recurrence at
follow-up 2 years postoperatively.

Conclusions
Inflammatory pseudotumour of
the lung is a collective phrase for
benign pulmonary lesions represent
ing an exaggerated response to in
flammation or attempted repair.
The causative agent or immune
trigger remains unknown. Excision
is both diagnostic and curative. The
biologic behaviour of the lesion may
be deceptive; although most lesions
are benign, aggressive behaviour as
well as spontaneous regression has
been recorded. Unless obvious cellu
lar atypia or increased mitotic activ
ity is noted, histologic examination
cannot distinguish reliably between
benign and aggressive lesions. Simi
larly, clinical and laboratory mark
ers are not helpful. Conservative
surgical excision carries minimal
risks and represents optimum thera
py, especially since the natural his
tory of the lesion is not known.
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Aerosol Ventilation Scintigraphy
in the Evaluation of Bronchopleural
Fistula: a Case Report and Literature
Review
Peter Hollett, MD, FRCPC;* Earle Wright, MD, FRCSC;t Carl Wesolowski. MD, FRCPC;* Richard
Harris, MB, ChB, FRCRJ
Radioaerosol scanning is simple to perform and is widely used in conjunction with
perfusion imaging to detect pulmonary emboli. It may also be a valuable tool for the
early diagnosis of postpneumonectomy bronchopleural fistula. The authors present
an illustrative case in which radioactive aerosol imaging was used to confirm a
bronchopleural fistula secondary to pneumonectomy for squamous cell carcinoma.

La scintigraphie par radio-aerosol est de realisation facile et elle est largement
utilisee en association avec 1’imagerie par perfusion pour deceler l’embolie
pulmonaire. Elle peut egalement etre precieuse pour diagnostiquer precocement les
fistules bronchopleurales post-pneumonectomie. Les auteurs presenter^ un cas
illustrant comment l’imagerie a l’aide d’un aerosol radioacif servit a confirmer une
fistule bronchopleurale secondaire a une pneumonectomie pour epithelioma epidermoide bronchique.

bronchopleural fistula (BPF) is
an abnormal connection be
tween the major airways of the lung
and the pleural cavity. Although the
causes of BPF include spontaneous
rupture, pulmonary infarction, em
pyema, bronchiectasis, perforating
chest trauma and suppurative pneu
monia, BPF occurs most frequently
after pulmonary surgery.1 Of the
conditions described in the litera
ture, pneumonectomy is associated
with the highest rate of fistula
development (cumulative incidence
5% to 7%).2 Recent studies have
shown an increased occurrence as-

A

sociated with the use of a hinged
device for the delivery of surgical
staples.2 The development of a post
pneumonectomy BPF is a serious
complication with a death rate of up
to 19.5%.3 If BPF is diagnosed
early, resuturing of the bronchial
stump is possible. Usually, however,
the diagnosis is delayed, and other
approaches must be used: open tho
racic window, modified thoracoplas
ty, delayed bronchial suture with an
overlying muscle graft and transbronchial occlusion with doxycycline and blood,4 lead sinkers5 or
methyl-2-cyanoacrylate.6
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The initial detection of BPF is
often based on a persistent or ex
panding air fluid level seen on up
right chest radiographs. More direct
methods such as bronchoscopy,
bronchography and thoracocentesis
after endobronchial instillation of
methylene blue dye are invasive and
undesirable for ill postoperative pa
tients.
Several reports have appeared de
scribing the value of radionuclide
techniques for evaluating BPF,37-13
but they have not been widely used.
A second noninvasive approach
with quantitative phonopneumography has also proved useful in identi
fying both leaks and their location
when used in conjunction with
transbronchial balloon occlusion.14
We report a case of bronchopleu
ral fistula developing after pneumo
nectomy, which was demonstrated
by a noninvasive, commonly per
formed nuclear medicine ventilation
study.

Case Report
A previously healthy 63-year-old
fisherman presented with two brief
episodes of bright red hemoptysis
over a 3-week period. This was
associated with a gradually increas
ing dull, right anterior chest-wall
pain. There was no history of
cough, fever or sputum production.
The patient denied any recent trauCJS, VOL. 34, NO. 5, OCTOBER 1991
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ma or weight loss but had a history
of heavy cigarette smoking. Physi
cal examination revealed tracheal
deviation to the right, decreased
breath sounds at the right lung
base and mild clubbing of the fin
gers.
Chest radiographs showed re
cently evolved hyperinflation at the
right lung base, raising the possibil
ity of an endobronchial lesion. Flex
ible fiberoptic bronchoscopy con
firmed an obstructing mass of the
right bronchus intermedius. The tu
mour and mediastinal nodes were
explored by rigid bronchoscopy and
mediastinoscopy, and a biopsy was
done. There were no visibly en
larged nodes and the carina was
mobile. The specimens showed a
well-differentiated squamous cell
carcinoma with keratinization but
no nodal involvement.
Hematologic and biochemical lab
oratory investigations gave normal
results. Arterial blood gases showed
mild hypoxia and hypercapnia. Pre
operative pulmonary function
studies showed vital capacity and
forced expiratory volume at one
second to be 76% and 75% of
predicted normal values respective
ly. Nuclear medicine bone scanning
yielded normal results.
A right pneumonectomy was
then performed. During this proce
dure, the long end of the double
lumen endotracheal tube apparently
slipped over the carina into the
right main-stem bronchus and was
inadvertently stapled at the time of
bronchial closure with the TA-55
stapler (Autosuture Company Cana
da, St-Laurent, Que.) and 4.5-mm
staples. This complication was im
mediately recognized by failure to
ventilate the patient. The staples
were rapidly removed with forceps,
and the tube was properly posi
tioned in the left main-stem bron
chus. The bronchial stump was
then resected higher up and closed
with interrupted sutures of 3-0 silk.
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The stump was further reinforced
with a viable intercostal muscle
bundle. No bronchial air leak under
water was observed at 40 cm of
sustained endotracheal pressure.
Postoperatively, atrial fibrillation
and bronchospasm developed and
were treated with digoxin and salbutamol respectively. There was no
clinical evidence of cardiac failure.
The resected specimen was a
well-differentiated squamous carci
noma arising in the bronchus inter
medius. The tumour was largely
endobronchial with limited paren
chymal spread. The resected mar
gins showed no evidence of tumour.
A total of 13 lymph nodes were
found in the hilar region of the
specimen and were all negative for
malignant cells. A lymph node re
moved from the region of the azy
gos vein was also tumour-free. The
lesion was thus classified as
T1N0M0.
The patient was discharged home
8 days postoperatively. He was
afebrile and had no cardiac arrhyth
mia. There was only minimal bron
chospasm for which salbutamol was
prescribed.

Three days after discharge, he
was readmitted with pyrexia, blood
stained sputum and atrial fibrilla
tion. Serial chest radiographs
showed a possible increased volume
of air in the right hemithorax com
patible with a bronchopleural fistula
(BPF). Chest-tube, intercostal
closed drainage was instituted, and
a cardiologist was consulted. The
atrial fibrillation was eventually
controlled after several days of
treatment with digoxin, verapamil
and quinidine.
While awaiting stabilization of
the arrhythmia and before further
surgery, we decided to assess the
role of nuclear medicine techniques
in the differentiation of BPF and
possible pulmonary embolism.
Technetium-labelled macroaggre
gates of albumin, as expected,
showed no right lung activity and a
normally perfused left lung, exclud
ing acute pulmonary embolism. The
radioaerosol study (Fig. 1) revealed
normal ventilation to the left lung
but also right thoracic activity, with
aerosol evident in the chest tube.
This was regarded as firm evidence
of a BPF.

FIG. 1. Aerosol ventilation scintigram with technetium sulfur colloid shows that
there is normal ventilation to left lung, but aerosol is evident in chest tube in right
thorax (arrow).

AEROSOL VENTILATION SCINTIGRAPHY

Ten days after admission, the
patient’s condition was fully stabi
lized, and an open thoracic window
procedure was performed on the
right chest wall. An Eloesser flap
was placed in the mid-axillary line
and 5-cm segments of two underly
ing ribs were resected. The pres
ence of a BPF was readily con
firmed by air bubbling through the
fibrin material covering the bronchi
al stump. The hemithorax cavity
was packed with Bridine-soaked
gauze. The patient had an uncom
plicated postoperative course and
was discharged home on a program
of daily packing of the post
pneumonectomy space.
A repeat radioaerosol study ap
proximately 6 months later helped
confirm the clinical impression of
closure of the BPF.

Discussion
Aeration was assessed by having
the patient inhale a nebulized solu
tion of technetium sulfur colloid
(Tc-Sc), which, unlike many other
imaging agents, is not transported
across bronchoepithelial mem
branes and maintains high targetto-background contrast for an ex
tended period. A total of 1.0 GBq of
Tc-Sc is placed in the nebulizer
(CIS — US, Bedford, Mass.). The
usual amount of Tc-Sc deposited in
the lungs by a ventilation aerosol is
estimated at 50 to 60 mBq. This
delivers a radiation burden of no
more than 4 mGy to the lungs and
0.2 mGy to the whole body,7 com
parable to doses delivered during
other diagnostic procedures. No

mortality or morbidity has been
reported from use of this simple
test. Others3-7-13 have documented
the value of krypton-8lm and xe
non-133 for the diagnosis of BPF.
Radioactive gases are notoriously
difficult to store, contain and moni
tor especially after patient use and
cannot be used in many intensive
care settings (e.g., for portable ex
aminations) for safety reasons. Be
cause of the portability, safety, sim
plicity of handling and ready avail
ability of radioaerosols, many nucle
ar medicine departments have con
verted from the use of radiogases to
technetium radioaerosol.
Two earlier reports have been
published, demonstrating BPF
using a technetium radioaerosol:
Tc-albumin fog7 and Tc-DTPA.9
To our knowledge this is only the
third case in which a radioaerosol
was used for the diagnosis of BPF
and the first using Tc-Sc. This is
interesting given the ubiquitous use
of Tc-Sc and that it could precede,
and indeed be part of, an examina
tion to differentiate an early BPF
from pulmonary emboli.
The paucity of literature suggests
that this study is infrequently used
to investigate possible BPF. Unfor
tunately, therefore, no sensitivity or
specificity can be quoted. A pro
spective series may help resolve this
question. In our case, BPF was
diagnosed with radioaerosol before
the characteristic progression of
thoracic radiographic changes. Be
cause of this potential for early
diagnosis, we encourage the use of
this simple noninvasive technique in
the investigation and follow-up of
bronchopleural fistula.
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Laser Therapy of Vulvar Lichen Sclerosus
et Atrophicus
G.C.E. Stuart, MD, FACOG, FRCSC; J.G. Nation, MD, FRCSC; V.S. Malliah, MD, FRCSC;
D.I. Robertson, MD, PhD, FRCPC
Seven patients with a histologic diagnosis of lichen sclerosus et atrophicus of the
vulva were treated by laser ablation of the affected area to a depth of 1.0 to 2.0 mm.
The inpatient procedure was performed under general anesthesia with a carbon
dioxide laser unit. Healing was complete 6 weeks postoperatively. All but one
patient was free of recurrent symptoms at follow-up, which ranged from 12 to 37
months. Laser ablation is an acceptable treatment for patients who have symptoms
due to lichen sclerosus of the vulva that are refractory to other measures.

Sept patientes porteuses d’un diagnostic histologique de lichen sclerosus et
atrophicus de la vulve ont ete traitees par ablation au laser de la surface affectee,
jusqu’a une profondeur de 1,0 a 2,0 mm. Les patientes ont ete hospitalisees et
l'intervention fut pratiquee sous anesthesie generate a l’aide d’un laser au bioxyde
de carbone. La cicatrisation etait complete 6 semaines apres l’operation. A
l’exception d’une, toutes les patientes etaient exemptes de symptomes de recidive a
l’examen de controle effectue apres 12 a 37 mois. L’ablation au laser est une
intervention acceptable pour traiter les patientes qui ont les symptomes du lichen
sclerosus de la vulve et qui ne repondent pas a d’autres mesures.

ichen sclerosus (LS) et atro
phicus is a disease process that
is a frequent histologic finding in
patients with a history of vulvar
pruritus and white atrophic plaques
on the perineum and surrounding
skin. Therapy of LS is usually pro
tracted. It is aimed at providing
symptomatic relief but not necessar
ily correcting the underlying disor
der. Such therapy has included the
topical use of testosterone, deriva
tives of vitamin A, topical corticos
teroids in selected patients and even
surgical excision. This paper pro
vides a preliminary report of the
effective use of ablative therapy

L

using the carbon dioxide laser in a
group of six patients.
Lichen sclerosus is most common
in postmenopausal women, al
though it has been documented in
prepubertal and reproductive-age
females.1 It usually presents initially
as a pigmented papule but rapidly
takes on the more characteristic
appearance of a thinned, whitegrey parchment-like plaque. Edema,
bullae and loss of the normal skin
folds due to atrophy may develop.
Ulceration, ecchymosis and excoria
tion may reflect the pruritus. The
histologic appearance is character
ized by varying degrees of hyper
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keratosis, atrophy of the stratum
malpighii, hydropic degeneration of
the basal layer and a flattening of
the rete ridges. The superficial col
lagen is homogenized, and beneath
it lies a band-like mononuclear in
flammatory infiltrate.2
The standard therapy in the postpubertal patient has been the topi
cal application of testosterone.3
This is usually prescibed to relieve
symptoms and is a lifetime therapy.
Refractory cases have been treated
with intradermal alcohol injections
with variable results. In young pre
pubertal patients, corticosteroids
have been used as an adjunct to
proper hygiene and bland emmolients.4 The use of etretinate orally
produced clinical improvement in
six of eight patients reported by
Mark, Jensen and Hoel.5 Similar
success has been reported by Romppanen and colleagues.6
Surgical therapy has been report
ed sporadically. Rettenmaier and as
sociates7 described four patients in
whom a “skinning vulvectomy’' and
split-thickness skin graft were used
to treat the disease. One patient had
a late recurrence 45 months postop
eratively, involving the grafted skin.
Laser ablation of the vulvar skin
in five patients with a history of
refractory vulvar pruritus has been
reported as effective by Ovadia, Levavia and Edelstein.8 In their paper
four patients reported symptomatic
improvement 12 months after treat
ment. However, this report did not
specify a histologic diagnosis of LS.
CJS, VOL. 34, NO. 5, OCTOBER 1991
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Materials and Methods
In this report, seven women had
evidence of LS. They ranged in age
from 43 to 62 years (mean 52.5
years). Four women were post
menopausal. All patients were mul
tiparous. The presenting symptom
was pruritus in all these women,
and it had been present for an
average of 6 years (range from 3 to
10 years). All had previously been
treated with topical testosterone for
6 to 36 months without notable
relief of the pruritus.
Biopsies were obtained before
laser therapy, and all slides were
reviewed by a single pathologist
(D.I.R.) to confirm the diagnosis.
Laser therapy was performed
using a carbon dioxide laser with a
power density of 600 to 900
W /cm 2 to effect tissue destruction
to a depth of 2 mm. Although,
macroscopically, the area of abnor
mality extended from 2 to 6 cm, the
area treated included the labia mi
nora and periclitoral area as demar
cated by the hymenal ring proximally and the hairline distally in all
cases. The urethral meatus and
anus were not involved in any of the
patients. The procedure was carried
out under general anesthesia, and
the average duration of hospital
stay was 4.7 days. Patients in this
series were hospitalized for manage
ment of postoperative pain and to
establish an appropriate regimen of
perineal care. This regimen included
washing with hydrogen peroxide
and blowing dry with a hair dryer
four times per day until surface
epithelialization had taken place.
Complete re-epithelialization had
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occurred in all patients by 6 weeks
after treatment. Five patients were
free of symptoms and visible recur
rence of disease with a follow-up of
12 to 27 months. One patient con
tinued to use testosterone topically
once per week to control symptoms
of pruritus although no disease was
visible.

Discussion
The thickness of stratified squa
mous epithelium of the vulvar tis
sue including the deepest rete pegs
rarely exceeds 1 mm. The superfi
cial skin appendages are not com
monly involved in LS. It might be
expected, therefore, that in a dis
ease process such as LS controlled
ablation of the epithelium to a
depth of 2 mm would eliminate the
abnormality and allow appropriate
epithelialization to occur from the
margins of the wound and the deep
appendages of the skin. Provided
that the low-power density (600 to
900 W /cm2) is used in the laser
beam so as to minimize deep ther
mal injury, satisfactory healing
without scarring should occur.
These principles appear to have
been realized in the patients report
ed. Repeat biopsy as part of the
formal follow-up protocol was not
used in this series but could be
considered in the future as an eval
uation of the long-term efficacy of
this therapeutic modality.
Lichen sclerosus may cause both
patient and physician significant
frustration. Diagnosis requires one
or more biopsies of the involved
areas to rule out associated vulvar

neoplasia and to confirm the char
acteristic histologic appearance of
LS. Primary therapy consists of
careful perineal hygiene and avoid
ance of any local irritants. Testos
terone, applied topically, may re
lieve symptoms. Ablative laser ther
apy may offer patients with disease
refractory to topical therapy an al
ternative treatment with minimal
morbidity and a favourable long
term outcome.
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Significant biliary excretion o f antibiotics can have a very disruptive effect on
intestinal flora, which may promote the emergence o f resistant strains o f bacteria and
cause diarrhea.12 This can add substantially to the cost of treatment.3
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serum LDH and serum alkaline phsphatase levels have been reported. Kidney ( < 1%): Increased serum creatinine
and BUN have occasionally been observed. Central Nervous System (0.2%): Headache.

P R E S C R IB IN G INFO RM ATION

Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see fable
with recommended mode of reconstitution according to route of administration).

Action
In vitro studies indicate that the bacterial action of Claforan (cefotaxime sodium) a semi synthetic cephalosporin
antibiotic, results from inhibition of cell wall synthesis.

Indications and Clinical Uses
Treatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible
strains of the designated micro organisms in the diseases listed below.
Lower respiratory tract in fe c tio n s: pneumonia and lung abscess caused by Streptococcus pneumoniae
(formerly Diplococcus pneumoniae), other streptococci (excluding enterocci, e.g. S. taecalis), Straphylococcus
aureus (penicillinase and non penicillinase producing), Escherichia coli, Hemophilus influenzae, (including
ampicillin resistant strains) and unspecified Klebsiella species.
U rinary tra ct in fe c tio n s: caused by Escherichia coli, unspecified Klebsiella species (including K. pneumoniae),
Proteus mirabilis, indole positive Pmteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
Bacteremia / S epticem ia: caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens.
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non-penicillinase producing, S. epidermidis,
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus.
Intra-abdom inal infections: caused by Escherichia coli, and unspecified Klebsiella species.
G ynecological infections: including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by
E. coli, Group A streptococci and Staphylococcus epidermidis-, anaerobic bacteria including unspecified Peptococcus
and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although clinical cures
were achieved, bacteriological follow-up was not available.
Central nervous system in fe c tio n s: meningitis and ventriculitis caused by Haemophilus influenzae, Neisseria
meningitidis, Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli. Claforan is not active
against Listeria monocytogenes.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in
wound and intra-abdominal infections against some strains of unidentified Bactemides and anaerobic cocci.
Claforan has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus faecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative
organisms and to determine their susceptibilities to Claforan. Therapy may be instituted before results of susceptibility
studies are known; antibiotic treatment should be re-evaluated once these results become available.
P rophylactic U s e : The administration of Claforan perioperatively (preoperatively, intraoperatively and postoperatively)
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (e.g. abdominal
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as
with a non absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism
so that appropriate therapy may be instituted.

Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin
or the penicillin groups of antibiotics.

Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudom em branous colitis has been reported w ith the use of cephalosporins (and other broad spectrum
antibiotics); therefore, it is im portant to consider its diagnosis in patients w ho develop diarrhea during
the adm inistration of Claforan. This colitis can range from m ild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic.
Moderate to severe cases should be managed with fluid, electrolyte and protein supplemntation as indicated.
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic
specifically effective in antibiotic-associated pseudomembranous colitis (e.g. vancomycin) or other suitable therapy
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions).

Precautions
Claforan (cefotaxime sodium) should be prescribed with cauton in individuals with a history of lower gastro
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child-bearing potential requires that the anticipated benefits be weighed against the
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the
patient's condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended,
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and
prolonged serum antibiotic concentrations.
Positive direct Coomb's test is known to develop in individuals during treatment with the cephalosporin group of
antibiotics, including cefotaxime sodium.
In laboratory tests a falso positive reaction to glucose may occur with reducing substances but not with the use
of specific glucose oxidase methods.

Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
H ypersensitivity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflammation with intravenous
administration. Pain, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%); Colitis,
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan
treatment. Hem ic and Lymphatic System ( < 1%): Mild, reversible leukopenia, granulocytopenia and thrombo
cytopenia have been reported. Some patients developed positive direct Coomb's test during treatment with
Claforan. G enitourinary System ( < 1%): Moniliasis, vaginitis. Liver ( < 1%): Transient elevations in SGOT, SGPT,

Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or
treatment is available. Treatment of overdosage should be symptomatic.

Dosage and Administration

The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the infection
and condition of the patient.

Guidelines for Dosage of Claforan (cefotaxime sodium)

Type of Infection

Daily Dose
(g)

Frequency and Route
1 g IM (single dose)

Uncomplicated Gonorrhea

1

Uncomplicated infections

2

1 g every 12 hours IM or IV

3-6

1-2 g every 8 hours IM or IV

6-8

2 g every 6-8 hours IV

Moderately severe to severe infections
Very severe infections (e.g. septicemia, CNS)
Life-threatening infections

up lo 12

2g every 4 hours IV

To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are
as follows.
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate
antibiotic levels are present in the serum and tissues at the start of surgery
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.

Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.

Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates:
0-1 week of age
50 mg / kg IV q 12 h
1-4 weeks of age
50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe
infections (including central nervous system infections).
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary
tract infections and may be required for several months after therapy has been completed, persistent infections may
require prolonged treatment. Doses less than those recommended should not be employed.

Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2 the dose of Claforan should be
halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on sex, weight, and age of the patient)
may be used to convert these values into creatinine clearance.
Males.

Weight (kg) x (140 - age)

Females;

0.85 x above value

72 x serum creatinine

Administration
Intra m u scu la r: Claforan should be injected well within the body of a relatively large muscle such as the upper
outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a
blood vessel.
Intra venous: The intravenous route is preferable for patients with bacteremia, bacterial spticemia, or other severe
or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from
such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if
shock is present or impending.
For bolus administration a solution containing 1 or 2 g of Claforan can be injected over a period of 3 to 5 minutes.
Using an infusion system, it may also be given over a longer period of time through the tubing system by which
the patient may be receiving other intravenous solutions. Butterfly* or scalp vein type needles are preferred for this
type of infusion. However, during infusion of the solution containing Claforan, it is advisable to discontinue
temporarily the administration of other solutions at the same site.

ADD-Vantage* Vial
When administering Claforan using the ADD-Vantage* Drug Delivery system, Claforan powder is added directly to a
single-dose flexible plastic ADD-Vantage* diluent container. Claforan 1 g or 2 g may be reconstituted in 50 mL or
100 mL of 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP.

Stability
Solutions of Claforan reconstituted in 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP in the
ADD-Vantage* flexible containers maintain satisfactory potency for 12 hours at room temperature.

Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, in vials containing 500 mg,
1.0 and 2.0 g of cefotaxime sodium and in ADD-Vantage* vials containing 1.0 and 2.0 g of cefotaxime sodium
(expressed as acid on a dry basis).
S to ra g e : Claforan in the dry state should be stored at room temperature protected from light and heat.

Product monograph available on request.
*Reg’d TM of Abbott Laboratories.
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Diagnostic Peritoneal Lavage
as an Indicator for Therapeutic Surgery
J.P. Fryer, MD; T.L. Graham, RN; H.M-T. Fong, MD, FRCSC; C.M. Burns, MD, FRCSC
Diagnostic peritoneal lavage (DPL) has been reported to be extremely accurate in
identifying intra-abdominal injury. Many studies, however, fail to indicate clearly if
the procedure is helpful in determining which patients require truly therapeutic
surgical intervention, because not all injuries need such surgery. In this study the
authors reviewed the charts of 174 patients with blunt abdominal trauma and, by
applying strict criteria to define a therapeutic laparotomy, sought to determine,
retrospectively, whether DPL was useful for indicating the need for therapeutic
surgery.
Although 94% of patients with positive findings from DPL underwent a
laparotomy, only 65% underwent one that was clearly of therapeutic value. Although
other factors may have partially contributed to the discrepancy between these results
and those generally referred to in the trauma literature, this study suggests that
criteria providing a strict definition of a therapeutic laparotomy must be universally
applied when analysing the value of DPL.

Le lavage peritoneal diagnostique (LPD) a ete decrit comme tres precis pour
identifier les lesions intra-abdominales. Toutefois, plusieurs etudes n’ont pas reussi
a montrer clairement si cette intervention est utile pour determiner quels patients
necessiteront une operation a visee therapeutique, parce que toutes les blessures
ne requierent pas ce type de chirurgie. Dans cette etude, les auteurs ont etudie les
dossiers de 174 patients victimes de traumatismes abdominaux fermes et, a l’aide de
criteres stricts pour definir la laparotomie therapeutique, ils ont tente d’etablir, en
retrospective, si le LPD avait ete utile pour indiquer le besoin d'une chirurgie
therapeutique.
Meme si 94 % des patients qui avaient des resultats de LPD positifs ont subi une
laparotomie, 65 % seulement en ont subi une qui etait clairement d’interet
therapeutique. Bien que d’autres facteurs aient pu contribuer partiellement a la
difference observee entre ces resultats et ceux qui sont signales dans la presse
medicale, cette etude indique que des criteres permettant une definition stricte de la
laparotomie therapeutique devraient etre universellement appliques, quand on
analyse l’importance du LPD.

iagnostic peritoneal lavage
(DPL) is used to aid the sur
geon in deciding whether or not a
laparotomy is necessary in a patient
who has suffered abdominal trau
ma. Since Root’s milestone paper in

D

19651 the technique has been wide
ly used in blunt abdominal trauma.
Numerous studies have assessed
the accuracy of DPL.2' 9 Cumulative
ly these studies indicate a 97.5%
accuracy rate with a positive lavage
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(range from 79% to 99%) and a 98%
accuracy rate with a negative lavage
(range from 95% to 99%) for an
accuracy of 97.8% overall. The
false-positive rate is 2.5% and the
false negative rate is 2.2%.8
These studies employed the stan
dard criteria for identifying a posi
tive lavage (Table I ).1289 Generally,
if the criteria for a positive lavage
are met, a laparotomy is subse
quently performed. The predictive
accuracy of the lavage is based on
the laparotomy findings. Various
criteria have been used to identify a
positive laparotomy. Laparotomy is
considered to be positive by
some21011 if there is organ injury or
hemoperitoneum, and by others12'13
if further surgical intervention is
required. However, the exact details
of this intervention are rarely scru
tinized closely. In some studies114
the criteria for a positive laparoto
my are not defined at all.
Some researchers131516 suggest
that an unacceptable number of
laparotomies are performed unnec
essarily (27% to 62%) and that
these procedures are not without
morbidity (19% to 23%) and mortal
ity (1.6%).1617
The aim of this study is to evalu
ate, through a strict definition of
Table I. Standard Criteria for Positive
Peritoneal Lavage in the Assessment of
Abdominal Trauma
Free aspiration of > 5 mL of blood
Red blood cell count of > 100 000/mm3'
Leukocyte count of > 500/mm3'
Amylase > 200 Caraway units (370 U/L)*
Presence of bile, bacteria on food
particles*
Lavage fluid via Foley catheter or chest
tube
'Analysis of lavage fluid returns.
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“therapeutic surgery,” the useful
ness of DPL in identifying the vic
tims of blunt abdominal trauma
who truly require therapeutic sur
gery.

Patients and Methods
At the Health Sciences Centre in
Winnipeg the trauma service per
formed 200 DPLs on victims of
multiple trauma (148 men, 52 wom
en) during the period 1980 to 1985
inclusive. This particular period was
chosen because it predated the
widespread use of computed tomog
raphy in this institution. These
cases were analysed retrospectively
by reviewing hospital charts, autop
sy findings and operating-room re
ports.
The indications for DPL as recog
nized by the Health Sciences Centre
trauma service are as follows:
• Equivocal findings on physical
examination of the abdomen.
• Unreliable results of the physi
cal examination because of associat
ed injuries (e.g., lower rib fractures,
pelvic fractures, vertebral fractures
or spinal cord injuries).
• An altered level of conscious
ness (head injury, drugs, alcohol).
• Unexplained hypotension.
The Health Sciences Centre trau
ma service does not adhere strictly
to the standard criteria for a posi
tive DPL (Table 1). A lavage is
considered positive if there is free
aspiration of 5 mL or more of gross
blood through the lavage catheter
or if newsprint or its equivalent
cannot be read through the catheter
draining the lavage fluid from the
peritoneal cavity.18 Conversely, a
DPL is considered negative if there
is no gross blood aspirated and
newsprint is readable through the
lavage return. In eight cases the
lavage fluid returns were sent to the
laboratory for microanalysis. The
exact reasons for submitting these
472
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particular specimens for microanal
ysis are unclear as this has not been
adopted as a routine policy with the
Health Sciences Centre trauma pro
tocol. It is difficult, in retrospect, to
determine the exact role that these
microanalysis results may have
played in the decision-making proc
ess at the time.
Based on a positive DPL, or on a
change in the patient’s clinical sta
tus, several patients subsequently
had a laparotomy. The laparotomies
were reviewed and were classified as
either therapeutic or nontherapeutic. A therapeutic laparotomy is one
that involves attempted correction,
using surgical techniques, of inju
ries that would result in death or
serious morbidity if not treated
promptly. Injuries that satisfy these
criteria can be divided into four
categories (Table II).
For the purposes of this study, a
true-positive DPL, therefore, is one
in which a positive DPL is followed
by a therapeutic laparotomy or, in
the patient not operated on, by an
autopsy that reveals intra-abdomi
nal injuries (Table II), suggesting
that the patient would have benefit
ed from a therapeutic laparotomy.
Conversely, a false-positive DPL is a
positive DPL that is followed by a
nontherapeutic laparotomy or, in
the patient not operated on, by
either an uncomplicated course in
hospital and subsequent discharge
or by a negative autopsy (based on
injuries listed in Table II). A true
negative DPL, therefore, is a nega
tive DPL that is followed by either a
nontherapeutic laparotomy, uncom
plicated survival to discharge or a
negative autopsy (Table II). Finally,
a false-negative DPL is a negative
DPL that is followed either by a
therapeutic laparotomy or by posi
tive findings at autopsy (Table II).
All DPLs were performed by a
senior surgical resident or by a
more junior member of the trauma
service housestaff under the direct

supervision of a senior surgical resi
dent. One hundred and sixty-six
DPLs were performed by the percu
taneous trocar insertion tech
nique.1314 This technique involves
initial catheter drainage of the uri
nary bladder followed by surgical
preparation and draping of the
lower abdomen. A small (approxi
mately 1 cm) transverse skin inci
sion is made in the midline at a
point 2 cm below the umbilicus.
With firm, steady, manual force the
trocar-catheter device is directed
into the pelvic peritoneal cavity by
maintaining the device at an angle
of approximately 20° from an imag
inary line perpendicular to the ab
dominal wall in the midline. A dis
tinct “pop” is typically felt or heard
as the peritoneal cavity is entered.
The trocar is subsequently removed
and a syringe is used to aspirate
from the remaining catheter. If the
lavage is not positive, 1 L of normal
saline is infused into the peritoneal
cavity. If the patient is cooperative
and there is no suspicion of under
lying spinal injury the patient is
turned from side to side to allow
proper distribution of lavage fluid.
Next, the empty 1-L bag of normal
saline is dropped to the floor to
Table II. C ategories o f Injuries R equiring a
Therapeutic Laparotom y
Category
1

2

3

4

Description
Active bleeding fro m any
intraperitoneai source o r an
expanding retroperitoneal
hem atom a not considered
m anageable using other
m odes o f therapy
P erforation or devitalization of
any portion o f the
gastro inte stin a l or
genitourinary tra ct
S ig n ifica n t injury o f the
pancreas w here excessive
leakage of pancreatic
enzym es is anticipated
D isruption of the in te g rity o f the
diaphragm o r bilia ry tra ct, or
any o ther injuries w h ich are
co n siste n t w ith the above
d e fin itio n o f a therapeutic
la parotom y but do n o t f it into
the oth er categories

DIAGNOSTIC PERITONEAL LAVAGE

allow drainage of the DPL fluid
from the peritoneal cavity. If the
fluid fails to drain from the perito
neal cavity, an additional litre of
normal saline is infused. If drainage
still does not occur, the procedure
is abandoned.
In the remaining eight cases an
open technique (minilaparotomy)
was used.4’13'1449

trauma cases managed by the
Health Sciences Centre trauma ser
vice and experience with DPL is
shown in Fig. 1. The 200 patients
who underwent DPL included 174
with blunt abdominal injuries and
26 with penetrating abdominal inju
ries. Only the blunt injuries will be
discussed further.
Breakdown of the etiologic fac
tors involved in the blunt injuries
revealed that motor-vehicle acci
dents were implicated in 140 cases,
assaults in 17, falls in 8 and indus
trial accidents in 6 cases; in 3 cases
the etiology was undetermined. Of
the 174 DPLs performed for assess
ment of blunt abdominal trauma, a

Findings
The average age of the 200 pa
tients was 32.6 years (range from
14 to 88 years).
The annual volume of abdominal

FIG. 1. Cases of abdominal trauma seen at Health Sciences Centre trauma service
between 1980 and 1985. DPL = diagnostic peritoneal lavage.

Table III. Findings on Positive Lavage (n = 125)
Injuries
Meeting criteria for therapeutic
laparotomy, category
Mode of assessment

Not meeting
criteria for
therapeutic
laparotomy

1

2

3

4

3

2

37 (7*)
1

2

44 (7*)

Laparotomy
No laparotomy: autopsy
No laparotomy: survival
to discharge

64
1

11
-

-

-

-

-

Total

65

11

6

3

’ Laparotomy performed, but indications for laparotomy unclear from operative report.

positive result was obtained in 125
and a negative result in 49.
A laparotomy was performed in
117 of the 125 positive lavages.
The reasoning behind the decision
not to proceed with laparotomy in
the other eight cases was not clear
ly documented. Of these eight pa
tients, six recovered without com
plication; the other two died. One of
the patients who died had multiple
injuries and was rushed to the
operating room where it was decid
ed to perform an emergency thora
cotomy first because of the clinical
impression that there was injury to
the thoracic aorta. This patient died
during the thoracotomy and at au
topsy was found to have massive
hemoperitoneum associated with a
large liver laceration as well as
severe intrathoracic and intracranial
injuries. The second patient who
died had laparotomy deferred on the
basis of the clinical assessment. He
died of complications related to his
massive head injuries. Autopsy
demonstrated that the only intra
abdominal injury present was a su
perficial splenic laceration associat
ed with no significant hemoperito
neum. This indicates that the deci
sion to defer laparotomy was cor
rect. Therefore in the eight cases in
which no laparotomy was per
formed despite a positive DPL,
seven would not have benefited
from the surgery.
When the operative reports of
the 117 patients who underwent
laparotomy after a positive DPL
were analysed, 64 (55%) were found
to have had active intra-abdominal
bleeding consistent with category 1
of Table II (Table III). An additional
16 (14%) were found to have inju
ries consistent with categories 2, 3
and 4 (Table III). Therefore, 80
(69%) of 117 patients with a posi
tive DPL subsequently underwent a
therapeutic laparotomy. The re
maining 37 (31%) laparotomies per
formed after a positive DPL were
CJS, VOL. 34. NO. 5, OCTOBER 1991
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considered to be nontherapeutic. In
30 of these there was no further
surgical intervention after the abdo
men was opened. In the other seven
cases, although there were further
surgical interventions, they ap
peared to be of questionable thera
peutic importance on retrospective
analysis. It is recognized that these
interventions may well have been
the result of the operating sur
geon’s prudence based on the over
all clinical situation at the time of
the surgery; however, this factor is
lost to retrospective analysis.
Therefore of the 125 patients
with positive DPL, 8 did not under
go a laparotomy and 1 of these may
have benefited from a laparotomy.
Of the 117 who underwent a lapa
rotomy, 80 had some form of thera
peutic surgical intervention and 37
did not. Therefore a positive result
with DPL correctly identified the
need for a therapeutic laparotomy
in 81 out of 125 (65%) cases. The
false-positive rate was 35%.
In this series 35% of positive
DPLs were based on aspiration of
gross blood, and they correctly
identified the need for a therapeutic
laparotomy in 74% of cases. The
remaining 65% of positive DPLs
were based on the inability to read
newsprint through the lavage re
turns and they correctly identified
the need for a therapeutic laparoto
my in 35% of cases.
There were 49 negative lavages.
On the basis of changes in clinical
status, laparotomies were subse
quently performed in five of these
patients and four of the laparoto
mies were therapeutic. No laparoto
my was performed in 44 of the
patients with a negative DPL. Of
this group 32 survived to discharge
and 12 died (Table IV). At autopsy
it was revealed that 3 of the 12 had
injuries that may have benefited
from a therapeutic laparotomy. One
of these three patients had a mas
sive hemoperitoneum with associat
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tetter14 indicated that higher accu
racy and a lower complication rate
are obtained if the open technique
(minilaparotomy) is used.1516 Al
though the use of the open tech
nique is not universally supported,5
most of the studies in the literature
employed an open technique.2-45'7 In
this series, the open technique was
accurate in all eight cases in which
it was used. These numbers may be
too small to indicate a statistically
significant improvement over the
percutaneous technique, but they
certainly support the advantages of
the open technique. Retrospective
ly, it is unclear why the open tech
nique was used in these particular
eight patients, hence the possibility
of preselection bias must be consid
ered.
Another factor that may have
contributed to the discrepancies in
the results is the difference in the
criteria used to identify a positive
lavage. The standard criteria used
in most of the studies in the literature1-5-7-8-9 were not adhered to, and
judgement was based on either the
initial aspiration of more than 5 mL
of gross blood or the inability to
read newsprint through the lavage
returns as described by Olson and
colleagues.18-20 In this series 35% of
positive DPLs were based on aspira
tion of gross blood, and they cor
rectly identified the need for a ther
apeutic laparotomy in 74% of cases.
The other 65% of positive DPLs
were based on the inability to read
newsprint through the lavage re-

ed liver lacerations, and the other
two had massive retroperitoneal he
matomas. Although associated head
injuries were likely the cause of
death in all three cases, one cannot
ignore the possibility that the
above-mentioned injuries may have
contributed significantly. Of the 49
patients who had a negative DPL, 7
had intra-abdominal injuries which
either benefited from or would like
ly have benefited from a therapeutic
laparotomy.
Therefore, a negative result with
DPL correctly indicated that a lapa
rotomy was unnecessary in 42
(86%) of 47 cases. The false nega
tive rate was 14%.
The accuracy of DPL was 71% in
this series overall.

Discussion
Obvious discrepancies exist be
tween the findings in this study and
those in the general literature.
First, the use of the percutaneous
insertion technique in most cases
may account for some inaccuracy,
because the most common compli
cation of the percutaneous tech
nique is intraperitoneal bleeding,14
and this may result in a false-posi
tive DPL, leading to a non
therapeutic laparotomy. In at least
two cases in this series in which the
percutaneous technique was used,
the procedure itself was strongly
implicated as being the cause of the
hemoperitoneum. Pachter and Hofs-

Table IV. Findings on Negative Lavage (n = 49)
Injuries
Meeting criteria tor
therapeutic laparotomy,
category
Mode of assessment

1

2

Laparotomy
No laparotomy: autopsy
No laparotomy: survival
to discharge

4
3

-

Total

7

3
-

4
-

Not meeting
criteria for
therapeutic
laparotomy
1
9
32
42

DIAGNOSTIC PERITONEAL LAVAGE

turns, and they correctly identified
the need for a therapeutic laparoto
my in 35% of cases. This suggests
that a major reason for the discrep
ancies of this study’s results with
others may be due to the use of this
method of assessing the DPL fluid
returns, since most studies adhere
to the standard criteria (Table I). In
only eight cases was the lavage
fluid sent for microanalysis. The
microanalysis proved to be 88%
correct in indicating which patients
needed a therapeutic laparotomy
and which patients did not. In fact
in four of the eight cases in which
DPL fluid was submitted for mi
croanalysis there was disparity be
tween the gross assessment (i.e.,
ability to read newsprint) of the
lavage results and the microanal
ysis.
In three of the four cases the
microanalysis results were clearly
correct in indicating that a thera
peutic laparotomy was unnecessary
when the gross results suggested
the contrary. In the fourth case the
gross findings indicated that a ther
apeutic laparotomy was necessary
and, therefore, even though microa
nalysis suggested the contrary, a
laparotomy was performed. An ex
panding retroperitoneal hematoma
was found and this was controlled
with prolonged local pressure.
Therefore one could argue that the
microanalysis had failed to recog
nize the need for intervention. The
apparent difference in predictive ac
curacy between assessment by mi
croanalysis and assessment by gross
Table V.

methods, cannot be considered to
be statistically significant due to the
small numbers in the microanalysis
group. Also there was undoubtedly
some degree of preselection bias
involved in selecting the patients
who had lavage fluid sent for mi
croanalysis.
A third factor likely contributing
to the discrepant results of this
study is the application of strict
criteria for indicating whether or
not a laparotomy has been of thera
peutic value. Similar criteria are
lacking in most reviews of DPL and
tend to be vague and unspecified
when they are employed.
Although results in the literature
vary, they generally indicate that
for assessing intra-abdominal injury
the overall accuracy of computed
tomography is comparable to that
of DPL.112122 In our centre, com
puted tomography was used to as
sess blunt abdominal trauma in 34
cases in 1987 and 1988.21 Comput
ed tomography correctly indicated
the need for therapeutic laparotomy
in three of five cases and correctly
indicated that a therapeutic laparot
omy was not required in 26 (90%)
of 29 cases. The overall accuracy of
the procedure was 85%. Unfortu
nately these numbers cannot be
used for direct comparison with
those obtained for DPL because the
patients who underwent DPL obvi
ously represented a more severely
injured patient population (88
[51%] of 174 were subsequently
found to have injuries that would
benefit from a therapeutic laparoto

N u m e r ic a l S c o r i n g S y s t e m f o r A s s e s s i n g B lu n t A b d o m i n a l T r a u m a B a s e d o n P h y s ic a l
E x a m in a t io n o f t h e A b d o m e n *

Score of

1t

Score of 2%

Score of 3§

T e n d e rn e ss

Rebound

A b sent bow el sounds

D is t e n s io n

G u a r d in g

A b d o m in a l r ig id it y

C o n t u s io n
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my whereas the CT group was
found to have only 6 [17%] of 34
patients with such injuries).
Based on a retrospective review
of the initial physical examination
of the abdomen, we used a numeri
cal scoring system (Table V) to
divide the patients in this series into
two groups: those with positive and
those with negative physical exami
nations. The false-positive rate of
physical examination for predicting
the need for a therapeutic laparoto
my was 38.9% compared with the
37% false-positive rate for DPL.
The false-negative rate for physical
examination was 39.5% compared
with 14% for DPL. The overall
accuracy for a single physical exam
ination was 61% compared with
71% for DPL. One would expect the
accuracy of physical examination to
improve if assessment was cumula
tively based on several serial exami
nations.
When assessing the abdomen of
a victim of blunt abdominal trauma
the question of paramount impor
tance is: Does this patient need a
laparotomy? Unfortunately, DPL is
primarily designed to answer a dif
ferent question: Is blood present in
the peritoneal cavity? By associa
tion, the presence of intraperitoneal
blood seems quite accurately to in
dicate that serious intra-abdominal
injuries are present.21011 This is
supported by the findings of this
study since all 16 cases in which a
therapeutic laparotomy was per
formed for reasons other than ac
tive hemorrhage (i.e., criteria 2, 3
and 4 in Table II) were associated
with a positive DPL. However, in
four cases in which the DPL was
negative a laparotomy was per
formed because of clinical deteriora
tion, and significant injuries requir
ing therapeutic surgical interven
tion were found subsequently. The
explanation for these unsatisfactory
results is not clear but may possibly
represent aberrancies in the stanCJS, VOL. 34. NO. 5, OCTOBER 1991
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continued from page 449

dard DPL technique or may reflect
the inaccuracy of the gross method
of assessing DPL fluid used in this
series.
The results of this retrospective
study are not consistent with those
generally quoted in the trauma liter
ature. Several factors have been
identified which may have con
tributed to this. Based on our find
ings, we would make the following
recommendations.
• The open technique should in
most situations be used in prefer
ence to the percutaneous technique.
• The newsprint technique
should be discarded and microanal
ysis using the standard criteria (Ta
ble I) should be routine.
• Future studies of DPL or
other methods of assessing blunt
abdominal trauma should employ a
standard set of criteria to indicate
which patients had injuries that
warranted a therapeutic laparoto
my. The emphasis for such studies
would therefore be to evaluate the
ability of the investigative modality
to identify injuries requiring thera
peutic surgical intervention rather
than its ability to identify intra
abdominal injuries regardless of
their significance.

References
1. R oot HD. Hauser CW. McK inley CR et
al: Diagnostic peritoneal lavage. Surgery
1965; 57; 633-637
2. P erry JF, Strate RG; Diagnostic perito
neal lavage in blunt abdominal trauma:
indications and results. Surgery 1972;
71; 898-902
3. T hal ER, Shires GT: Peritoneal lavage
in blunt abdominal trauma, ,4m J Surg
1973; 125: 6 4 -6 9

4. Encrav LH, B enjamin Cl, Strate RG et
al: Diagnostic peritoneal lavage in blunt
abdominal trauma. J Trauma 1975; 15:
854-859
5. A hmad WN, P olk HC: Blunt abdominal
trauma. Arch Surg 1976; 111; 489-492
6. D rew R, Perry J, Fischer R: The expe
diency of peritoneal lavage in children.
Surg Gynecol Obstet 1976; 142: 161 —
167
7. Fischer RP, B everlin BC, Encrav LH et
476

JCC, VOL. 34, NO 5, OCTOBRE 1991

al: Diagnostic peritoneal lavage. Four
teen years and 2,586 patients later. Am
JSurg 1978; 136: 701-704
8. Gomez GA. A lvarez R, P lasencia G et
al: Diagnostic peritoneal lavage in the
management of abdominal trauma: a
reassessment. J Trauma 1987; 27: 1-5
9. P erry JJ, Demeules JE, Root HD: Diag
nostic peritoneal lavage in blunt abdomi
nal trauma. Surg Gynecol Obstet 1970;
131: 742-724

10. T hal ER: Evaluation of peritoneal la
vage and local exploration in lower
chest and abdominal stab wounds. J
Trauma 1977; 17: 642-648
11. Fabian TC, Mancianti EC, W hite TJ et
al: A prospective study of 91 patients
with both CT and peritoneal lavage
following blunt abdominal trauma. J
Trauma 1986; 26: 602-609
12. Duus BR, Hansh O, Dam P et al:
Peritoneal lavage for the evaluation of
patients with equivocal signs after ab
dominal trauma. Acta Chir Scand 1986;
152: 601-604
13. R yan IJ, K yes FN, Horner WR et al:
Critical analysis of open peritoneal la
vage in blunt abdominal trauma. Am J
Surg 1986; 151: 221-223
14. Pachter HL, Hofstetter SR: Open and
percutaneous paracentesis and lavage
for abdominal trauma. A randomized
prospective study. Arch Surg 1981;
116: 318-319
15. Rothenberc S, Moore E, M arx J et al:
Selective management of blunt abdomi
nal trauma in children — the triage role
of peritoneal lavage. J Trauma 1987;
27:1101-1106
16. Lowe RJ, Boyd DR, Fold FA: The
negative laparotomy for abdominal trau
ma. J Trauma 1972; 12: 853-861
17. Maynard A, Oropega C: Mandatory op
eration for penetrating wounds of the
abdomen. Am J Surg 1968; 115: 307312
18. Olson WR. Redman HC, H ildreth DH:
Quantitative peritoneal lavage in blunt
abdominal trauma. Arch Surg 1972;
104: 536-543

19. Myers RA, Cowley RA, A garwal NN: A
safe semi-open procedure for diagnostic
peritoneal lavage. Surg Gynecol Obstet
1981; 153: 739-740
20. Parvin S, S mith DE. A sher WM et al:
Effectiveness of peritoneal lavage in
blunt abdominal trauma. Ann Surg
1975; 181: 255-261
21. Matsubara TK, Fong HMT, Burns CM:
Computed tomography of abdomen
(CTA) in management of blunt abdomi
nal trauma. J Trauma 1990; 30: 410417
22. Pacliarello MD, Hanna SS, Gregory
WD et al: Abdominopelvic computerized
tomography and open peritoneal lavage
in patients with blunt abdominal trau
ma: a prospective study. Can J Surg
1987; 30: 10-13

Minimal Access Surgery
An international symposium on minimal
access surgery will be held Nov. 17-19,
1991 at the Ritz-Carlton Hotel, Kansas
City, Mo. During this 3-day symposium
leading practitioners of advanced sur
gery from around the world will present
the latest techniques to surgeons, pri
mary care physicians and nurses. Spon
sored by Surgix and Shawnee Mission
Medical Center. Registration fee: $500
(US) before Nov. 1, 1991, $600 (US)
after Nov. 1. For further information
contact: Monique Basom, Ste. 355,
9119 W 74th St., Shawnee Mission, KS
66204: phone (913) 432-5428, fax
(913)432-7749.

Advanced Endoscopic Surgery
The University of California, Davis, Of
fice of Continuing Education is present
ing a course on advanced endoscopic
surgery, Dec. 5 and 6, 1991, at the
University of California Davis School of
Medicine, Davis, Calif. The course will
provide a follow-up to laparoscopic cho
lecystectomy and teach the additional
skills required to perform laparoscopic
appendectomy, lymphadenectomy, bileduct exploration, enterolysis, esopha
geal myotomy, hernia repair, intestinal
resection, vagotomy and pleurectomy.
Credit: 17 hours Category 1. Fee: $3
200 (US). For further information con
tact: Office of Continuing Medical Edu
cation, UC Davis Medical Center, 2701
Stockton Blvd., Sacramento, CA
95817; phone (916) 734-5390, fax
(916)736-0188.

Trauma Conference
The 3rd annual California Trauma Con
ference will be held at the Hyatt Regen
cy Hotel, Sacramento, Calif., Jan. 9-11,
1992. For more information contact:
Office of Continuing Medical Education,
UC Davis School of Medicine, 2701
Stockton Blvd., Sacramento, CA
95817; phone (916) 734-5390, fax
(916)736-0188.
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Eccrine Spiradenoma: a Report
of Malignant Transformation
C.J. Engel, MB, FRCSC;*$ G.E. Meads, MD, FACS, FRCSC;* N.G. Joseph, MD;t
W. Stavraky, MD, FRCSC*
The authors report the case of a 21-year-old man who had malignant transformation
within an eccrine spiradenoma involving the big toe. Although benign eccrine
spiradenoma is not an uncommon cutaneous adnexal tumour, malignant change in
this tumour is rare. To the authors’ knowledge only 16 cases have been reported
previously. Two histologically distinct components were seen in the tumour: typical
eccrine spiradenoma, constituting a small part of the tumour, and carcinoma with
areas of transition. The patient was treated by below-knee amputation and
superficial inguinal node dissection. There was no evidence of recurrence 2 years
after surgery.

Les auteurs decrivent le cas d’un homme de 21 ans qui subit une transformation
maligne d’un epithelioma sudoripare touchant le gros orteil. Bien que l'epithelioma
sudoripare benin ne soit pas une tumeur cutanee annaxielle rare, sa transformation
maligne Test. A notre connaissance, seulement 16 cas ont ete signales auparavant. A
l’histologie, deux composantes distinctes furent observees dans la tumeur : un
epithelioma sudoripare typique qui constituait une petite partie de la tumeur, et le
carcinome avec des regions de transition. Le patient fut traite par amputation sous
le genou et dissection superficielle des ganglions inguinaux. Aucun signe de
recidive n’etait observable, 2 ans apres l’operation.

ccrine spiradenomas were first
described by Kersting and Helwig1 in 1956, as a benign tumour of
sweat glands. Since then sporadic
reports of malignant transformation
within these benign lesions have
appeared in the literature.2-9 In all,
16 cases have been documented to
date.2-9 We report our experience
with this uncommon entity.

E

Case R eport

A 21-year-old white man was
admitted for excision of a recurrent
lesion on the dorsolateral aspect of
the right great toe. The lesion was
first noted when the patient was 9
years old. It had been cauterized on
several occasions. When the patient
was 13 years old, local excision of
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the tumour was performed. Histo
logic examination showed a benign
eccrine spiradenoma. The lesion re
curred locally approximately 6
weeks after excision and grew very
slowly until 2 years before we saw
him, when it began to grow more
rapidly. The patient was then lost to
follow-up until he presented in Feb
ruary 1988.
The patient had a bilobed, pain
less. fluctuant lesion, measuring 4
cm across, on the dorsolateral as
pect of the right great toe involving
the nail bed. One suspicious lymph
node was palpable in the right in
guinal area. Radiographs of the
right foot showed no bony abnor
mality. Social history included a
five-pack-aryear smoking history,
moderate alcohol intake, no illicit
drug use and no risk factors for
human immunodeficiency virus.
Under general anesthesia local
resection was performed. The tu
mour was found to extend onto the
dorsum of the foot along the exten
sor hallucis longus tendon to the
level of the proximal head of the
first metatarsal.
Histologic examination of the
specimen showed malignant trans
formation in a benign eccrine spir
adenoma with involvement of deep
and proximal resection margins.
A work-up to identify possible
metastases included liver function
tests, chest radiography, computed
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tomography of the abdomen, and
magnetic resonance imaging of the
right lower extremity and abdomen.
All of these were negative for meta
static disease.
Staff from the Department of
Oncology and Department of Der
matology were consulted. Treat
ment options were discussed with
the patient, who elected to have a
below-knee amputation. This was
performed along with a superficial
right inguinal node dissection. His
tologic examination revealed no re
sidual tumour, and lymph nodes
contained no malignant cells.
There has been no evidence of
metastatic disease since the opera
tion in 1988.

with vesicular nuclei, multiple mi
cronucleoli and frequent mitotic fig
ures (Fig. 3). There was focal squa
mous differentiation. The deep and
proximal resection margins were
positive for malignant cells. A re
view of the original tumour excised

8 years earlier showed features of
benign eccrine spiradenoma.
Examination of the below-knee
amputation specimen showed no re
sidual tumour, and the inguinal
lymph nodes were negative for ma
lignant cells.

Pathological Findings
Grossly the specimen measured
1 4 X 4 X 4 cm. It was composed of
multiple confluent tumour nodules
up to 4 cm in size arranged in a
linear fashion. Microscopic exami
nation revealed sharply demarcated
lobules of tumour cells, located in
the dermis and focally infiltrating
into the subcutaneous tissue (Fig.
1). There were areas of cystic
change and necrosis. Two distinct
components were seen in the tu
mour. Approximately one-third of
the tumour showed typical features
of benign eccrine spiradenoma com
posed of masses of tumour cells
formed of two types of epithelial
cells arranged in intertwining cords
and partially forming small lumina.
The cells of the first type had small
dark nuclei, and the second type
had large pale nuclei (Fig. 2). The
remaining tumour showed evidence
of malignant transformation with
areas of transition. The histologic
features of the carcinomatous areas
varied from fairly well-differentiated
tubular structures lined by either a
single or double layer of cells to
sheets of undifferentiated large cells
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FIG. 1. Low-power view of tumour demonstrates sharply demarcated tumour
lobules separated by delicate fibrous septa, located in dermis (hematoxylin-eosin,
original magnification X 5.8).

FIG. 2. Area of tumour showing benign eccrine spiradenoma. Note characteristic
two types of cells arranged in intertwining cords (hematoxylin-eosin, original
magnification X 420).

ECCRINE SPIRADENOMA

Discussion
Eccrine sweat glands are one of
the many adnexal structures in the
skin. They are simple tubular
glands that open directly to the
skin; their thin watery secretion is
important in regulating body heat.
Although present everywhere in
skin, they are concentrated in the
axillae, palms of the hands and

soles of the feet. Malignant eccrine
sweat-gland tumours are extremely
uncommon. They can be divided
into two main groups: eccrine ade
nocarcinomas that occur de novo in
normal skin and those developing
within pre-existing benign eccrine
lesions.
In a review of 46 patients with
eccrine spiradenoma, Mambo4 found

FIG. 3. Histologic features of malignant eccrine spiradenoma. (Top) In some areas
malignant cells form well-differentiated tubules, but in other areas these tubules are
not as well defined (arrows) (hematoxylin-eosin, original magnification X 420). (B)
Undifferentiated carcinoma composed of large cells with vesicular nuclei, prominent
micronucleoli and frequent mitotic figures (arrows) (hematoxylin-eosin, original
magnification X 680).

no sex preference. All patients were
white, ranging in age from 17 to 77
years (mean 42.6 years). The high
est incidence was in the fourth
decade. The majority of lesions
were solitary. Lesions are reported
to range in size from 1.5 to 10 cm.7
Only 16 cases of malignant trans
formation in eccrine spiradenoma
have been reported.2-9. They oc
curred on the extremities (eight),
trunk (seven) and neck (one). No
sex predilection was noted. The
patients ranged in age from 26 to
85 years. The lesions ranged in size
from 0.8 to 10 cm. In nine patients
complete surgical excision proved
curative, two had local recurrence,
and metastases developed in five
patients. Four patients died. Follow
up information was not available in
two cases.
The typical history is that of a
long-standing cutaneous nodule
that begins to enlarge, often rapid
ly. This may be associated with
ulceration and colour change.
These tumours have variable histo
logic features, ranging from undif
ferentiated areas to carcinoma with
squamous and glandular differentia
tion.2-9 Sarcomatoid areas with os
teoclast-like giant cells also have
been described.2 These lesions have
variable growth rates, are destruc
tive and tend to recur.
The histologic characteristics of
the tumour in our case were similar
to those reported previously.2-9
Areas of benign eccrine spiradeno
ma and carcinoma with transition
confirmed the diagnosis of malig
nant transformation. The malignant
areas showed features similar to
classic-type eccrine sweat-gland car
cinoma — fairly well-differentiated
tubular structures in some areas
and large undifferentiated cells in
other areas. There was also focal
squamous differentiation.
The natural course of this malig
nant tumour varies. Patients with
lymph-node metastases have been
CJS, VOL. 34, NO. 5, OCTOBER 1991
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reported as doing well 7 years after
surgical excision,2 whereas death
from diffuse metastases has been
reported only a few months after
excision.8-9 Although only a few
cases of malignant eccrine spiradenoma are reported, this tumour is
considered generally as a highgrade sweat-gland carcinoma.10
The method of spread of these
tumours appears to be both lym
phatic and hematogenous. Several
cases of pulmonary metastases in
the absence of local recurrence or
regional node involvement have
been reported.5-9
The appropriate management of
malignant eccrine spiradenoma ap
pears to be wide local excision. The
role of adjuvant radio- and chemo
therapy is not yet well defined.
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Proteus, indole positive and negative
Haemophilus influenzae
Providencia species
Anaerobes

Bacteroides fragilis
MEFOXIN® may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas
spp., most strains of enterococci, many strains
of Enterobacter cloacae, and m ethicillinr e s is ta n t s t a p h y lo c o c c i and L is te ria
monocytogenes.
Clinical experience has demonstrated that
MEFOXIN® can be administered to patients who
are also receiving carbenicillin, gentamicin,
tobramycin, or amikacin (see PRECAUTIONS
and ADMINISTRATION).
PROPHYLACTIC USE

MEFOXIN® may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal or
abdominal hysterectomy and abdominal surgery
when there is a significant risk of postoperative
infection or where the occurrence of post
operative infection is considered to be especially
serious.
In patients undergoing cesarean section, intra
operative (after clamping the umbilical cord)
and postoperative use of MEFOXIN® may
reduce the incidence of surgery related post
operative infections.

2 6 5 -2 6 8

10. S anta C ruz DJ: Sweat gland car
cinomas: a comprehensive review. Semin
Diagn Pathol 1987; 4: 3 8 - 7 4
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Effective prophylactic use depends on the time
of administration. MEFOXIN® usually should be
given one-half to one hour before the operation.
Prophylactic administration should usually be
stopped within 12 hours. It has been generally
reported that continuing administration of any
antibiotic beyond 24 hours following surgery
increases the possibility of adverse reactions
but, in the majority of surgical procedures, does
not reduce the in cid e n ce of subsequent
infection.
If signs of postsurgical infection should appear,
specimens for culture should be obtained for
identification of the causative organism(s) so
that appropriate treatment may be instituted.

CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN® is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
sensitivity reactions to MEFOXIN®, cepha
losporins, penicillinsorotherdrugs. MEFOXIN®
should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence
of partial cross-allergenicity between cephamycins and the other beta-lactam antibiotics,
penicillins and cephalosporins. Severe reactions
(including anaphylaxis) have been reported
with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported
w ith v ir tu a lly a ll a n tib io tic s in c lu d in g
MEFOXIN®. This colitis can range from mild to
life threatening in severity. Antibiotics should
therefore be prescribed with caution in indi
viduals with a history of gastrointestinal disease,
particularly colitis. It is important to consider a
diagnosis of pseudomembranous colitis in
patients who develop diarrhea in association
with antibiotic use. While studies indicate that a
toxin produced by Clostridium difficile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form of
allergy, particularly to drugs, should receive
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs,
adm inistration of the drug should be dis
continued. Serious hypersensitivity reactions
may require treatment with epinephrine and
other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced when
MEFOXIN® is administered to patients with
transient or persistent reduction of urinary
output due to renal insufficiency (see DOSAGE
AND ADMINISTRATION) because high and
prolonged serum antibiotic concentrations can
occur from usual doses.
In patients treated with MEFOXIN® a false
positive reaction to glucose in the urine may
occur with Benedict’s or Fehling's solutions but
not with the use of specific glucose oxidase
methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum concen
trations of cefoxitin exceed 100pg/mL. Serum
samples from patients treated with MEFOXIN®
should not be analyzed for creatinine if with
drawn within two hours of drug administration.
High concentrations of cefoxitin in the urine
may interfere with measurement of urinary 17hydroxy-corticosteroids by the Porter-Silber
reaction, and produce false increases of modest
degree in the levels reported.
Increased nephrotoxicity has been reported
fo llo w in g c o n c o m ita n t a d m in istra tio n of
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient's condition is
essential and if super-infection occurs during
therapy, appropriate measures should be taken.
Should an organism become resistant during
antibiotic therapy, another antibiotic should be
substituted.

Use in Pregnancy
The safety of MEFOXIN® in the treatment of
infections during pregnancy has not been
established. If the administration of MEFOXIN®
during pregnancy is considered necessary, its
use requires that the anticipated benefits be
weighed against possible hazards to the fetus.
Reproductive and teratogenic studies have been
performed in mice and rats and have revealed no
evidence of impaired fertility or harm to the fetus
due to MEFOXIN®.
There are no controlled studies in pregnant
women.
Nursing Mothers
Cefoxitin is excreted in human milk. Caution
should be exercised if use is indicated.
Children
In children 3 months of age or older, higher
doses of MEFOXIN® (100 m g/kg /d a y and
above) have been associated with an increased
incidence of eosinophilia and elevated SGOT.

ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse
reactions rarely required cessation of treatment
and usually have been mild and transient.
Local Reactions
Throm bophlebitis has occurred with in tra 
venous administration. Some degree of pain and
tenderness is usually experienced after intra
muscular injections using water. Induration has
occasionally been reported.
Allergic
M a c u lo p a p u la r rash, u rtic a ria , p ru ritu s ,
eosinophilia, fever and other allergic reactions
including anaphylaxis have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported rarely.
Blood
Eosinophilia, leukopenia, neutropenia, hemo
lytic anemia, and thrombocytopenia and bone
marrow depression have been reported. Some
individuals, particularly those with azotemia,
may develop positive direct Coombs tests
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase and
jaundice have been reported.
Cardiovascular Function
Hypotension.
Renal Function
Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure has
been reported rarely. The role of MEFOXIN® in
changes in renal function tests is difficult to
assess, since factors predisposing to prerenal
azotemia or to impaired renal function have
often been present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN® can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously
or intramuscularly as required. (See complete
m o n o g ra p h on A D M IN IS T R A T IO N and
RECONSTITUTION.)
Intravenous Administration
The intravenous route is preferable for patients
with bacteremia, bacterial septicemia, or other
severe or life-threatening infections, or for
patients who may be poor risks because of
lowered resistance resulting from such debili
ta tin g conditions as m alnutrition, trauma,
surgery, diabetes, heart failure, or malignancy,
particularly if shock is present or impending.
TREATMENT DOSAGE
Adults
The usual a d u lt dosage is 1 g or 2 g of
MEFOXIN® every 6 to 8 hours. Dosage and
route of administration should be determined by

severity of infection, su sce p tibility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.
Usual Adult Dosage
T y p e of
in fe c tio n

D a ily
Dosage

F re q u e n c y
a n d R o u te

Uncomplicated
forms* of in
fections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

1 g every 6-8 h
I.V. or I.M.

Moderately
severe or severe
infections

6-6 g

1 g every 4 h
or
2 g every 6-8 h I.V.

Infections
commonly
needing antibiotics in higher
dosage (e.g. gas
gangrene)

12 g

2 g every 4 h
or
3 g every 6 h I.V.

‘ Including patients in whom bacteremia is absent or
unlikely

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
for at least 10 days to guard against the risk of
rheum atic fever or g lom erulonephritis. In
staphylococcal and other infections involving a
collection of pus, surgical drainage should be
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients with
reduced renal function but a reduced dosage
should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given. After
a loading dose, the following recommendations
for maintenance dosage may be used as a guide:
MAINTENANCE DOSAGE OF
MEFOXIN® IN ADULTS
WITH REDUCED RENAL FUNCTION
RENAL

DOSE

FREQUENCY

Mild
impairment

50-30

1-2 g

every 8-12 h

Moderate
impairment

29-10

1-2 g

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

Severe
impairment
Essentially
no function

A t p re se n t th e re is in s u ffic ie n t d a ta to
recommend a specific dosage for children with
impaired renal function. However, if the adminis
tration of MEFOXIN® is deemed to be essential
the dosage should be modified consistent with
the recommendations for adults (see Table
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN® is recommended as follows:
Vaginal or abdominal hysterectom y and
abdominal surgery
2 g adm inistered in tra m u scu la rly o r in tra 
venously just prior to surgery (approximately
one-half to one hour before initial incision).
The second and third 2 g doses should be
administered at 2-6 hour intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord has
been clamped. The second and third 2 g doses
should be given intravenously or intram us
cularly four hours and eight hours after the first
dose.

AVAILABILITY
MEFOXIN® is supplied as sterile powder in
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
3548Ca - 1 g c e fo xitin as sodium salt in
ADD-Vantage® vial
3549C a - 2 g c e fo xitin as sodium sa lt in
ADD-Vantage® vial
For full details on preparation and adminis
tration with ADD-Vantage® vials - please
consult Product monograph.
Storage
MEFOXIN® in the dry state should be stored
below 30°C. The d ry m aterial as w e ll as
solutions tends to darken, depending on storage
conditions; product potency, however, is not
adversely affected.

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST

C R E A T IN IN E
CLEARANCE
m L /m in

F U N C T IO N

In severe infections, the total daily dosage in
infants and children may be increased to
200 mg/kg, but not to exceed 12 g per day.
MEFOXIN® is not recommended forthe therapy
of meningitis. If meningitis is suspected, an
appropriate antibiotic should be used.

(342-a,11,90)

MSD
3386
MEMBER

I PAAB

In patients undergoing hem odialysis, the
loading dose of 1 - 2 g should be given after each
hemodialysis, and the maintenance dose should
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants
and Children (See WARNINGS for Neonates
under ADMINISTRATION in the com plete
monograph.)
P r e m a tu r e In fa n ts
w ith B o d y W e ig h ts
A bove 1500 g

20-40 mg/kg every 12 h I.V.

N e o n a te s

01-

1 week of age 20-40 mg/kg every 12 h I.V.
4 weeks of age
20-40 mg/kg every 8 h I.V.

In fa n ts

1 month to 2 years
of age

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

C h ild r e n

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.
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Duodenal Ulcer Hemorrhage in the
Puerperium
N.O. Aston, FRCS;* S. Kalaichandran, MRCOG;t J.V.L. Carr, MRCOGt
Hemorrhage from a peptic ulcer during pregnancy is a rare complication that occurs
most frequently near term or in the puerperium. A case of massive hematemesis
from a duodenal ulcer on the third puerperal day is described. Emergency surgery
with vagotomy and pyloroplasty was performed. The mother had no symptoms of
peptic ulceration until the onset of mild abdominal pain 4 days before delivery.

L’hemorragie d’un ulcere gastroduodenal durant la grossesse represente une
complication rare qui survient, le plus souvent, lorsque la patiente est rendue
presque a terme ou durant le puerperium. On decrit un cas d’hematemese massive
causee par un ulcere duodenal, qui survint au troisieme jour du puerperium. Une
chirurgie comprenant vagotomie et pyloroplastie fut pratiquee en urgence. La mere
n’avait presente aucun symptome d’ulcere gastroduodenal jusqu’a l’apparition de
douleurs abdominales legeres, 4 jours avant l’accouchement.

eptic ulcers are uncommon in
pregnancy and the puerperium.
Complications and death are rare.1
The last two recorded deaths from
peptic ulcer complications in Eng
land and Wales were perforations of
esophageal and duodenal ulcers.2
We report a case of life-threatening
hemorrhage in the puerperium from
a duodenal ulcer.

P

Case Report
A 29-year-old woman (gravida 4,
para 2) was admitted at 39 weeks’
gestation after 2 days of diffuse
abdominal pain. The antenatal peri
od had been uncomplicated. Her
prepregnancy medical history was
unremarkable, and she had never

had any peptic ulcer symptoms. On
examination there was no abdomi
nal or uterine tenderness. The uter
ine size corresponded to dates, and
the fetal heart rate was normal. Her
blood pressure was raised at
140/90 mm Hg. Three days after
admission proteinuria developed, so
labetolol hydrochloride, 200 mg
twice daily, was prescribed. On the
fourth day the patient went into
spontaneous labour and was deliv
ered of a healthy girl weighing 2.95
kg.
The day after delivery the patient
felt faint and complained of nausea
and epigastric pain. Her pulse rate
was 80 beats/min and her blood
pressure 9 0 /5 0 mm Hg. There was
no hematemesis or melena. Her
symptoms resolved, and her blood
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pressure returned to normal after
treatment with intravenous fluids.
On the third puerperal day she had
a fresh hematemesis. Her pulse rate
was 100 beats/min and her systolic
blood pressure 60 mm Hg. The he
moglobin level was 80 gm /L and
the leukocyte count 2.8 X 109/L .
Blood transfusion was begun, and
she was transferred to the intensive
care unit. Six hours after the first
hematemesis she went into shock
with an unrecordable blood pres
sure. At emergency laparotomy a
posterior duodenal ulcer, 2 cm in
diameter, was found to have eroded
into the gastroduodenal artery. Di
rect pressure controlled the bleed
ing until transfusion restored a pal
pable aortic pulse. The ulcer was
then underrun with silk sutures. A
truncal vagotomy and pyloroplasty
were performed. She received a
total of 17 units of blood.
She was ventilated electively after
surgery. The postoperative period
was complicated by severe adult
respiratory distress syndrome and
bronchopneumonia. She made a full
recovery and was discharged home
25 days after surgery. A 3-month
course of cimetidine was prescribed.
She was well when examined at her
last outpatient visit 10 months after
delivery.

Discussion
Gastric acid production is re
duced during pregnancy and re
turns to normal in the puerperium.3
The reduction in acid production

ULCER HEMORRHAGE IN PUERPERIUM

alone cannot explain the great de
crease in peptic ulcer symptoms in
pregnancy.45 Reduced gastrointesti
nal motility, better nutrition, re
duced smoking and alcohol con
sumption, and better medical super
vision probably all contribute to the
low incidence of the disease during
pregnancy. Peptic ulcer complica
tions increase near term and in the
puerperium, and the majority of
mothers will not have had any pre
vious symptoms of peptic ulcer
ation.6 Complications are more
commonly associated with pre
eclampsia and eclampsia.7 Massive
hemorrhage from a gastric ulcer
has been reported in a patient with
pre-eclampsia treated with gluco
corticoids.8
The principles of the treatment of
peptic ulcer and its complications
do not change in pregnancy.9 When
access for surgery is limited near
term, cesarean section is advised.
Cimetidine and ranitidine cross the
placenta but do not appear to be
teratogenic.10 However, transient
liver impairment in a newborn has
been reported.11 These drugs are
also excreted in breast milk in a
higher concentration than in se
rum.10
The morbidity and mortality of
peptic ulcer complications are high
er for mother and fetus if diagnosis
or treatment is delayed.12 A diagno
sis of peptic ulcer should be consid
ered in any patient complaining of
epigastric pain in late pregnancy or
the puerperium. If there is an asso
ciated hypotensive episode urgent
endoscopy is mandatory. There
should be no delay in performing
surgical procedures.
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SESAP VI Critique
Critique SESAP VI
Item 30
Well-differentiated tumors produce greater quantities of carcinoembryonic antigen (CEA) than do poorly differentiated tumors. Regular
sequential assay of CEA is the best noninvasive technique to detect
recurrence postoperatively. Preoperative CEA level and Dukes’ class,
and therefore prognosis, are strongly correlated. CEA testing is neither
sensitive nor specific enough to be used for routine screening for
possible malignancies in an asymptomatic population. Although elevat
ed levels of CEA after resection of colon cancers are strongly associated
with subsequent tumor recurrence, postoperative CEA elevations are
more strongly predictive of recurrence when part of a steadily rising
trend. Depending on the preoperative level of CEA, several weeks may
be required for CEA to return to normal levels after complete excision
of a colon cancer.
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Sterile Ceftriaxone Sodium
For Injection
Therapeutic Classification
Antibiotic
INDICATIONS AND CLINICAL USES The treatment of the following infections when caused by susceptible strains of the
designated micro-organisms: Lower respiratory tract infections caused by E. coli, H. influenzae, K. pneumoniaeand species,
Staph, aureus, Strep, pneumoniae and species (excluding enterococci). Urinary tract infections (complicated and
uncomplicated) caused by E. coli, Klebsiella species, P. mirabilis and P. vulgaris. Bacterial septicemia caused by E coli,
H. influenzae, K. pneumoniae, Staph, aureus and Strep, pneumoniae (excluding enterococci). Skin and skin structure
infections caused by K. pneumoniae and species, P. mirabilis, Staph, aureus, Staph, epidermidis and Streptococcus
species (excluding enterococci). Bone and joint infections caused by Staph, aureus, Strep, pneumoniaeand Streptococcus
species (excluding enterococci). Meningitis caused by H. influenzae, l\l. meningitidis, and Strep, pneumoniae. Rocephin
should not be used for the treatment of meningitis caused by L. monocytogenes. Uncomplicated gonorrhea (cervical/
urethral and rectal) caused by N. gonorrhoeae (penicillinase and nonpenicillinase producing strains).
Prophylaxis: The preoperative administration of a single 1 g dose of Rocephin' (sterile ceftriaxone sodium) may reduce
the incidence of postoperative infections in patients undergoing vaginal or abdominal hysterectomy, coronary artery
bypass surgery, or in patients at risk of infection undergoing biliary tract surgery. If signs of post surgical infection should
appear, specimens for culture should be obtained for identification of the causative organism(s) so that the appropriate
therapy may be instituted. CONTRAINDICATIONS Rocephin® (sterile ceftriaxone sodium) is contraindicated in patients
with known allergy to ceftriaxone, other cephalosporins or penicillins. WARNINGS Before therapy with Rocephin® (sterile
ceftriaxone sodium) is instituted, careful inquiry should be made concerning previous hypersensitivity reactions to
ceftriaxone, other cephalosporins, penicillins or other allergens. Rocephin® should only be administered with caution to
any patient who has demonstrated any form of allergy particularly to drugs. Serious, and occasionally fatal hypersensitivity
(anaphylactoid) reactions have been reported in patients receiving cephalosporins. The reactions are more likely to occur
in persons with a history of sensitivity to multiple allergens. Rocephin® should be administered with caution to patients
with type I hypersensitivity reaction to penicillin. If an allergic reaction occurs, the administration of Rocephin® should be
discontinued and appropriate therapy instituted. Pseudomembranous colitis has been reported with the use of Rocephin®,
(and with broad-spectrum and other antibiotics). Therefore, it is important to consider its diagnosis in patients
administered Rocephin ‘ who develop diarrhea. Treatment with broad-spectrum antibiotics, including Rocephin®, alters
the normal flora of the colon and may permit overgrowth of Clostridia. Studies indicate that a toxin produced by Clostridium
difficile is one primary cause of antibiotic-associated colitis. Mild cases of colitis may respond to drug discontinuation
alone. Moderate to severe cases should be managed with fluid, electrolyte, and protein supplementation as indicated.
When the colitis is not relieved by discontinuation of Rocephin® administration or when it is severe, consideration should
be given to the administration of vancomycin or other suitable therapy. Other possible causes of the colitis should also
be considered. Rocephin’ therapy should be discontinued in patients who develop signs or symptoms suggestive of
gallbladderdiseaseandconServativemanagementconsidered.Theeffectof pre-existinggallbladderdiseaseis not known.
In a few patients administered Rocephin®, shadows suggesting “ sludge" have been detected by sonograms of the
gallbladder in those who remained asymptomatic and in those who became symptomatic. This condition appeared to be
reversible on discontinuation of Rocepltin*therapy. In afew symptomatic patients receiving 4 g ot Rocephin - who underwent
cholecystectomy, “sludge" containing traces of ceftriaxone was recovered from surgical specimens. Concretions
consisting of the precipitated calcium salt of ceftriaxone have been found in the gallbladder bile of dogs and baboons
treated with high doses of ceftriaxone. PRECAUTIONS General Hypoprothrombinemiaand alterations in prothrombin time
have occurred rarely in patients treated with Rocephin* (sterile ceftriaxone sodium) (see ADVERSE REACTIONS). Patients
with impaired vitamin K synthesis or low vitamin K stores (e.g. chronic hepatic disease and malnutrition) may require
monitoring of hematology and coagulation parameters during Rocephin* treatment. Vitamin K administration (10 mg
weekly) may be necessary if the prothrombin time is prolonged before or during treatment. Prolonged treatment with
Rocephin* may result in overgrowth of non-susceptible organisms and organisms initially sensitive to the drug. If
superinfection occurs, appropriate measures should be taken. Rocephin* should be administered with caution to individuals
with a history of gastrointestinal disease, particularly colitis. Renal and Hepatic Impairment Although transient elevations
of BUN and serum creatinine have been observed in clinical studies, there is no other evidence that Rocephin” , when
administered alone, is nephrotoxic. In severe renal impairment (creatinine clearance of less than 10 mL/min), periodic
monitoring of serum ceftriaxone concentrations is recommended. The maximum daily dose should not exceed 2 g. In
severe renal impairment associated with clinically significant hepatic impairment, close monitoring of serum ceftriaxone
concentrations, at regular intervals, is recommended. If there is evidence of accumulation, dosage should be decreased
accordingly. Interactions Interactions between Rocephin ‘ and other drugs have not been fully evaluated. Pregnancy The
safety of Rocephin® in the treatment of infections during pregnancy has not been established. Rocephin* should only be
used during pregnancy if the likely benefit outweighs the potential risk to the fetus and/or the mother. Ceftriaxone has been
detected in the umbilical cord blood, amniotic fluid and placenta. Nursing Mothers Ceftriaxone is excreted in human milk
at low concentrations. The clinical significance of this is unknown; therefore, caution should be exercised when Rocephin'
is administered to a nursing mother. Neonates The safety of Rocephin” in neonates (birth to one month of age) has not
been established. In wfrostudies have shown that ceftriaxone can displace bilirubin from serum albumin. Caution should
be exercised when considering Rocephin Ktreatmentfor hyperbilirubinemic neonates especially if premature. Elderly Patients
The elimination of ceftriaxone may be reduced in elderly patients possibly due to impairment of both renal and hepatic
function. Drug-Laboratory Test Interactions Ceftriaxone may interfere with urine glucose determinations utilizing the
copper-reduction test (CLINITEST), but not utilizing the glucose-oxidase test (DlASTIX or TES-TAPE) ADVERSE REACTIONS
During clinical trials with Rocephin* (sterile ceftriaxone sodium) the following adverse reactions have been observed:
Clinical Adverse Experiences: Dermatological: Rash (1.3%); exanthema, allergic dermatitis and pruritis (0.1 -1.0%).
Hematological: Anemia (0.1 -1.0% ); auto-immune hemolytic anemia and serum sickness (<0.1%). Hepatic: Jaundice,
reports (in asymptomatic and symptomatic patients) of ultrasonographic shadows suggesting precipitations in the
gallbladder and reports of gallbladder sludge (<0.1%). Urogenital: Moniliasis and vaginitis (0.1 -1.0%). Gastrointestinal:
Diarrhea (3.3%); nausea, vomiting, dysgeusiaand gastric pain (0.1 -1.0%); abdominal pain, colitis, flatulence, dyspepsia,
pseudomembranous colitis and stomatitis (<0.1%). Neurological: Dizziness and headache (0.1 -1.0% ); ataxia and
paresthesia (<0.1 %). Miscellaneous: Fever, chills, diaphoresis, malaise, burning tongue, flushing, edema and anaphylactic
shock (0.1 -1.0% ); bronchospasm, palpitations and epistaxis (<0.1%). Local Reactions at Injection Site: Pain (9.4%),
induration and tenderness (1 -2%); phlebitic reactions (0.1-1.0%); thrombophlebitis (<0.1 %). Laboratory Abnormalities:
Hematologic: Eosinophilia (4.6%), thrombocytosis (5.1%), leukopenia (2.0%); neutropenia, lymphophenia,
thrombocytopenia, increase or decrease in hematocrit, prolongation of prothrombin time and decrease in hemoglobin (0.1
-1.0%); leukocytosis, lymphocytosis, monocytosis, basophilia and decrease in prothrombin time (<0.1%). Hepatic: Increase
in AST (SGOT) (4.0%)°, ALT (SGPT) (4.8%)b, increase in alkaline phosphatase (1.0%); increase in bilirubin (0.1 -1.0%).
Urinary: Increase in BUN (1.1 %)c; increase in creatinine, erythrocyturia, proteinuria and presence of casts in urine (0.1
-1.0% ); glycosuria (<0.1 % ).b Incidence is more frequent in patients less than one year old.c Incidence is more frequent
in patients less than oneyearold and over 50 years old. SYMPTOMS AND TREATMENT OF OVERDOSAGE Ultrasonographic
shadows suggesting precipitations in the kidneys accompanied by calcium ceftriaxone precipitate in the urine was
observed in one patient dosed with Rocephin ” (sterile ceftriaxone sodium) at 10 g/day (2.5 times the maximum recommended
dose). No other case of overdosage has been reported to date with Rocephin®. No specific information on symptoms or
treatment is available. Excessive serum concentration of ceftriaxone cannot be reduced by hemodialysis or peritoneal
dialysis. Treatment should be symptomatic. DOSAGE AND ADMINISTRATION Rocephin®(sterileceftriaxone sodium) may
be administered intravenously or intramuscularly after reconstitution. Dosage and route of administration should be
determined by the severity of infection, susceptibility of the causative organisms, and condition of the patient. The
intravenous route is preferable for patients with septicemia or other severe or life-threatening infections. DOSAGE Adults:
Moderate and Severe Infections: Total daily I.M. or I.V dose 1 or 2 g daily. The daily dose may be given as 0.5 or 1 g q12h,
or 1 or 2 g q24h. There is limited experience with daily doses of 3-4 g administered as a single dose or two equally divided
doses. The total daily dose should not exceed 4 a. Uncomplicated Gonorrhea: Single dose of 250 mg I.M. Infants and
Children (one month to 12 years of age) Serious Miscellaneous Infections: Total daily I.M. or I.V. dose 50 or 75 mg/kg
administered as 25 or 37.5 mg/kg q12h. The total daily dose should not exceed 2 g. If body weight is 50 kg or more the
adult dose should be used. Meningitis: Total daily I.M. or I.V. dose -100 mg/kg administered as 50 mg/kg* q12h. * With
or without a loading dose of 75 mg/kg. The total daily dose should not exceed 4 g. With the exception of gonorrhea, which
is treated with a single dose, the administration of Rocephin* should be continued for a minimum of 48 to 72 hours after
the patient defervesces or after evidence of bacterial eradication has been obtained, usually 4 to 14 days. In bone and joint

infections the average duration of treatment during clinical trials was 6 weeks, with a range of 1 to 13 weeks, depending
on the severity of the infection. When treating infections caused by beta-hemolytic Streptococcus, it is recommended that
therapy be continued for at least 10 days. The average duration of therapy for infections associated with beta-hemolytic
Streptococcus during clinical trials was 2 weeks, with a range of 1 to 5 weeks, depending on the site and severity of the
infection. Prophylaxis (Vaginal or Abdominal Hysterectomy, Coronary Artery Bypass Surgery, Biliary Tract Surgery):
For preoperative use as prophylaxis before vaginal or abdominal hysterectomy, coronary artery bypass surgery, or biliary
tract surgery in patients at risk of infection, a single dose of 1 g administered 112 to 2 hours before surgery is recommended.
Impairment of Renal and/or Hepatic Function In patients with mild to moderate renal impairment, changes in the dosage
regimen are not required, provided liver function is intact. In cases of preterminal renal failure (creatinine clearance less
than 10 mL/min), periodic monitoring of serum ceftriaxone concentrations is recommended. The daily dosage should be
limited to 2 g or less. In patients with liver damage, there is no need for the dosage to be reduced provided renal function
is intact. In cases of coexistent renal and clinically significant hepatic insufficiency, close monitoring of serum ceftriaxone
concentrations, at regular intervals, is recommended. If there is evidence of accumulation, dosage should be decreased
accordingly. ADMINISTRATION Intramuscular: The reconstituted solution of Rocephin®should be administered by deep
intragluteal injection. It is recommended that not more than 1 g be injected at a single site. Pain on intramuscular injection
is usually mild and less frequent when Rocephin* is administered in sterile 1% Lidocaine solution. Intravenous (bolus)
Injection: The reconstituted solution should be administered over approximately 5 minutes. Short Intravenous Infusion:
The further diluted intravenous solution should be given over a period of 10 to 15 minutes in infants and children and 20
to 30 minutes in adults. NOTE: Rocephin® solution should not be physically mixed with aminoglycoside antibiotics nor
administered at the same site because of possible chemical incompatibility.
PHARMACEUTICAL INFORMATION
Reconstitution
For Intramuscular Use
Reconstitute Rocephin® powder with the appropriate diluent:
• Sterile Water for Injection
• Bacteriostatic Water for Injection
• 0.9% Sodium Chloride Injection
• 1% Lidocaine Solution
• 5% Dextrose Injection
Reconstitute as follows:
Reconstitution Table (IM)
Vial
Size

Volume to be
added to vial
mL

0.25 g

0.9

0.5 g

1.8

1.0 g

3.6

2.0 g

7.2

Approximate available
volume
mL

1f l
2

:

f

Approximate average
concentration
g/mL
0.25
0.25

4

0.25

8

0.25

Shake well until dissolved
NOTE: SOLUTIONS PREPARED FOR INTRAMUSCULAR USE OR ANY SOLUTION CONTAINING LIDOCAINE OR
BACTERIOSTATIC WATER FOR INJECTION SHOULD NEVER BE ADMINISTERED INTRAVENOUSLY.
M
For Intravenous Use
Reconstitute only with Sterile Water for Injection.
Reconstitute as follows:
Reconstitution Table (IV)
Volume to be
added to vial
mL

Approximate available
volume
mL

Approximate average
concentration
g/mL

0.25 g

2.4

2.5

0.1

0.5 g

4.8 .

5.0

0.1

1.0 g

9.6

10.0

0.1

Via!
Size

0.1
20.0
19.2
2.0 g
Shake well until dissolved. The prepared solution may be further diluted to the desired volume with any of the “Solutions
for IV Infusion" listed below.
Solutions for IV Infusion
0.9% Sodium Chloride Injection
5% Dextrose Injection
Dextrose and Sodium Chloride Injection
0.9% Sodium Chloride Injection in ADD-VANTAGE (Abbott) flexible diluent container, 50 mL and 100 mL
5% Dextrose Injection in ADD-VANTAGE (Abbott) flexible diluent container, 50 mL and 100 mL.
Pharmacy Bulk Package Reconstitution for Preparation of Intravenous Infusion Solutions
The closure of the pharmacy bulk vial shall be penetrated only one time after reconstitution, using a suitable sterile transfer
device or dispensing set which allows measured dispensing for the contents.
Reconstitution Table for Bulk Pharmacy Package
Vial
size

Volume to be
added to vial
mL

Approximate
available volume
mL

Approximate
average concentration
g/mL

10 g

95

100.0

0.1

Shake well until dissolved. Withdraw the required amount and dilute with one of the “ Solutions for IV Infusion” . Any
unused solution remaining within a period of 8 hours should be discarded.
Stability of Solutions - Storage
For complete stability and storage information, consult the Product Monograph.
Incompatibility:
Rocephin® should not be physically mixed with other antimicrobial agents.
Rocephin® should not be added to blood products, protein hydrolysates or amino acids.
Rocephin® should not be added to solutions containing calcium.
DOSAGE FORM
Availability:
1.Rocephin* Vials containing sterile powder equivalent to 0.25 g, 1 g and 2 g of ceftriaxone.
2. Rocephin® Vials containing sterile powder equivalent to 1 g and 2 g of ceftriaxone for use only with Abbott Laboratories
Limited ADD-VANTAGE (Abbott) 0.9% Sodium Chloride Injection U.S.P. or 5% Dextrose Injection U.S.P. in 50 mL and
100 mL containers.
3. Rocephin* Pharmacy Bulk Vials containing sterile powder equivalent to 10 g ceftriaxone (not for direct administration).
The availability of the pharmacy bulk vial is restricted to hospitals with a recognized intravenous admixture programme.
Storage:
Rocephin* sterile powder should be stored at a controlled room temperature (between 15° and 30°C) and protected from
light.
Product Monograph available on request.
References:
1. Hell K. Chemotherapy 1989:35:228-235.2. Rocephin* Product Monograph.
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Gastric Volvulus — a Late Complication
of Gastrostomy
Amin Alawadhi, MD, FRCSC; Shirley Chou, MD, FRCSC; Pierre Soucy, MD, FRCSC
Two cases of gastric volvulus are reviewed. Both patients were nonverbal, mentally
handicapped children, who were fed through a gastrostomy. They had intermittent
intolerance to bolus feeds through the gastrostomy, accompanied by abdominal
distension and vomiting of gastric contents. One had a previous partial
fundoplication and gastrostomy, and the other had had two pyloroplasties and
gastrostomy. The axis of torsion ran from the esophagogastric junction to the
gastrostomy site. Both children were treated by detorsion and gastropexy.
It is postulated that the gastrostomy served as a fixed point for the volvulus. This
was facilitated by the chronically dilated stomachs induced by bolus feeds. These two
cases are reported to alert the clinician to this possibility when a neurologically
impaired child with a gastrostomy presents with feeding difficulties and persistent
vomiting.

Deux cas de volvulus de l’estomac sont passes en revue. Les deux patients concernes
sont des enfants handicapes mentaux qui ne parlent pas et qui sont nourris par
gastrostomie. On a note une intolerance intermittente a l’alimentation par bolus via
la gastrostomie, accompagnee de distention abdominale et de vomissement du
contenu de l’estomac. L’un des enfants avait subi une plication partielle du fundus
avec gastrostomie, alors que l’autre avait eu deux pyloroplasties avec gastrostomie.
L’axe de torsion allait de la jonction oesophago-gastrique au site de la gastrostomie.
Les deux patients ont ete traites par correction de la torsion et gastropexie.
II est postule que la gastrostomie a servi de point fixe pour le volvulus. Ceci a ete
facilite par la dilatation chronique de l’estomac causee par l’alimentation en bolus.
Ces cas ont ete declares en vue d’alerter les cliniciens a cette possibility quand un
enfant deficient sur le plan neurologique et ayant subi une gastrostomie presente
des difficulty d’alimentation et des vomissements persistents.

astric volvulus in children is
rare. Three types have been
recognized according to the axis of
rotation: mesenteroaxial; organoaxial; and a combined form.1 We pres
ent two cases that occurred as a
complication of gastrostomy.

G

Case Reports
Case 1

A 13-year-old girl from a chronic
care facility had numerous admis

sions to the Children’s Hospital of
Eastern Ontario because of vomit
ing and inability to tolerate gastros
tomy tube feeds.
She was a product of normal
pregnancy and delivery but con
tracted encephalitis, which left her
with a progressively deteriorating
neurologic status. This led to multi
ple admissions for medical, orthope
dic, respiratory and nutritional com
plications. At 8 years of age she
had undergone partial fundoplica
tion and gastrostomy. In the ensu
ing years, she experienced intermit

tent vomiting and inability to toler
ate gastrostomy feeds. These epi
sodes would respond to conserva
tive management of intravenous hy
dration and gastrointestinal decom
pression through the gastrostomy
tube. Barium contrast studies of the
stomach and small bowel revealed
gastric volvulus.
At laparotomy, the stomach was
large. The greater curvature of the
body and antrum had rotated anteri
orly along a line connecting the
gastrostomy site to the gastroeso
phageal junction (Fig. 1). The stom
ach was straightened, and gas
tropexy and gastrostomy were per
formed.
Case 2

The second patient, a 9-year-old
girl, had severe mental retardation,
global developmental delay, deaf
ness in the right ear and dysmorph
ic facial features. Recurrent gastric
distension developed when she was
4 years old and required nasogastric
tube decompression.
Antral dysmotility was diagnosed,
so a Heineke-Mikulicz pyloroplasty
was performed. Although she im
proved initially, episodes of gastric

From the Department o f Surgery, Children’s Hospital o f Eastern Ontario, Ottawa, Ont.
Accepted for publication Sept. 24, 1990
Reprint requests to: Dr. Shirley Chou, Department o f Surgery, Children's Hospital o f Eastern
Ontario, 401 Smyth Rd., Ottawa, ON KIH 8L1

FIG. 1. Operative finding of volvulus
along esophagogastrostomy axis.
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distension recurred. At 7 years of
age she underwent a Finney pyloro
plasty and gastrostomy. This gave
temporary relief. The gastrostomy
was not effective in decompressing
the stomach, and a nasogastric tube
was always required.
An upper gastrointestinal series
revealed gastric volvulus. At opera
tion a large stomach was found
with a volvulus along an axis from
the gastrostomy site to the gastro
esophageal junction. After detor
sion, anterior gastropexy was per
formed.

Discussion
Gastric volvulus occurs when one
part of the stomach rotates along

an axis between two relatively fixed
points. The stomach is described as
having two axes: an organic axis,
which is a line joining the hiatus to
the pylorus, and a mesenteric axis,
which runs from the lesser to the
greater curvatures.2 Therefore,
three types of gastric volvulus have
been described: organoaxial; mesenteroaxial; and a mixed form. In our
patients, the axis around which
gastric rotation occurred was from
the hiatus to the gastrostomy site.
Both children had a large stomach,
which predisposes to volvulus for
mation3 when distended.
The delay in diagnosis was relat
ed to the spontaneous reduction of
the volvulus after decompression of
the stomach. Barium contrast study
without prior decompression of the

stomach would be required to ob
tain the diagnosis. These two cases
are presented to alert the clinician
to the possibility of gastric volvulus
when a neurologically impaired
child with a gastrostomy presents
with persistent feeding difficulties.

aspects of aesthetic surgery of the
breast is short, concise and factual
since it was written by the recognized
expert in the field, Marcia Goin. It is
worth reading at least twice, because a
thorough understanding of this aspect
of breast surgery is essential for the
technically good result to be translated
into a positive experience for the pa
tient. This chapter leads appropriately
into preoperative evaluation for breast
surgery. The ideal breast shape is de
fined and abnormalities are classified in
a manner that aids the surgeon in
making treatment decisions. Three im
portant paragraphs, entitled “When to
say yes and when to say no to aesthetic
breast surgery’’ should be read with
care and remembered.
There are nine chapters on the very
topical subject of breast augmentation.
A chapter on history and one on sili
cone technology are excellent and es
sential reading, as is the one on imag
ing of the augmented breast. All of the
current surgical approaches are dealt

with in detail, as are complications, how
to avoid them and how to treat them.
In the chapter on congenital and
developmental breast anomalies the dif
ficult problem of breast asymmetry in
its many forms is dealt with comprehen
sively. The importance of an accurate
definition of the problem and thorough
preoperative planning are emphasized
as well as the surgical technique.
Twenty-seven chapters (366 pages)
are appropriately devoted to reduction
mammoplasty. There is an interesting
short chapter on history as it relates to
the evolution of modern techniques. All
of these chapters are well illustrated,
and the authors are generous with their
“tips” on how to make things easier
and how to stay out of trouble. The
importance of preoperative assessment
and planning is emphasized repeatedly.
Twenty-one surgical approaches to re
duction mammoplasty are presented

References
1. Campbell JR: Volvulus of the stomach. In
W elch KJ, Randolph JA, Ravitch MM et
al (eds): Pediatric Surgery, Year Bk Med,
Chicago, 1986: 823-824
2. C ameron AEP, Howard ER: Gastric vol
vulus in childhood. J Pediatr Surg 1987;
22: 944-947
3. Carter R, Brewer LA ui, Hinsshaw DB:
Acute gastric volvulus. Am J Surg 1980;
140:99-106

BOOK REVIEWS
CRITIQUES DE LIVRES

AESTHETIC SURGERY OF THE
BREAST. Edited by Nicholas G. Georgiade, Gregory S. Georgiade and Ro
nald Riefkohl. 754 pp. Illust. W.B.
Saunders Company, London. 1990.
Price not stated.

This is an excellent text. It effectively
updates the contents of Dr. Nicholas
Georgiade’s 1983 publication Aesthetic
Breast Surgery. In 49 chapters the 93
contributors deal with the subject com
prehensively, with abundant illustra
tions and high-quality photographs.
The bibliographies for each chapter are
current and accurate.
Aesthetic surgery of the breast must
have as one of its goals preservation of
breast function and restoration of nor
mal anatomy. This requires knowledge
of breast embryology, anatomy and
physiology. The text and illustrations of
the first chapter give the reader a
thorough exposure to this essential
knowledge.
The second chapter on psychological
486
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Introducing a new regimen
for the effective management
of colorectal cancer
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T h e first m ajor
advance in
the treatment o f
Duke's D colorectal
cancer in 30 years
Leucovorin plus 5-F U
is an effective,
generally w ell tolerated
regim en that prolongs
su rvivals
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Most importantly, the improvement in response rate, duration of response,
and time to progression has beten translated into a survival advantage...
Erlichman etal.

A proven, effective, generally well
tolerated regimen th at prolongs survival.
SINCE LEUCOVORIN MAY ENHANCE THE TOXICITY OF FLUOROURACIL, LEUCOVORIN/ FLUOROURACIL
COMBINATION THERAPY FOR ADVANCED COLORECTAL CANCER SHOULD BE ADMINISTERED UNDER
THE SUPERVISION OF A PHYSICIAN EXPERIENCED IN THE USE OF ANTIMETABOLITE CANCER
CHEMOTHERAPY. PARTICULAR CARE SHOULD BE TAKEN IN THE TREATMENT OF ELDERLY OR
DEBILITATED COLORECTAL CANCER PATIENTS AS THESE PATIENTS MAY BE AT INCREASED RISK OF
SEVERE TOXICITY. DEATHS FROM SEVERE ENTEROCOLITIS, DIARRHEA AND DEHYDRATION HAVE BEEN
REPORTED IN ELDERLY PATIENTS RECEIVING LEUCOVORIN AND FLUOROURACIL. CONCOMITANT
GRANULOCYTOPENIA AND FEVER WERE PRESENT IN SOME BUT NOT ALL OF THE PATIENTS.
ACTIONS, CLINICAL PHARMACOLOGY
LEDERLE LEUCOVORIN Calcium (calcium folinate), the calcium salt ol folinic acid (citrovorum factor), is a
mixture of the diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid. The biologically active
component of the mixture is the (-)-L-isomer. It is a metabolite of folic acid and an essential coenzyme for
nucleic acid synthesis.
LEUCOVORIN is a reduced form of folic acid, which is readily converted to other reduced folic acid derivatives
(e g., tetrahydrofolate). Because it does not require reduction by dihydrofolate reductase as does folic acid,
LEUCOVORIN is not affected by blockage of this enzyme by folic acid antagonists (dihydrofolate reductase
inhibitors). This allows purine and thymidine synthesis, and thus DNA, RNA, and protein synthesis, to occur.
LEUCOVORIN may limit METHOTREXATE action on normal cells by competing with METHOTREXATE for the
same transport processes into the cell. LEUCOVORIN rescues bone marrow and gastrointestinal cells from
METHOTREXATE but has no apparent effect on pre-existing METHOTREXATE nephrotoxicity.
LEUCOVORIN is extensively converted to 5-methyltetrahydrofolate in the intestine prior to absorption. In this
form, it is a major component of the total active human serum folate. Oral absorption is saturable at doses
above 25 mg.
LEUCOVORIN enhances the cytotoxicity of fluoropyrimidines such as 5-fluorouracil (5 FU) by their
metabolites, methylene tetrahydrofolate and fluorodeoxyuridine monophosphate, forming a stable ternary
complex with thymidylate synthase, and thereby, decreasing intracellular levels of that enzyme and the product
thymidylate. The cell then dies as a result of thymine starvation.
INDICATIONS
For pre-treatment followed by 5-fluorouracil to prolong survival in the palliative treatment of patients with
advanced colorectal cancer.
CONTRAINDICATIONS
Not to be administered for the treatment of pernicious anemia or other megaloblastic anemias where Vitamin
Bi? is deficient. A hematologic remission may occur while neurologic manifestations continue to progress.
WARNINGS
Cryodesiccated powder reconstituted with Bacteriostatic Water for Injection containing benzyl alcohol should
only be used at doses below 10 mg/m2. (See PRECAUTIONS.)
Treatment-related deaths have been sporadically reported in patients treated with LEUCOVORIN plus
fluorouracil combination therapy regimens. In general, diarrhea or stomatitis/mucositis are the first indications
that severe and potentially life-threatening toxicity could develop. Patients who experience these symptoms
while receiving any combination therapy regimen incorporating LEUCOVORIN plus fluorouracil should be
carefully followed and further therapy should be withheld until these symptoms resolve.
LEUCOVORIN enhances the toxicity of fluorouracil. When these drugs are administered concurrently in the
palliative therapy of advanced colorectal cancer, the dosage of fluorouracil must be reduced. Although the
toxicities observed in patients treated with the combination of LEUCOVORIN plus fluorouracil are qualitatively
similar to those observed in patients treated with fluorouracil alone, gastrointestinal toxicities (particularly
stomatitis and diarrhea) are observed more commonly and may be more severe in patients receiving the
combination. (See PRECAUTIONS).
Therapy with LEUCOVORIN/fluorouracil must not be initiated or continued in patients who have symptoms of
gastrointestinal toxicity of any severity, until those symptoms have resolved. Patients with diarrhea must be
monitored with particular care until the diarrhea has resolved, as rapid clinical deterioration leading to death can
occur. Elderly or debilitated patients are at greater risk for severe toxicity receiving this therapy.
PRECAUTIONS
Because of the Ca++ content of LEUCOVORIN solutions, no more than 160 mg of LEUCOVORIN should be
injected intravenously per minute.
If the cryodesiccated powder is reconstituted with Bacteriostatic Water for Injection containing 0.9% benzyl
alcohol, doses greater than lOmg/m2are not recommended due to the benzyl alcohol content. If greater doses
are required (see DOSAGE & ADMINISTRATION), LEUCOVORIN Calcium for Injection (cryodesiccated powder)
should be reconstituted with Sterile Water for Injection USP and used immediately, or the preservative-free
liquid form, LEUCOVORIN Calcium Injection, should be used.
Drug Interactions:
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone,
and increase the frequency of seizures in susceptible children.
Preliminary animal and human studies have shown that small quantities of systemically administered
LEUCOVORIN enter the CSF primarily as 5-methyltetrahydrofolate and, in humans, remain 1-3 orders of
magnitude lower than the usual METHOTREXATE concentrations following intrathecal administration.
However, high doses of LEUCOVORIN may reduce the efficacy of intrathecally administered METHOTREXATE.
LEUCOVORIN may enhance the toxicity of fluorouracil. (see WARNINGS.)
Pregnancy - Teratogenic E ffects
Reproduction studies have been performed in rats and rabbits at doses at least 50 times the human dose and
have revealed no evidence of harm to the fetus due to LEUCOVORIN. There are, however, no adequate and

well-controlled studies in pregnant woman. Because animal reproduction studies are not always predictive of
human response, this drug should be used during pregnancy only if clearly needed.
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human
milk, caution should be exercised when LEUCOVORIN is administered to a nursing mother.
Pediatric Use
See Drug Interactions.
ADVERSE REACTIONS
Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
In combination regimens, the toxicity profile of 5 FU is enhanced by LEUCOVORIN. The most common
manifestations are mucositis, stomatitis, leukopenia, and/or diarrhea which may be dose-limiting. In clinical
trials with this drug combination these toxicities were found to be reversible with appropriate modification
of 5 FU administration.
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Folic acid is a water soluble vitamin converted in the body by the action of folate reductase
to folinic acid (LEUCOVORIN) which is rapidly eliminated in the urine.
Folic acid has low acute and chronic toxicity in man. No adverse effects have been
noted in adults after the ingestion of 400 mg/day for 5 months or 10 mg/day for 5 years.
Excessive amounts of LEUCOVORIN may nullify the chemotherapeutic effect of
folic acid antagonists.
DOSAGE AND ADMINISTRATION
LEDERLE LEUCOVORIN Calcium for Injection cryodesiccated powder 50 mg/vial and 350 mg/vial may be
used after reconstitution for intravenous or intramusculuar administration. The liquid injection 350 mg/35 mL
is used for intravenous or intramusculuar administration.
When LEDERLE LEUCOVORIN Calcium is used for LEUCOVORIN pre-treatment followed by 5-fluorouracil (5
FU) in the treatment of patients with advanced colorectal cancer, intravenous administration is employed.
Because of the Ca++ content of LEUCOVORIN solutions, no more than 160 mg of LEUCOVORIN should be
injected intravenously per minute.
Dosage
a) Advanced Colorectal Cancer
LEUCOVORIN is administered at 200 mg/m2 by slow intravenous injection immediately prior to dosing
with 370 mg/m25 FU (fluorouracil) by slow intravenous injection, for five consecutive days.
This 5 day treatment course may be repeated at 4 week (28 day) intervals, provided that the patient has
completely recovered from the toxic effects of the prior treatment course.
In subsequent treatment courses, the dosage of fluorouracil should be adjusted based on patient tolerance
of the prior treatment course. The daily dosage of fluorouracil should be reduced by 20% for patients who
experienced moderate hematologic or gastrointestinal toxicity in the prior treatment course, and by 30% for
patients who experienced severe toxicity. For patients who experienced no toxicity in the prior treatment
course, fluorouracil dosage may be increased by 10%. LEUCOVORIN dosages are not adjusted for toxicity.
AVAILABILITY
Single Dose V ials of 10 mg/mL
Single 35 mL vial. Each vial contains 350 mg LEUCOVORIN as LEUCOVORIN Calcium in solution. Product
Code 4545-23.
V ials of Cryodesiccated Powders
(50 mg/Vial, 350 mg/Vial)
I . 10 x 10 mL vials. Each 10 mL vial contains 50 mg of LEUCOVORIN as LEUCOVORIN
Calcium. Product Code 5330-72.
II. Single 30 mL vials. Each 30 mL vial contains 350 mg of LEUCOVORIN as
LEUCOVORIN Calcium. Product Code 4645-77.
Erlichman C et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal
carcinoma. J Clin O ro/ogy6(3):469-475,1988.
Petrelli N et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a
prospective randomized phase III trial. J Clin OzTco/ogy 7(10):1419-26,1989.
Doroshow JA et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose
continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients
previously unexposed to chemotherapy. J Clin Onco/ogy 8(3):491 -501,1990.
O'Connel M et al. Biochemical modulation of 5-fluorouracil (5FU) with leucovorin (LV): confirmatory evidence
of improved therapeutic efficacy in the treatment of advanced colorectal cancer. ASCO abstract # 408,1990
Poon MA et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and
quality of life in patients with advanced colorectal carcinoma. J Clin Oncology 7(10): 1407-18,1989.
Product monograph available on request.

® LEDERLE LEUCOVORIN is a registered trade mark of Cyanamid Canada Inc.
AN ORIGINAL
BRAND SAME MEDIC INE

CYANAMID CANADA INC.
Markham

ORIGINAL ARTICLES

Surgical Treatment of Achalasia
in a General Hospital
Louis Perrault, MD;* Gilles Beauchamp, MD, FRCSC;t Edouard Bastien, MD, FRCSC;*
Fernand Laurendeau, MD, FRCSC;* Gilles Jobin, MD, FRCPC;J Andre Archambault, MD, FRCPCJ

The authors report their experience with 43 patients treated for achalasia of the
esophagus in a general hospital between 1971 and 1986. Patients were divided into
two groups according to the type of surgery performed: group 1 — 29 patients
treated by Heller myotomy, performed by nine general surgeons between 1971 and
1983; and group 2 — 14 patients treated by transthoracic Heller myotomy with the
addition of a Belsey Mark-IV fundoplication.
Dysphagia was reduced postoperatively in 82.6% of patients in group 1 and 92.8%
of patients in group 2. Three patients in group 1 and one patient in group 2 had
persistent dysphagia. Ten patients in group 1 had symptoms of gastroesophageal
reflux (5 of them required a second antireflux procedure). In group 2, one patient
had symptoms of gastroesophageal reflux, but was treated successfully medically.
There was no difference in the degree of relief of dysphagia between the abdominal
and thoracic approach, or in whether the operation was performed by a general
surgeon without specific experience in the treatment of achalasia. The addition of a
fundoplication to a Heller myotomy appeared to lessen the problem of postoperative
gastroesophageal reflux. Since the Heller myotomy is technically difficult and may
lead to obstruction of the poorly emptying esophagus the authors recommend that it
be used selectively and only by the experienced esophageal surgeon.

Les auteurs rapportent leur experience avec 43 patients traites pour achalasie du
cardia dans un hopital general entre 1971 et 1986. Les patients ont ete divises en
deux groupes selon le type de chirurgie executee : le groupe 1 — 29 patients traites
a l’aide d’une myotomie de Heller effectuee par neuf chirurgiens generaux differents
entre 1971 et 1983; le groupe 2 — 14 patients operes par une myotomie de Heller
par voie transthoracique avec addition d’une fundoplicature de Belsey Mark-IV.
Apres [’intervention 82.6 % des patients dans le groupe 1 ont ete ameliores et
92.8 % des patients dans le groupe 2. Trois patients dans le groupe 1 et un patients
dans le groupe 2 ont presente de la dysphagie persistente. Dix patients ont presente
des symptomes de reflux gastro-oesophagien dans le groupe 1 et 5 d’entre eux ont
necessity une seconde intervention pour procedure anti-reflux. Un patient dans le
groupe 2 a presente des symptomes de reflux gastro-oesophagien et a re?u un
traitement mecale efficace. Aucune difference dans le soulagement de la dysphagie
n’a ete notee que le patient ait ete opere par voie transabdominale ou transthoraci
que ou que l’intervention ait ete effectuee par un chirurgien general sans
entrainement specifique dans la chirurgie de l’oesophage. Le reflux gastro-oesopha
gien pathologique en post-operatoire semble etre plus frequent chez les patients
operes par myotomie de Heller seule par rapport aux patients ayant subi une
fundoplicature associee. A cause de la difficulty technique d’une telle procedure et
du potentiel obstructif de cette operation face a un oesophage aperistaltisque, les
auteurs croient que cette procedure doit etre utilisee de fafon selective et effectuee
par un chirurgien avec expertise en chirurgie oesophagienne.

chalasia of the esophagus is a
benign, but incurable, disease1
characterized by intermittent dys
phagia and regurgitation. It is pro
duced by denervation of the esopha
gus with the absence of neurons in
Meissner’s and Auerbach’s plexus
es. The disease is uncommon and
may only be seen a few times a year
in a general hospital.
Surgery has been directed at pal
liation of the obstruction caused by
the poorly relaxing gastroeso
phageal sphincter.2 In 1914, Heller3
reported his results for the surgical
treatment of achalasia with an ante
rior and posterior myotomy o f the
distal esophagus. Zaaijer, in 1923,4
simplified the technique by using a
single rather than a double myoto
my.
Although the disease has been
known for many years, there are
several unresolved questions about
its treatment, such as the contro
versy between hydrostatic dilatation
and surgical myotomy5-8 and the
addition of an antireflux procedure
to a surgical myotomy.9-13
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radiography, endoscopy and ma
nometry.
The radiologic examination con
firmed the diagnosis of achalasia in
all patients with the classical signs:
esophageal distension, poor motili
ty, slow emptying, filiform aspect of
the gastroesophageal junction and
absence of air in the gastric fundus.
The esophageal dilatation was less
than 6 cm in all our patients and
none had a sigmoid dilatation.
Manometry and motility studies
were performed on 38 patients and
confirmed the diagnosis of achalasia
in every case. All patients were
shown to have poor motility, ab
sence of true peristalsis, presence of
tertiary waves, poor relaxation and
incoordination. In a few patients the
lower esophageal sphincter was not
recorded because it was impossible
to introduce the manometric cathe
ter into the stomach. Endoscopy
was performed preoperatively in 36
patients, and esophagitis was found
in 3.
To study our results, we divided
the patients into two groups ac
cording to the type of surgery per
formed. Group 1 included 29 pa
tients treated by a Heller myotomy,
which was performed by nine differ
ent surgeons between 1971 and
1983. Six of these procedures were
performed through a transabdomi
nal approach and 23 through a left
thoracic approach. Group 2 includ

In our general hospital from
1971 to 1983, we treated most of
our patients with a surgical myoto
my. Since 1979, some patients have
had a Heller myotomy and an an
tireflux procedure. In this paper we
report our experience and results.

Patients and Methods
The population treated in our
general hospital, which is a univer
sity affiliated hospital in the east
end of Montreal, is quite uniform
for race and economic status.
Between 1971 and 1986, 60 pa
tients with achalasia of the esopha
gus were referred to the hospital;
17 were referred after an operation
performed in another hospital and
were excluded from this study. The
remaining 43 patients (24 men, 19
women) were seen for the first time
at our hospital. They ranged in age
from 15 to 69 years (mean 33
years) (Table I).
Most patients were first assessed
by a gastroenterologist. All had
dysphagia as the presenting symp
tom. Regurgitation was present in
80%, and 30% had some weight
loss. The clinical symptoms had
been present for 1 to 240 months.
Before 1980 the preoperative pa
tient assessment consisted of a clin
ical evaluation of symptoms fol
lowed by upper gastrointestinal cine

Table I. Data on 43 Patients With Achalasia of the Esophagus, Treated at the Hopital
Maisonneuve-Rosemont Between 1971 and 1986
Characteristic
Age, yr
Range
Mean
Sex
Male
Female
Duration of symptoms
preop, mo
Range
Mean
Preop dilatation, no.
Preop perforation, no.
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Group 1 (1971-1983),
n = 29

Group 2 (1979-1986)
n = 14

13-69
39.6

17-69
31.0

14
15

8
6

9-240
65.7
4
4

1-204
36.0
2
1
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ed 14 patients, operated on by one
general thoracic surgeon with a
major interest in esophageal dis
ease, who used a transthoracic Hell
er myotomy with a modified fourstitch Belsey antireflux fundoplication procedure.
Fifteen percent of all patients had
a trial of esophageal dilatation be
fore surgery. In one patient, hydro
static dilatation resulted in an eso
phageal perforation.
The esophagus was always
reached through a left transthoracic
approach and was mobilized with
preservation of the vagus nerves
and without division of the phrenoesophageal membrane for group 1
patients. After exposure of the
esophagus, the myotomy was usual
ly performed over a nasogastric
tube for patients in group 1 and
over a no. 50 French Maloney bou
gie for patients in group 2. The
esophageal myotomy ranged in
length from 8 to 10 cm. For six
patients who had an abdominal pro
cedure, the esophagus was ap
proached through a midline incision
with the division of the phrenoesophageal membrane is followed by an
8- to 10-cm long esophageal myoto
my. Most operations were per
formed by senior residents under
direct staff supervision.

Results
Peroperative perforation occurred
in six patients. In one patient, the
perforation led to early reoperation
with application of an omental
patch. In the other five the perfora
tion was repaired by suturing the
mucosa. In no case did the perfora
tion necessitate a fundoplication. In
group 1, there were four perfora
tions (14%) and in group 2, three
(21%). One patient in group 2 re
quired prolonged hospitalization be
cause of a postoperative esophageal
leak. Complications of the opera-

SURGERY FOR ACHALASIA

tion occurred in 15% of patients
with no major debilitating conse
quences. One patient in group 1
died 17 days after operation of a
ruptured abdominal aortic aneu
rysm.
The postoperative results were
good to fair in all patients with
perforation except one, who com
plained of recurrent dysphagia. Dys
phagia persisted in four patients
(three in group 1 and one in group
2). All these patients had under
gone transthoracic Heller myotomy
as a primary procedure. Dilatation
was performed postoperatively in
two patients without benefit. One
patient in group 2 had a repeat
myotomy for dysphagia, which led
to improvement.
In group 1, 10 (40%) patients (9
transthoracic approach, 1 transab
dominal approach) had symptoms of
gastroesophageal reflux postopera
tively. The diagnosis was confirmed
by endoscopy in seven patients and
by 24-hour pH monitoring in four
of them. Five patients from group 1
had sufficient symptoms uncon
trolled by medication to require an
antireflux procedure. Two had a
transabdominal Toupet fundoplication, one a Belsey fundoplication
and another had a transthoracic
Nissen fundoplication for a peptic
stenosis. A total esophagectomy
was performed in one patient for a
severe peptic stenosis, and esopha
geal replacement was done with left
colon.
In group 2, one patient com
plained of severe gastroesophageal
reflux symptoms. The diagnosis of
esophagitis and gastroesophageal
reflux was proven by endoscopy
T a b le II.

and 24 hours’ pH monitoring. So
far, the response to medical treat
ment has been satisfactory.
Follow-up in group 1 was not
regular until 1980. Some patients
returned because dysphagia re
curred or new symptoms appeared.
In 1984, all the patients with no
recent follow-up were called back
for an interview by the senior au
thor. The patients were generally
satisfied with the degree of relief
from dysphagia. When symptoms
were present further assessment
was carried out by radiologic exami
nation, endoscopy and manometry.
After 1980, all patients were fol
lowed up annually. The mean fol
low-up was 57 months (79 months
for group 1 and 30 months for
group 2).
The final results were classified
in three groups (Table II). Excellent
and good results were obtained if
the patient had major improvement
in preoperative symptoms with no
or little residual dysphagia and no
gastroesophageal symptoms. Pa
tients with fair results were those
with improvement but with occa
sional dysphagia or episodes of gas
troesophageal reflux necessitating
medication. Patients with poor re
sults had no improvement of their
dysphagia or had severe gastroeso
phageal reflux necessitating reoper
ation.

Discussion
In this paper, we have reviewed
our experience with the treatment
of achalasia in a general hospital
where several general surgeons

Postoperative Results
R e s u lts , %

G ro u p

E x c e lle n t/g o o d

F a ir

Poor

1 (n = 29)
2 ( n = 14)

41.3
57.1

41.3
35.7

17.4
7.2

Total (n = 43)

46.5

39.5

14.0

were involved. The radiologic and
manometric data confirmed the di
agnosis of achalasia in all patients.
Follow-up of these patients was
complete, and all the patients were
questioned about postoperative
symptoms. However, manometry,
endoscopy and radiologic examina
tion were not repeated after surgery
in every patient.
Generally the patients in this
study were satisfied with the relief
of their dysphagia. There appeared
to be no difference whether the
operation was done through the
abdomen or the thorax or by a
general surgeon without specific
training in esophageal surgery.
However, five patients from group 1
needed reoperation for severe gas
troesophageal reflux. In group 2,
treated by a trained esophageal sur
geon, there were fewer cases of
reflux after myotomy, but the fol
low-up is shorter. For a true evalua
tion of the long-term results, sever
al years’ follow-up are needed be
cause it may take that long for
gastroesophageal reflux to appear.
We recently saw two patients who
presented 20 years after a Heller
myotomy and had Barrett’s meta
plasia of their entire esophagus.
The results of this study demon
strate that most patients with
achalasia are relieved of their symp
toms by Heller myotomy no matter
whether a general surgeon or a
surgeon trained in esophageal sur
gery does the procedure. About half
of the patients will have excellent
results while the other half will
have fair results. Six of our patients
were not satisfied with the opera
tion because of recurrence of dys
phagia or development of gastro
esophageal reflux. However, about
one-third of the group 1 patients
presented with pathologic gastro
esophageal reflux, and 15% had to
undergo a second operation.
Ellis and colleagues1415 have stat
ed that a transthoracic Heller myoCJS, VOL. 34, NO. 5, OCTOBER 1991
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tomy is a simple operation, which
should not be complicated by the
addition of an antireflux procedure.
Andreollo and Earlam, 16 in a review
of the literature, appeared to con
firm this opinion about the low
incidence of gastroesophageal re
flux after a simple Heller myotomy.
However, others17-20 have recom
mended a partial fundoplication at
the time of a Heller myotomy. The
difficulty and danger of using a
total or partial fundoplication in the
treatment of patients with achalasia
has also been raised. 21’22
An antireflux procedure after a
Heller myotomy is technically more
difficult in a patient with achalasia
than in a patient with standard
gastroesopheal reflux and needs
some expertise and training. Gener
al surgeons do not always have
sufficient experience to perform an
adequate antireflux procedure com
bined with a Heller myotomy. For
these reasons, we tend to agree
with Bjorck and colleagues23 and
Murray24 that fundoplication should
be used only selectively in
achalasia.
Because esophageal achalasia is
rare and the Heller myotomy is
rarely performed in a general hospi
tal, we think that the use of a
transthoracic Heller myotomy is
probably the safest procedure.25
The addition of an antireflux proce
dure incurs the risk of reoperation
for obstruction in a poorly empty
ing esophagus and should be used
selectively. It is certainly not recom
mended for the occasional esopha
geal surgeon.
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T h e Akin Procedure in Hallux Valgus
Patrick Kinnard, MD, FRCSC; Simon Cantin, MD
A retrospective study of 28 Akin procedures was undertaken to assess their results.
Patient satisfaction, clinical findings and roentgenographic measurements were
evaluated after follow-up periods of 12 to 42 months. The outcome was excellent in
nearly 60% of the patients, especially those whose discomfort was related to the
laterally deviated great toe and to the prominence of the first metatarsal head.

Une etude retrospective de 28 operations d’Akin a ete entreprise afin d’evaluer les
resultats de cette intervention. La satisfaction des patients, les observations
cliniques et les mesures radiographiques ont ete evaluees apres un suivi de 12 a 42
mois. Les resultats ont ete excellents chez pres de 60 %des patients, specialement
chez ceux dont les malaises etaient relies a une deviation laterale du gros orteil et a
la saillie de la tete du premier metatarse.

Akin1 described a proce
I ndure1925consisting
of resection of
the medial eminence of the first
metatarsal and the adjacent lip of
the proximal phalanx combined
with a closed wedge osteotomy of
the proximal phalanx. We under
took this study to assess the value
of this procedure.

Patients and Methods
The study was carried out retro
spectively on 19 patients (all wom
en) who underwent 28 Akin proce
dures (bilateral in 9 patients) be
tween 1985 and 1988.
The patients ranged in age from
23 to 62 years (mean 55 years). The
preoperative diagnosis was painful
bunion with an intermetatarsal
angle ranging from 7.5° to 20°
(average 12.8°). Nearly all patients

complained of pain, esthetic dissat
isfaction and difficulty in fitting
shoes.
The patients were assessed clini
cally and radiographically, preoperatively and postoperatively, by an
independent observer in the absence
of the senior author. The subjective
assessment (Table I) included dis
cussion of preoperative and postop
erative pain in the first and lesser
metatarsals, possible improvement
in shoe fitting, the esthetic appear
ance of the foot and anticipated
general satisfaction with the inter
vention.
The objective assessment (Table
I) included clinical examination of
the foot and weight-bearing x-ray
films, measuring the angle between
the first metatarsal and the toe, the
angle between the first and second
metatarsals and the congruity of
the metatarsophalangeal joint.2
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Surgical Technique

A metatarsophalangeal arthrotomy is done, developing a capsulotendinous flap with a distal at
tachment, followed by resection of
the medial prominence of the first
metatarsal head without adductor
release and a closed wedge osteot
omy without shortening of the
proximal phalanx of the great toe.
After medial capsulorrhaphy, the
osteotomy is fixed, under direct
vision, with two smooth Kirschner
wires through the osteotomy site,
correcting any axial deviation of the
great toe (Fig. 1).
The great toe is immobilized in a
hallux valgus traction splint and
partial weight-bearing is allowed.
The Kirschner wires are removed
after 4 weeks, but the splint is
maintained for an additional 2
weeks.
Follow-up

The follow-up ranged from 12 to
42 months (average 28 months).

Results
No short-term postoperative com
plications were encountered. There
was no infection, delayed union,
nonunion or avascular necrosis, but
three patients had mild neuromas
for which no treatment was neces
sary. No patients complained of
postoperative stiffness of the toes.
The postoperative result was graded
as excellent in 16 feet (nine pa
tients); as satisfactory in 9 feet
CJS, VOL. 34, NO. 5, OCTOBER 1991
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(eight patients) because, despite
complete pain relief, the patients
were somewhat disappointed with
the esthetic results or had mild
shoe-fitting problems; and as unsat
isfactory in 3 feet (two patients)
(Table II).
Of the feet with incongruous
metatarsophalangeal joints, three
were graded as excellent and four
were graded as satisfactory.

Discussion
Many surgical procedures involv
ing both soft tissues and bone have
been proposed for the correction of
symptomatic hallux valgus.2-9
Osteotomy of the first metatarsal
has been shown to give satisfactory
results, but shortening of the first
metatarsal after surgery may shift
weight bearing, leading to metatar
salgia in the lateral rays.7'1041
The Akin procedure is directed to

the correction of the valgus posi
tion of the hallux and the medial
prominence of the first metatarsal
head without changing the length
of the first metatarsal and the load
distribution across the foot.
Because this osteotomy does not
correct the factors responsible for
the hallux valgus deformity, it is
biomechanically unsound and is
therefore controversial as a primary
corrective procedure.12
Postoperative results of the Akin
procedure in this study were satis
factory, but there was a correlation
between patient satisfaction and in
creasing angle between the first and
second metatarsals (Table II), and
this has been observed by oth
ers.2,443
Postoperative pain relief under
the lateral metatarsals may be ex
plained by the fact that patients
tolerated more weight on the first
ray than before the surgery.
The obliquity of the first metatar

Table I. Objective and Subjective Assessments of 19 Patients (28 Feet) Who Underwent the Akin
Procedure for Hallux Valgus
Assessment
Subjective
Pain, no. of feet
Hallux
Lateral rays
Callosities, no. of feet
Hallux
Lateral rays
Shoe-fitting problems, no. of feet
Esthetic dissatisfaction, no. of feet
Objective
Neuromas, no.
Motion, incongruous metatarsophalangeal joint
Hallux angle,0
Range
Mean
Angle between 1st and 2nd metatarsals,0
Range
Mean

Preoperative

Postoperative

28
12

3
8

13
12
26
24

4
7
9
9

0

3

sophalangeal joint, which was un
changed with the Akin procedure,
did not interfere with the gait pat
tern nor give any symptoms or
complaints.

Conclusion
The indication for performing the
Akin procedure is limited to cases
of hallux valgus in which the prob
lems stem mainly from the valgus
position of the hallux or the medial
prominence of the metatarsal head,
or both, with mild or moderately
increased intermetatarsal angle and
no symptomatic degenerative arthri
tis.
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Excellent
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492

No. feet

Range

Mean

16
9
3

7.5 - 20
7 .5 - 1 7
1 4 .0 -1 7 .5

12.6
13.1
15.5
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FIG. 1. Roentgenogram in 43-year-old
woman after Akin procedure for hallux
valgus. Corrective closing wedge is
secured with two Kirschner wires.

HALLUX VALGUS
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and anatomical differences that necessi
tate an altered approach with respect to
assessment and treatment. Finally, the
topic of gynecomastia is defined with
respect to incidence and etiology. The
importance of clinical evaluation is
stressed, and a number of surgical
approaches are well illustrated.
This book covers a significant pro
portion of most plastic surgery prac
tices. It will enhance the knowledge of
most plastic surgeons and serve as a
useful reference text. It should certainly
be available to all residents training in
the specialty of plastic surgery.

greatly increased its diagnostic and
therapeutic application. The use of ste
reotaxy in the management of brain
tumours has been an inevitable conse
quence of this technology, as may be
the case in the future in the manage
ment of extracranial neoplastic and vas
cular disease. Thus, this book is timely.
The author’s commitment to the
modern development of stereotactic
methodology as it applies to neuro
oncology is well known and respected.
Although he has written a great deal in
the past on this topic, the present work
is a culmination of much of his experi
ence and is a welcome addition to the
library. No one is better able to present
an authoritative account of the present
state-of-the-art application of stereotaxy
to neuro-oncology.
Nearly half of the text is dedicated to
the history and fundamentals of stereo
taxy. These range from a lucid descrip
tion of stereotactic instrumentation, in
cluding the various systems available
and the principles underlying their us
age, to the requirements of a stereotact
ic operating theatre. The reader is given
a mix of practical and theoretical infor
mation regarding these topics that is
the most comprehensive to date. Com
puter-related parts and applications are
appraised and the analytical methods
underlying stereotactic localization are
summarized. Mention is made through
out the text of the use of stereotactic
angiography in the planning of trajecto
ries for biopsy and tumour resection.

BOOK REVIEWS
continued from page 486

with their indications and advantages.
The complications and limitations of the
various procedures are identified. There
is a good chapter on how to deal with
the massive hypertrophic breast and an
all-too-brief one on comparison of cari
ous reduction mammoplasty techniques.
There are four chapters on breast
ptosis, including an interesting histori
cal one. In these chapters the problem
is defined and classified, and a few
surgical techniques are illustrated. The
limitations of surgery for breast ptosis
are not adequately stated in this rather
brief section.
The chapter on congenital anomalies
of the nipple and areola is excellent. It
contains a short section on the anatomy
followed by a useful classification.
Techniques for surgical correction are
well illustrated and relate well to the
underlying pathologic condition. Proba
bly the most difficult problem to correct
in aesthetic breast surgery is the tuber
ous breast. The pathologic characterist
ics of this deformity are clearly identi
fied with suggested surgical techniques
for its correction. The preoperative and
postoperative photographs clearly illus
trate the limitations of these tech
niques. The tuberous breast is dealt
with again in the chapter on problems
in aesthetic breast surgery and their
management. The photographs suggest
that quite good results are possible.
The remainder of this chapter is helpful
in identifying and suggesting solutions
to problems that, fortunately, are rare.
The chapter on aesthetic breast sur
gery in orientals deals with the social

A.D. Courtemanche, MD, FRCSC
Department of Surgery
The University of British Columbia
Vancouver, BC
V5Z 4E3

TUMOR STEREOTAXIS. Patrick J.
Kelly. 409 pp. Illust. W.B. Saunders
Company/Harcourt Brace Jovanovich,
Inc., Philadelphia. 1991. $162. ISBN
0-7216-53 6 0 -X

Simply stated, stereotaxis is an analyti
cal, surgically applicable method for
accurately and reliably defining a point
or volume in three-dimensional space.
Its history dates back to the turn of the
century, and, although it was widely
used in human neurosurgery in the
1950s and 1960s, its marriage with
digital imaging and computer technolo
gies during the past 15 years has

continued on page 505
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histam ine H2-receptors. The prim ary clinically
important pharmacologic activity of PEPCID® is
inhib ition o f gastric juice secretion. PEPCID®
reduces the acid and pepsin content, as well as the
volume, of basal, nocturnal, and stimulated gastric
secretion.

INDICATIONS AND CLINICAL USE
PEPCID® (famotidine) is indicated in the treatment
of the follow in g conditions where a controlled
reduction of gastric secretion is required:
1. Treatment of acute duodenal ulcer;
2. Prophylactic use in duodenal ulcer;
3. Treatment of acute benign gastric ulcer;
4. T re a tm e n t of p a th o lo g ic a l hyp e rs e c re to ry
conditions (e.g., Zollinger-Ellison Syndrome);
5. Treatm ent of gastroesophageal reflux disease
(GERD).
PEPCID® I.V. is indicated in some hospitalized
patients w ith pathological hypersecretory con
ditions or intractable ulcers, or as an alternative to
the oral dosage form for short-term use in patients
who are unable to take oral medication.

CONTRAINDICATIONS
H y p e rs e n s itiv ity to any c o m p o n e n t of this
medication.

PRECAUTIONS
Patients with Severe Renal Insufficiency
Dosing intervals may need to be prolonged in
p a tie n ts w ith advanced renal in s u ffic ie n c y
(creatinine clearance <10 mUmin.) to adjust for the
longer elim ination half-life of fam otidine. (See
CLINICAL PHARMACOLOGY and DOSAGE AND
ADMINISTRATION).
Drug Interactions
Studies with famotidine in man, in animal models,
and in vitro have shown no significant interference
with the disposition of compounds metabolized by
the hepatic microsomal enzymes, e.g., cytochrome
P450 system . Compounds tested in man have
in clu d e d w a rfa rin , th e o p h y llin e , ph enyto in ,
diazepam , am inopyrine and a n tipyrine . Indo
cyanine green as an index of hepatic blood flow
and/or hepatic drug extraction has been tested and
no significant effects have been found.
Use in Gastric Ulcer
Gastric malignancy should be excluded prior to
initiation of therapy of gastric ulcer with PEPCID®.
Symptomatic response of gastric ulcer to PEPCID®
therapy does not preclude the presence of gastric
malignancy.
Use in Pregnancy
Reproductive studies have been performed in rats
and ra b b its at oral doses of up to 2000 and
500 mg/kg/day, respectively (approximately 2500
and 625 times the maximum recommended human
dose, respectively), and have revealed no evidence
of im paired fertility or harm to the fetus due to
PEPCID®. There are, however, no adequate or
well-controlled studies in pregnant women.
Since the safe use of PEPCID® in pregnant women
has not been established, the benefits of treatment
with PEPCID® should be weighed against potential
risks.
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PEPCID® (famotidine) is usually well tolerated;
m ost adverse re a c tio n s have been m ild and
transient. The adverse reactions listed below have
been reported during clinical trials in 2333 patients.
In those controlled clinical trials in which PEPCID®
was compared to placebo, the overall incidence of
adverse experiences in the group which received
PEPCID®, 40 mg at bedtime, was similar to the
placebo group. No antiandrogenic or other adverse
hormonal effects have been observed.
The fo llo w in g a d ve rse re actions have been
reported at a rate of greater than 1% in patients on
therapy with PEPCID® in controlled clinical trials,
and may be causally related to the drug: headache
(4.6%), dizziness (1.2%), constipation (1.2%) and
diarrhea (1.6%).
Other reactions have been reported in clinical trials
but occurred under circumstances where a causal
relationship could not be established. However, in
these rarely reported events, that possibility cannot
be excluded. Therefore, these observations are
listed to sente as alerting information to physicians.
Gastrointestinal

8.0%

Nausea
Vomiting
Anorexia
Abdominal discomfort
Dry mouth

1.6%
0.9%
0.5%
0.3%
0.2%

Nervous System/Psychiatric

7.3%

Insomnia
Somnolence
Anxiety
Paresthesia
Depression
Libido decreased

0.6%
0.4%
0.3%
0.3%
0.2%
0.1%

Respiratory
Bronchospasm

4.4%
<0.1%

Body as a Whole

3.0%

Fatigue
Asthenia
Fever

0.6%
0.3%
0.2%

Musculoskeletal

1.7%

Musculoskeletal pain
Arthralgia

0.1%
0.1%

Skin

1.7%

Pruritus
Rash
Alopecia
Flushing
Acne
Dry skin

0.4%
0.3%
0.2%
0.2%
0.1%
0.1%

Cardiovascular

1.0%

Palpitations

0.2%

Special Senses

0.9%

Taste disorder
Tinnitus
Orbital Edema
Urogenital

0.1%
0.1%
<0.1%
0.9%

The adverse re actions reported for PEPCID®
Tablets may also occur w ith PEPCID® I.V. In
addition, transient irritation at the injection site has
been observed with PEPCID® I.V.
The following additional adverse reactions have
been reported since th e drug was m arketed:
urticaria, liver enzymes abnormalities, cholestatic
jaundice, anaphylaxis, angioedema.
The fo llo w in g a d ve rse re a ctio n s have been
reported; however, a causal relationship to therapy
with PEPCID® has not been established: agitation,
confusion, hallucinations, grand mal seizures, rare
cases of impotence, thrombocytopenia, pancyto
penia, leukopenia and agranulocytosis.
Laboratory Abnormalities
Laboratory param eters may be affected during
treatm ent w ith PEPCID®, but the changes are

u s u a lly not c o n sid e re d serio us. Am ong the
laboratory changes that were reported during
clinical trials were increases in AST, ALT, BUN, and
serum creatinine. These changes were rarely of
clinical significance.
Only three patients had to be discontinued from
therapy because of laboratory adverse experiences,
however laboratory abnormalities were present at
baseline.

SYMPTOMS AND TREATMENT
OF OVERDOSAGE
There is no experience to date with deliberate
overdosage. Doses of up to 800 mg/day have been
em ployed in patients with pathological hyper
secretory con d itio n s with no serious adverse
effects. In the event of overdosage, treatment should
be sym p tom a tic and supportive. U nabsorbed
m aterial should be removed from the ga stro
intestinal tract, the patient should be monitored,
and supportive therapy should be employed.
The oral LD50 of famotidine in male and female rats
and mice was >5000 mg/kg.

DOSAGE AND ADMINISTRATION
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Acute Therapy
The recommended adult oral dosage of PEPCID®
(famotidine) for acute duodenal ulcer is 40 mg once
a day at bedtime. Treatment should be given for 48 weeks, but the duration of treatment may be
shortened if healing can be documented. Healing
occurs within 4 weeks in most cases of duodenal
ulcer.
Maintenance Therapy
For the prevention of recurrence of duodenal ulcer,
it is recommended that therapy with PEPCID® be
continued with a dose of 20 mg once a day at
bedtim e, fo r a duration of up to 6-12 months
depending on the severity of the condition.
BENIGN GASTRIC ULCER
Acute Therapy
The recommended adult oral dosage for acute
benign g a s tric u lce r is 40 mg once a day at
bedtim e. T re a tm e n t should be given fo r 4 to
8 weeks, but the duration of treatment may be
shortened if healing can be documented.
PATHOLO GICAL HYPERSECRETORY CON
D ITIO N S (S U C H AS ZO LLIN G E R -E LLIS O N
SYNDROME)
The d o sage of PEPCID® in pa tie n ts w ith
pathological hypersecretory conditions varies with
the individual patient. The recommended adult oral
starting dose fo r pathological hypersecretory
conditions is 20 mg q6h. In some patients, a higher
starting dose may be required. Doses should be
adjusted to individual patient needs and should
continue as long as clinically indicated. Doses up to
800 m g/day have been adm inistered to some
patients with severe Zollinger-Ellison syndrome.
GASTROESOPHAGEAL REFLUX DISEASE
The recommended dosage for the symptomatic
relief of gastroesophageal reflux disease is 20 mg
of famotidine twice a day.
For the tre a tm e n t of esophageal e rosion or
ulceration associated with gastroesophageal reflux
disease, the recommended dosage is 40 mg of
famotidine twice a day.
Intravenous Administration
In some hospitalized patients with pathological
hypersecretory conditions or intractable ulcers, or
in patients who are unable to take oral medication,
PEPCID® I.V. may be administered. The recom
mended dosage is 20 mg every 12 hours.
Intravenous injection therapy should be changed to
oral treatment as soon as the acute situation is
under control.
Concomitant Use with Antacids
Antacids may be given concomitantly if needed.
Dosage Adjustment for Patients with Severe
Renal Insufficiency
In patients with advanced renal insufficiency, i.e.,
with a creatinine clearance less than 10 mLVmin., the
elim ination ha lf-life of PEPCID® may exceed
20 hours reaching approximately 24 hours in anuric
patients.
To avoid excess accumulation of the drug, the
dosing interval of PEPCID® may be prolonged to
36-48 hours as indicated by the patient's clinical
response.

PHARMACEUTICAL INFORMATION
Tablets
Each tablet for oral administration contains either
20 mg or 40 mg of famotidine.
Injection
Each mL of the solution for intravenous injection
contains 10 mg of famotidine and the following
inactive ingredients: L-aspartic acid 4 mg, mannitol
20 mg, and Water for Injection, q.s., 1 mL. The
multidose injection also contains benzyl alcohol
0.9% added as preservative.
STABILITY AND STORAGE
RECOMMENDATIONS
PEPCID® I.V. Solution
Store at 2 - 8°C. Protect from light. If solution
freezes, bring the solution to room temperature;
a llow s u ffic ie n t tim e to s o lu b iliz e all the
components.
Diluted PEPCID® I.V. Solutions should be used
within 24 hours due to the possibility of microbial
contamination during preparation.
NOTE: P a re n te ra l drug pro d u c ts should be
inspected visually for particulate matter and
d is -c o lo u ra tio n prio r to a d m inistra tion
whenever solution and container permit.
RECONSTITUTED SOLUTIONS
Parenteral Products
Dilution of PEPCID® I.V.
for Infusion
Volume of
PEPCID® I.V. Compatible Final
Solution
I.V. Solution Volume
2 mL

3 mL

2 mL

8 mL

2 mL

100 mL

Final
Concen
tration

5 mL 4 mg/mL
10 mL 2 mg/mL
102 mL 0.196 mg/mL

Rate of
Infusion
Not less than
2 minutes
Not less than
2 minutes
15-30
minutes

PEPCID® I.V. Solutions are compatible with:
Water for Injection
0.9% Sodium Chloride Injection
5% Dextrose Injection
10% Dextrose Injection
Lactated Ringer’s Injection
Sodium Bicarbonate Injection 5%

AVAILABILITY OF DOSAGE FORMS
Tablets PEPCID® (fam otidine tab lets) are Dshaped, film-coated tablets supplied as follows:
No. Ca 8102 - 20 mg beige coloured, coded 963.
Available in bottles of 100 tablets.
No. Ca 8103 - 40 mg light brownish orange, coded
964. Available in bottles of I00 tablets.
Each tablet for oral administration contains the
following non-medicinal ingredients: hydroxypropyl
cellulose, hydroxypropyl m ethylcellulose, iron
oxides, magnesium stearate, m icrocrystalline
cellulose, starch, talc, titanium dioxide.
No. Ca 3539 - PEPCID® I.V., 10 mg per 1 mL, is a
clear, colourless solution and is available as a nonpreserved unit dose containing 2 mL of injectable
solution. Available in 10 x 2 mL vials.
No. Ca 3541 - PEPCID® I.V., 10 mg per 1 mL, is a
clear, colourless solution and is available as a
p re s e rv e d m u ltip le dose c o n ta in in g 4 mL of
injectable solution. Available in 4 mL vials.
Each mL of the solution for intravenous injection
contains the following non-medicinal ingredients:
L-aspartic acid 4 mg, mannitol 20 mg, and Water
for Injection q.s. 1 mL. The multidose injection also
c o n ta in s be nzyl alcoh ol 0.9 % added as
preservative.

subjects; mean gastric acid secretion was inhibited
by 86% and 94%, respectively, for a period of at
least 10 hours. Similar doses given in the morning
suppressed food-stimulated acid secretion in all
subjects, with mean suppression of 76% and 84%,
respectively, 3 to 5 hours after drug, and of 25%
and 30%, respectively, 8 to 10 hours after drug;
however, in some subjects who received the 20 mg
dose, the a n tisecretory effect was dissipated
earlier, within 6-8 hours. There was no cumulative
effect with repeated doses. The basal nocturnal
intragastric pH was raised by evening doses of 20
and 40 mg of PEPCID® to mean values of 5.0 and
6.4, respectively. When PEPCID® was given in the
morning, the basal daytime interdigestive pH at 3
and 8 hours after 20 or 40 mg of PEPCID® was
raised to about 5.0.
Fasting and postprandial serum gastrin levels may
be s lig h tly e le va te d du ring periods of drug
antisecretory effect, and with chronic therapy an
incre ase in g a stric bacterial flo ra may occur.
Gastric emptying and exocrine pancreatic function
are not affected by PEPCID®.
The presence of gastroesophageal reflux disease
appears to correlate best with the percentage of
time over 24 hours during which the esophagus is
e xp osed to acid. In gastroe soph agea l re flu x
disease patients, 20 mg twice a day and 40 mg
twice a day of PEPCID® reduced intraesophageal
acid exposure into the normal range as measured
by 24 hour intraesophageal pH m onitoring. In
clinical studies of gastroesophageal reflux disease
patients with endoscopically verified erosive or
ulcerative esophagitis, 40 mg twice a day was more
e ffe c tiv e tha n 20 mg tw ice a day in h e a lin g
esophageal lesions. Both dosage regimens were
superior to placebo.
Other Effects
Systemic pharmacologic effects of PEPCID® in the
CNS, cardiovascular, respiratory or en docrine
system s have not been found to date. Serum
prolactin levels do not rise after intravenous bolus
doses of 20 mg PEPCID® and no antiandrogenic
effects have been detected.
Pharmacokinetics
PEPCID® is incompletely absorbed. The bioavaila
bility of oral doses is 40-45%. Bioavailability may
be slightly increased by food, or slightly decreased
by antacids; however, these effects are of no
clinical consequence. PEPCID® undergoes minimal
first-p a ss m etabolism . A fte r oral doses, peak
plasma levels occur in 1-3 hours. Plasma levels
after multiple doses are similar to those after single
doses. Fifteen to 20% of PEPCID® in plasma is
protein bound. PEPCID® has an elimination half-life
of 2.5-3.5 hours. PEPCID® is eliminated by renal
(65-70%) and metabolic (30-35%) routes. Renal
clearance is 250-450 mL/min., indicating some
tubular excretion.
Twenty-five to 30% of an oral dose and 65-70% of
an intravenous dose are recovered in the urine as
un chang ed com pound. T h e only m e ta b o lite
identified in man is the S-oxide. There is a close
relationship between creatinine clearance values
and the elimination half-life of PEPCID®. In patients
with severe renal insufficiency, i.e., cre atinine
clearance less than 10 mL/min., PEPCID® elimi
nation h a lf-life may exceed 20 hours and a d 
justment of dosing internals may be necessary (see
P R E C A U TIO N S , D OSAG E AND A D M IN IS 
TR A TIO N ). In e ld e rly pa tients, th e re are no
clinically significant age-related changes in the
pharmacokinetics of PEPCID®.
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In both normal volunteers and hypersecretors,
PEPCID® inhibited basal nocturnal and daytime
gastric secretion, as well as secretion stimulated by
a variety of stimuli, such as pentagastrin and food.
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After oral administration, the onset of the antisecretory effect occurred w ithin one hour; the
maximum effect was dose-dependent, occurring
within one to three hours. Duration of inhibition of
secretion was 10 to 12 hours. After intravenous
administration, the maximum effect was achieved
within 30 minutes. Single intravenous doses of
10 and 20 mg inhibited basal nocturnal secretion
for a period of 10-12 hours. The 20 mg dose was
associated with the longest duration of action in
most subjects. Single oral doses of 20 and 40 mg
inhibited basal nocturnal acid secretion in all
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Pneumatic Antishock Garment Decreases
Hemorrhage and Mortality From Splenic
Injury
J. Ali, MD, FRCSC, FACS; K. Duke
The effect of the pneumatic antishock garment (PASG) in controlling hemorrhage
and death from splenic injury was studied in a canine model. Twelve (two groups of
6) anesthetized dogs had their spleens crushed. Carotid blood pressure, carotid
blood flow, splenic artery flow and abdominal aortic flow, as well as the death rate
and blood loss, were measured. Group 1 dogs did not have PASG inflation, but
group 2 dogs had PASG inflation to an intraperitoneal pressure of 60 mm Hg. All
group 1 dogs died within 27 to 58 minutes, but all group 2 dogs survived. Blood
loss was 9.4 ± 1 .4 mL/min in group 1 and 1.6 ± 0.9 mL/min in group 2. In group
1 carotid artery blood pressure, carotid artery flow, splenic artery flow and
abdominal aortic flow fell from 120 ± 10 mm Hg, 284 ± 12 mL/min, 194 ± 18
mL/min and 285 ± 10 mL/min respectively to 0 with death of the animals. By 2
hours in group 2 dogs the carotid artery blood pressure had dropped from 116 ± 12
to 99 ± 12 mm Hg, and over the same period carotid artery flow, splenic artery flow
and abdominal aortic flow fell from 296 ± 8 mL/min, 190 ± 26 mL/min and 279 ±
16 mL/m in respectively to 259 ± 14 mL/min, 39.0 ± 6 mL/min and 45 ± 11
mL/min respectively. Thus, inflation of the PASG maintained carotid artery blood
pressure while decreasing splenic, abdominal and aortic flow as well as splenic
hemorrhage, with a decrease in the death rate, over a 2-hour period.

L’effet du vetement pneumatique anti-shock (VPAS) en ce qui a trait au controle de
l’hemorrhagie et de la mort dues a la lesion splenique a ete etudie chez un modele
canin. Douze chiens anesthesies (deux groupes de 6) subirent un ecrasement de la
rate. La tension arterielle carotidienne, les debits arteriels carotidien et splenique et
celui de l’aorte abdominale, de meme que la mortalite et la perte sanguine furent
mesures. Les chiens du groupe 1 n’avaient pas de vetement antichoc pneumatique
(VACP), alors que les chiens du groupe 2 portaient un VACP gonfle de fagon a avoir
une pression intraperitoneale de 60 mm Hg. Tous les chiens du groupe 1 sont morts
apres 27 a 58 minutes; tous les chiens du groupe 2 ont survecu. La perte sanguine
fut de 9,4 ± 1,4 mL/min dans le groupe 1 et de 1,6 ± 0,9 mL/min dans le groupe
2. Dans le groupe 1, la tension arterielle carotidienne, le debit arteriel carotidien, le
debit arteriel splenique et le debit de l’aorte abdominale baisserent de 120 ± 10
mm Hg, 284 ± 12 mL/min, 194 ± 18 mL/min et 285 ± 10 mL/min, respectivement, a 0 lors du deces des animaux. Chez les chiens du groupe 2, apres 2 heures, la
pression carotidienne avait baisse de 116 ± 12 a 99 ± 12 mm Hg; au cours de la
meme periode, les debits arteriels carotidien, splenique et aortique chuterent de 296
± 8 mL/min, 190 ± 26 mL/min et 279 ± 16 mL/min, respectivement, a 259 ± 14
mL/min, 39 ± 6 mL/min et 45 ± 11 mL/min. Le gonflement du VACP permit done
de maintenir la tension arterielle carotidienne tout en reduisant les debits de l’artere
splenique et de 1’aorte abdominale, de meme que l'hemorragie splenique et la
mortalite, sur une periode de 2 heures.
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A

lthough the pneumatic antishock garment (PASG) was de
scribed over 80 years ago1 it only
became widely used in the prehospi
tal care of trauma patients with the
institution of the Advanced Trauma
Life Support program.2 In spite oi
its continued wide use in this con
text, the garment has generated
considerable controversy recently.
Controlled randomized clinical
studies have failed to demonstrate
any benefit from its application
when definitive care was provided
within 45 minutes of the trauma
incident.34 However, several clinical
reports have suggested that the
PASG is effective in controlling he
morrhage from ectopic pregnancy,
abdominal aortic aneurysm, pelvic
fractures and similar situations.5-8
Splenic injury is a major cause of
intra-abdominal hemorrhage result
ing from blunt and penetrating inju
ry to the abdomen.9 A trend toward
conservative nonoperative manage
ment of splenic injury has been
recognized in the literature recent
ly.9-10 Isolated splenic injury, partic
ularly in the pediatric age group,
has been reported to be successfully
managed nonoperatively.9-11 The
PASG has been shown to increase
systolic blood pressure, primarily
through an increase in systemic
vascular resistance, and its applica
tion has been shown to decrease
intra-abdominal arterial blood
flow.1213 It would appear, therefore,
that the PASG may play a role in
controlling hemorrhage and reduc
ing the death rate after splenic
injury. These possibilities were
therefore studied in a canine model
of splenic injury.

PASG IN SPLENIC INJURY

Materials and Methods
Twelve, healthy, adult, mongrel
dogs, weighing between 20.5 and
32.0 kg, were anesthetized with
sodium thiopental and mechanically
ventilated on 50% oxygen, nitrous
oxide and 1% halothane with a tidal
volume of 10 m L/kg and a respira
tory rate of 15/min. A specially
designed PASG for dogs allowed
lower limb as well as abdominal
compartment inflation. A polyethyl
ene catheter was introduced into
the right carotid artery in the neck
and attached to a pressure trans
ducer and a multichannel recorder
for continuous monitoring of carot
id artery blood pressure. Intraperitoneal pressure was mea
sured with a calibrated intraperitoneal catheter that was bal
loon-tipped and fluid-filled. Carotid
artery blood flow, aortic blood flow
and splenic artery blood flow were
monitored by precalibrated electro
magnetic flow probes of appropriate
size placed around the vessels as
previously described.1415 All flow
and pressure measurements were
conducted at end-expiration as pre
viously described.1415 Blood loss
was measured by aspirating blood
from the peritoneal cavity at lapa
rotomy and weighing the sponges.
The rate of blood loss was estimat
ed by dividing the total blood loss
over the period of survival in min
utes.
At laparotomy, after insertion of
the electromagnetic flow probes, a
vascular occluder was placed
around the splenic artery, tightened
and then exteriorized. The spleen
was then crushed on both sides of
the splenic hilum with a crushing
clamp and returned to the periton
eal cavity with the vascular occlud
er secured. The peritoneal cavity
was then closed with a continuous
0 silk suture. The splenic artery
occluder was then released, and the
animals were randomly assigned to

two groups of six each: group 1, in
which the PASG was applied but
the compartments were not inflated,
and group 2, in which the PASG
was inflated to an intraperitoneal
pressure of 60 mm Hg. The pres
sure of 60 mm Hg was chosen
because in our laboratory that was
the intraperitoneal pressure re
quired to normalize carotid artery
blood pressure after a drop of 30
mm Hg in blood pressure from
hemorrhagic hypotension.
Measurements were made at
baseline before release of the vascu
lar occluder and at 15 minutes, 1
hour and 2 hours after release of
the vascular occluder. After a maxi
mum of 2 hours or upon death of
the animal the vascular occluder
was again secured and the periton
eal cavity opened. Intra-abdominal
blood loss was then determined
from suction of blood as well as
weighing of sponges.
Comparisons between groups
were conducted by analysis of vari
ance followed by the application of
the multiple range test of Tukey.

Within-group comparisons were
conducted using paired f-tests, with
a probability value of 0.05 being
considered statistically significant.

Results
Data are presented as means ±
standard deviation, and the mea
surements were in mean pressures
or flows as opposed to systolic or
diastolic measurements.
Death Rate

All group 1 animals died within
58 minutes of hemorrhage, the time
of death ranging from 27 to 58
minutes after the occluder was re
leased. In contrast, all group 2
animals survived the entire 2 hours
of the study.
Blood Loss

Over the 27 to 58 minutes of
survival the total blood loss was
422 ± 82 mL in group 1, and the

FIG. 1. Carotid artery blood pressure decreased immediately with hemorrhage in
both groups of animals. Group 1 animals (dotted bars) had further precipitous fall
to 0 mm Hg whereas group 2 animals (white bars) maintained blood pressure with
pneumatic antishock garment (PASG) inflation.
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measured blood loss in group 2
animals was 184 ± 36 mL. The
estimated rate of blood loss in
group 1 was therefore 9.4 ± 1 . 4
m L/m in compared with 1.6 ± 0.9
m L/m in in group 2 animals. Both
the total blood loss and the rate of
blood loss were significantly greater
(p < 0.05) in group 1 animals.
Carotid Blood Pressure

Baseline carotid blood pressure
was similar in both groups (Fig. 1).
At 15 minutes after hemorrhage
there was a statistically significant
drop in carotid artery blood pres
sure in group 1 from 120 ± 10
mm Hg to 78 ± 16 mm Hg, and
although there was a trend toward
a decrease in carotid artery blood
pressure at 15 minutes after he
morrhage in group 2 this did not
reach statistical significance.
By 1 hour the blood pressure in
all group 1 animals had dropped to
0, but in group 2 animals the blood
pressure was maintained at 102 ±
14 mm Hg; by 2 hours the blood
pressure had dropped to 99 ± 12
mm Hg in group 2, a statistically
significant drop from baseline mea
surements.

significantly different from the
1-hour measurement but was signif
icantly different from the baseline
value.
Splenic Artery Flow

From similar baseline values in
both groups of animals there was a
significant drop in splenic artery
flow at 15 minutes in both groups
(160 ± 12 mL/min in group 1 and
54 ± 8 mL/min in group 2). The
decrease in flow in group 2 was,
however, greater than in group 1 at
15 minutes after release of the
vascular occluder (p < 0.05, Fig.
3). By 1 hour the splenic artery
flow in group 2 was maintained at
46 ± 9 mL/min, but in all the
group 1 animals the splenic artery
flow had dropped precipitously to 0.
At 2 hours after hemorrhage sple
nic artery flow in group 2 had
decreased slightly (p < 0.05) to 39
± 6 mL/min.
Abdominal Aortic Flow

The abdominal aortic flow pat

tern was similar to that of splenic
artery flow (Fig. 4). From similar
baseline values of 285 ± 10
mL/min and 279 ± 16 mL/min
there was a decrease in abdominal
aortic flow to 180 ± 10 mL/min in
group 1 and 62 ± 10 mL/min in
group 2, respectively, at 15 minutes
after release of the occluding clamp.
By 1 hour the aortic flow had
precipitously decreased to 0 in
group 1, and was maintained at 51
± 9 mL/min in group 2, with a
further small decrease to 45 ± 11
mL/min by 2 hours (p < 0.05
compared with the 15-minute value,
not significant compared with the
1-hour value).

Discussion
This study demonstrates that in
flation of the PASG does not com
pletely arrest splenic hemorrhage
but decreases it significantly. The
garment was clearly effective in
maintaining carotid artery blood
pressure as well as improving sur
vival from an otherwise fatal splenic

Carotid Artery Flow

Carotid artery flow was similar at
baseline in both groups of animals
(Fig. 2). At 15 minutes there was a
statistically significant drop in ca
rotid artery flow in group 1, but the
flow was maintained at 280 ± 10
m L/m in in group 2 animals. With
in 1 hour of hemorrhage group 1
animals had their carotid artery
flow precipitously drop to 0, but in
group 2 carotid artery blood flow
was maintained at 269 ± 10
m L/m in, a value significantly lower
than baseline values. By 2 hours
group 2 animals had maintained
their carotid artery blood flow at
259 ± 14 mL/min, which was not
498
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FIG. 2. Carotid artery flow decreased precipitously with hemorrhage but was
maintained above 250 mL/min with PASG inflation. Group 1 = dotted bars, group
2 = white bars.
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injury. The decrease in hemorrhage
is explained by the measured de
crease in abdominal aortic and sple
nic artery blood flow, which is
probably secondary to the increase
in intra-abdominal pressure, which
leads to a decreased transluminal
arterial pressure.

Although there is still controver
sy concerning the role of the PASG
in prehospital care it appears from
this study that hemorrhage from
solid intra-abdominal viscera may be
significantly decreased by inflation
of the PASG and that there still
may be a role for this device. Clear

FIG. 3. Splenic artery flow was initially higher in group 1 animals (dotted bars) but
precipitously decreased to 0 mL/min. In group 2 animals (white bars) splenic
artery flow decreased but was still present at 2 hours.

mL/min

FIG. 4. Abdominal aortic flow followed same pattern as splenic artery flow.

ly, definitive control of hemorrhage
will require surgical exploration
when massive hemorrhage from a
splenic injury occurs. However,
until surgical expertise is available
the PASG may support the circula
tion as well as decrease hemorrhage
and mortality before surgical inter
vention. In two large randomized
clinical reports34 that suggested no
benefit from PASG inflation in pre
hospital care, definitive care was
available within 45 minutes after
the actual trauma. In some circum
stances definitive surgical care may
not be as readily available, and
there may be a role for the PASG in
stabilizing patients until definitive
surgical intervention is possible. A
recent randomized study of prehos
pital care of trauma patients con
cluded that intravenous fluid admin
istered in the field does not affect
the outcome in prehospital stabili
zation of trauma patients. This pop
ulation of traumatized patients also
were within 45 minutes of definitive
trauma care. However, the result of
this study16 does not justify removal
of intravenous fluids from our resuscitative armamentarium.
In much the same way the PASG,
although not proven to be of bene
fit when prehospital care is of short
duration, may indeed provide some
benefit when the period of resusci
tation before definitive care is more
prolonged. In our study the infla
tion of the PASG did not stop
intra-abdominal hemorrhage com
pletely. However, there was a sub
stantial decrease in hemorrhage
that will allow time for surgical
intervention. When a conservative
nonoperative approach is chosen
the PASG may decrease the require
ment for blood replacement by de
creasing blood loss. This is a major
consideration with the increasing
risk of blood-borne diseases such as
acquired immunodeficiency syn
drome and may also lead to sponta
neous arrest of splenic hemorrhage
CJS, VOL. 34. NO. 5, OCTOBER 1991
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DIFLUCAN
(fluconazole/pfizer)

AN OPPORTUNISTIC WAY
TO TREAT FUNGAL INFECTION
PRODUCT INFORMATION
NAME OF DRUG
DIFLUCAN TABLETS
DIFLUCAN INTRAVENOUS INFUSION 2 mg/mL in 0.9% SODIUM CHLORIDE
(fluconazole)
THERAPEUTIC CLASSIFICATION Antifungal
ACTIONS: Fluconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C14-alpha-demethylation. Mammalian cell dem ethylation is much less sensitive to
fluconazole inhibition. The subsequent loss of normal sterols correlates w ith the
accumulation of 14-alpha-methyl sterols in fungi and may be responsible for the fungistatic
activity of fluconazole.
INDICATIONS AND CLINICAL USE: DIFLUCAN (fluconazole) is indicated for the treatment
of: 1. Oropharyngeal and esophageal candidiasis. DIFLUCAN is also effective for the
treatment of serious system ic candidal infections, including urinary tract infection,
peritonitis, and pneumonia. 2. Cryptococcal meningitis. 3. Prevention of the recurrence of
cryptococcal meningitis in patients with acquired immunodeficiency syndrome (AIDS).
Specimens for fungal culture and other relevant laboratory studies (serology,
histopathology) should be obtained prior to therapy to isolate and identify causative
organisms. Therapy may be instituted before the results of the cultures and other laboratory
studies are known; however, once these results become available, anti-infective therapy
should be adjusted accordingly.
CONTRAINDICATIONS: DIFLUCAN (fluconazole) is contraindicated in patients who have
shown hypersensitivity to fluconazole or to any of its excipients. There is no information
regarding cross hypersensitivity between fluconazole and other azole antifungal agents.
Caution should be used in prescribing DIFLUCAN to patients with hypersensitivity to other
azoles.
WARNINGS: Patients with baseline abnormal liver function tests and those who develop
abnormal liver function tests during DIFLUCAN (fluconazole) therapy should be monitored
for the development of more severe hepatic injury. Although serious hepatic reactions have
been rare and the causal association with DIFLUCAN uncertain, if clinical signs and
symptoms consistent with liver disease develop that may be attributable to fluconazole,
DIFLUCAN should be discontinued, (see ADVERSE REACTIONS).
Immunocompromised patients, especially those with AIDS, who develop rashes during
treatment with DIFLUCAN should be monitored closely and the drug discontinued if lesions
progress, (see ADVERSE REACTIONS).
PRECAUTIONS
Use in Pregnancy: There are no adequate and well-controlled studies in pregnant women.
DIFLUCAN (fluconazole) is not recommended in pregnant women unless the potential
benefit outweighs the potential risk to mother and fetus.
Use in Nursing Mothers: It is not known whether fluconazole is excreted in human milk.
Because many drugs are excreted in human milk, caution should be exercised when
DIFLUCAN is administered to a nursing woman.
Use in Children: The clinical use of DIFLUCAN in children below 13 years of age has not
been established.
Use in Elderly: DIFLUCAN was well tolerated by patients aged 65 years and over.
Drug Interactions
Cimetidine and Antacids Absorption of orally administered DIFLUCAN does not appear to
be affected by gastric pH. Cimetidine did not affect oral bioavailability of fluconazole to a
clinically meaningful extent; reduction of about 13% in AUC (area under the plasma
concentration-time curve) and 21% in peak plasma concentration (Cmax) was observed.
Administration of magnesium/aluminum hydroxide formulation, just prior to DIFLUCAN
adm inistration had no clinically relevant effects on the absorption or elim ination of
fluconazole in normal volunteers.
Cyclosporine DIFLUCAN administered at 100 mg daily dose does not affect cyclosporine
pharmacokinetic levels in patients with bone marrow transplants. There have been several
reports in the literature associating concomitant administration of high doses of DIFLUCAN
with an increase in cyclosporine plasma concentrations in renal transplant patients with or
w ith o u t impaired renal function. Therefore, when DIFLUCAN and cyclosporine are
coadministered, cyclosporine levels should be monitored and cyclosporine dose accordingly
adjusted.
Warfarin DIFLUCAN increased the prothrombin time after warfarin administration in healthy
males. Though the m agnitude of change was sm all (12% ), careful m onitoring of
prothrombin time in patients receiving coumarin-type anticoagulants is recommended.
Hydrochlorothiazide Concomitant administration of multiple doses of DIFLUCAN and
hydrochlorothiazide was associated with increases in fluconazole plasma levels which were
not considered to be clinically significant.
Sulfonylurea-Oral Hypoglycemics The potential fo r hypoglycemia due to decreased
elimination and increased blood levels of sulfonylurea oral hypoglycemics (glibenclamide,
glipizide and tolbutamide) has been demonstrated with concomitant administration of
DIFLUCAN. Blood glucose levels should be m onitored closely and the dose of the
hypoglycemic agent should be adjusted as necessary.
Phenytoln Concomitant administration of DIFLUCAN at steady state and phenytoin at steady
state resulted in an increase of up to 75% in AUC phenytoin. Since phenytoin has a low
therapeutic ratio, phenytoin plasma levels should be closely monitored when DIFLUCAN is
coadministered. The dose of phenytoin should be adjusted to maintain therapeutic levels.
Rifampin Concomitant adm inistration of DIFLUCAN and rifampin resulted in a 25%
decrease in the AUC and a 20% shorter half-life of fluconazole. The dosage of fluconazole
should be increased by 25% when fluconazole is administered with rifampin.
Zidovudine (AZT) and/or Pentamidine Isethionate Though no formal interaction studies have
been completed for DIFLUCAN and concomitant zidovudine and/or pentamidine isethionate,

these drugs have been used together in patients with AIDS with no clinically important
difference in the pattern of adverse events.
Orug/Laboratory Test Interactions: None known.
ADVERSE REACTIONS: Sixteen percent of over 4000 patients treated with DIFLUCAN
(fluconazole) in clinical trials of 7 days or more experienced adverse events.
Treatment was discontinued in 1.5% of patients due to adverse clinical events and in 1.3%
of patients due to laboratory test abnormalities.
Adverse clinical events were reported more frequently in HIV infected patients (21%) than in
non-HIV infected patients (13%). However, the patterns of adverse events in HIV infected
and non-HIV infected patients were similar. The proportions of patients discontinuing
therapy due to clinical adverse events were similar in the two groups (1.5%). The two most
serious adverse clinical events noted during clinical trials with DIFLUCAN were: 1. Exfoliative
skin disorders 2. Hepatic necrosis Because most of these patients had serious underlying
disease (predominantly AIDS or malignancy) and were receiving multiple concomitant
medications, including many known to be hepatotoxic or associated with exfoliative skin
disorders, the causal association of these reactions with fluconazole is uncertain. Two cases
of hepatic necrosis and one exfoliative skin disorder (Stevens-Johnson syndrome) were
associated with a fatal outcome.
The following treatment-related clinical adverse events occurred at an incidence of 1% or
greater in 4,048 patients receiving fluconazole for 7 or more days in clinical trials: Nausea
3.7% Headache 1.9% Skin Rash 1.8% Vomiting 1.7% Abdominal Pain 1.7% Diarrhea
1.5% Other treatment-related clinical adverse events which occurred less commonly (0.2 to
<1%) are presented by organ system below:
Skin and Appendages: pruritus.
Musculoskeletal: myalgia.
Central and Peripheral Nervous System: convulsions, dizziness, paresthesia, tremor, vertigo.
Autonomic Nervous System: dry mouth, increased sweating.
Psychiatric: insomnia, somnolence.
Gastrointestinal: anorexia, constipation, dyspepsia, flatulence.
Liver and Biliary System: cholestasis, hepatocellular damage.
Special Senses: taste perversion.
Hematopoietic: anemia
General: fatigue, malaise, asthenia, fever.
LABORATORY TEST ABNORMALITIES
Liver Function: Clinically significant increases were observed in the following proportions
of patients: AST (SG0T) 1%, ALT (SGPT) 1.2%, Alkaline Phosphatase 1.2%, Total bilirubin
0.3%. The incidence of elevated serum transaminases was independent of age or route
(p.o. or i.v.) of administration but was greater in patients taking DIFLUCAN concomitantly
with one or more of the following medications: rifampin, phenytoin, isoniazid, valproic acid,
or oral hypoglycemic agents. Clinically significant increases also were more frequent in
patients who: 1) had SGOT or SGPT elevations greater than three times the upper limit of
normal (>3xULN) at the time of entering the study (baseline), 2) had a diagnosis of hepatitis
at any time during the study and, 3) were identified as alcohol abusers. The overall rate of
serum transaminase elevations of more than 8 tim es the upper lim it of normal was
approximately 1% in patients treated with DIFLUCAN during clinical trials. (See table below)
Percent
Number
Percent
Number*
Percent
Drugof
Percent
DrugLab
of
Abnormal
Related
Patients
Parameter
Abnormal
Related
Patients
Baseline < 3xULN
Baseline > 3xULN
4.2
0.8
3007
9.4
3.8
2874
4.8
1.0
3.1
0.0
Non-Hepatitis Patients
Hepatitis Patients
3.9
0.8
10.6
1.9
2900
SGOT
160
4.4
1.0
11.4
2.1
2799
140
SGPT
Non-Alcohol Abuse
Alcohol Abuse
4.2
0.9
3018
SGOT
42
9.5
2.4
4.7
1.0
2899
SGPT
10.0
2.5
40
Never Received
Received
I.V. Fluconazole
I.V. Fluconazole
4.2
0.9
2916
SGOT
144
5.6
1.4
4.7
1.0
2800
SGPT
139
5.0
0.7
<65 Years Old
2.65 Years Old
4.3
0.9
2783
SGOT
277
4.3
1.1
4.8
1.0
2681
SGPT
258
3.9
1.2
* Note: Only patients who had measurements at baseline and during therapy were included.
Renal Function: Clinically significant increases were observed in the following proportions
of patients: blood urea nitrogen (0.4%) and creatinine (0.3%).
Hematological Function: Clinically meaningful deviations from baseline in hematologic
values which were possibly related to DIFLUCAN were observed in the following proportions
of patients: hemoglobin (0.5%), white blood cell count (0.5%), and total platelet count
( 0 . 6 % ).
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Symptoms: Presently, there are no known sym ptom s of DIFLUCAN (fluconazole)
overdosage in man.
Treatment: In the event of overdosage, symptomatic treatment (with supportive measures
and gastric lavage if necessary) may be adequate. Fluconazole is largely excreted in urine. A
three hour hemodialysis session decreases plasma levels by approximately 50%.
Mice and rats receiving very high doses of fluconazole, whether orally or intravenously,
displayed a variety of nonspecific, agonal signs such as decreased activity, ataxia, shallow
respiration, ptosis, lacrimation, salivation, urinary incontinence and cyanosis. Death was
sometimes preceded by clonic convulsions.
DOSAGE AND ADMINISTRATION
Oral and Intravenous Treatment: Fluconazole is well absorbed and excreted predominantly
unchanged in urine following oral administration in man. The oral bioavailability is
essentially complete (greater than 90%), and is independent of dose. Peak plasma
concentrations after oral administration are attained rapidly, usually within 2 hours of
dosing. Since oral absorption is rapid and almost complete, the daily dose of DIFLUCAN
(fluconazole) is the same for oral and intravenous administration. The terminal plasma
elimination half-life is approximately 30 hours (range 20-50 hours).
The daily dose of DIFLUCAN and the route of administration should be based on the
infecting organism, the patient’s condition and the response to therapy. Treatment should
be continued until clinical parameters and laboratory tests indicate that an active fungal
infection has been cured or has subsided. An inadequate period of treatment may lead to
recurrence of active infection. Patients with AIDS and cryptococcal meningitis or recurrent
oropharyngeal candidiasis usually require maintenance therapy to prevent relapse.
SGOT
SGPT

53
65
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allowing removal of the PASG. In
applying the PASG in this manner,
however, prolonged application of
this device beyond 4 hours must be
avoided so that complications such
as compartment syndrome, neuro
vascular damage and even amputa
tion17 will not result from its inap
propriate use.
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Recommended Adult Dosages
Loading Dose: Administration of a loading dose on the first day ot treatment, consisting
of twice the usual daily dose, results in plasma concentrations close to steady state by
the second day. Patients with acute infections should be given a loading dose equal to
twice the daily dose, not to exceed a maximum single dose of 400 mg, on the first day ot
treatment.
Oropharyngeal Candidiasis: 100 mg once daily. Treatment should be continued for at least
2 weeks to decrease the likelihood of relapse.
Esophageal Candidiasis: 100 mg to 200 mg once daily. Patients should be treated for a
minimum of 3 weeks and for at least 2 weeks following resolution of symptoms.
Systemic Candidiasis: 200 mg to 400 mg once daily. These patients should be treated for a
minimum of 4 weeks and for at least 2 weeks following resolution of symptoms.
Cryptococcal Meningitis: 200 mg to 400 mg once daily. Although the duration of therapy
for cryptococcal meningitis is unknown, it is recommended that the initial therapy should
last a minimum of 10 weeks.
Prevention o f Recurrence of Cryptococcal Meningitis in AIDS: 200 mg once daily.
DIFLUCAN (fluconazole) may be administered either orally or by intravenous infusion. The
intravenous infusion of DIFLUCAN should be adm inistered at a maximum rate of
approximately 200 mg/hour given as a continuous infusion. See Directions for Use .
Dosage in Patients With Impaired Renal Function
Fluconazole is cleared primarily by renal excretion as unchanged drug. In patients with
impaired renal function, an initial loading dose of 50 to 400 mg should be given. After the
loading dose, the daily dose (according to indication) should be based on the following
table:
Creatinine Clearance (mL/min)
Percent o f Recommended Dose
>50
100%
21-50
50%
11-20
25%
Patients receiving
one recommended
regular hemodialysis
dose after each dialysis
When serum creatinine is the only measure of renal function available, the following formula
(based on sex, weight, and age of the patient) should be used to estimate the creatinine
clearance.
Males:
Weight (kg) x (140-age)
72 x serum creatinine (mg/TOO mL)
Females:
0.85 x above value
Composition: DIFLUCAN Tablets (pink) contain 50, 100 or 200 mg fluconazole. Also
contains the following non-medicinal ingredients: microcrystalline cellulose, dibasic calcium
phosphate anhydrous, povidone, croscarmellose sodium, FD & C Red No. 40 aluminum lake
dye, and magnesium stearate.
DIFLUCAN I.V. for infusion is a sterile solution of fluconazole in saline at a concentration of
2 mg/mL which is made iso-osmotic with sodium chloride 9 mg/mL.
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Directions for Use: Inspect visually fo r particulate m atter or discoloration p rior to
administration. Do not use if cloudiness or precipitation is evident.
Reject the contents as unsterile if the metal seal is broken. NOT INTENDED FOR
MULTIDOSE USE: discard any portion not used when the seal is first broken.
Connect an intravenous giving set to the bottle of DIFLUCAN (fluconazole) intravenous
solution and also insert a venting set through the bung. Infuse DIFLUCAN intravenous
solution at a m axim um rate o f 200 m g/h o u r Flush DIFLUCAN intravenous solution
remaining in the giving set with sterile normal saline.
Because fluconazole is available as a dilute saline solution, in patients requiring sodium or
fluid restriction, consideration should be given to the rate of fluid administration.
Incompatibility: It is recommended that DIFLUCAN I.V. be infused separately.
Compatibility: Administration sets ( “giving” sets).
DIFLUCAN I.V. infusion is com patible w ith (i.e. not susceptible to absorption) sets
constructed of a delivery tube (PVC) luer lock (modified phenylene oxide), flash ball (latex)
drip chamber (polypropylene) and piercing spike (polypropylene).
DOSAGE FORMS
Availability: DIFLUCAN TABLETS are available as pink tablets containing 50 mg, 100 mg
and 200 mg of fluconazole.
Supplied in bottles (opaque polyethylene) of 50 or 100 tablets.
DIFLUCAN I.V. is available as a sterile aqueous solution fo r direct infusion. Each mL
contains 2 mg fluconazole and 9 mg sodium chloride. Supplied in clear glass bottles of 100
mL, affording doses of 200 mg fluconazole, sealed with a rubber bung.
STORAGE
DIFLUCAN TABLETS (fluconazole) 50,100, and 200 mg: Store below 30°C.
DIFLUCAN I.V. (fluconazole) 2 mg/mL: Store below 30°C. Do not freeze.
References: 1. DIFLUCAN new drug submission, Data on file, Pfizer Canada Inc.
2. Product monograph-DIFLUCAN*.
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Expanded Polytetrafluoroethylene Patch
in Hernia Repair: a Review of Clinical
Experience
Ron A. Monaghan, MD; Sam Meban, MB, FRCSC
The use of an implantable prosthetic material is often needed to repair inguinal and
incisional hernias, especially when the local tissue is of poor quality or there is a
large defect that would cause excessive tension if closed without patching with
prosthetic material.
An expanded polytetrafluoroethylene (ePTFE) patch was used in 37 patients
between May 1986 and May 1990 to repair 25 direct inguinal and 12 incisional
hernias.
There was one recurrence in the group of patients with incisional hernia but none
in those with a direct inguinal hernia. The recurrence was due to poor collagen
ingrowth into the patch and subsequent herniation between two sutures. There were
no complications due to infection, adhesions, erosion or fistulization.
On the basis of this clinical experience, the authors conclude that the ePTFE
patch is almost an ideal abdominal wall substitute, but that because of poor
anchorage with tissue reaction alone, the success of the repair depends on the
technique of suture placement.

L’utilisation d’un materiau prosthetique implantable est souvent necessaire pour
reparer une hernie inguinale ou une hernie due a une incision chirurgicale,
particulierement quand le tissu local est de mauvaise qualite ou quand il s’agit d’une
breche importante dont la fermeture sans plaque de materiel prosthetique entrainerait une tension excessive.
Entre mai 1986 et mai 1990, une plaque de polytetrafluoroethylene expanse
(PTFEe) a ete utilisee pour corriger 25 hernies inguinales directes et 12 hernies
dues a une incision.
On a enregistre une recidive dans le groupe de patients qui avaient eu une hernie
d’incision mais aucune chez ceux qui avaient eu une hernie inguinale directe. Cette
recidive etait le resultat d’une mauvaise penetration du collagene dans la plaque et
d’une hernie subsequente entre deux sutures. II n’y a eu aucune complication par
infection, adhesion, erosion ou fistulisation.
A partir de cette experience clinique, les auteurs concluent que la plaque de
PTFEe est un substitut quasi ideal de la paroi abdominal, mais qu’a cause d’un
mauvais ancrage avec la reaction tissulaire seule, le succes de la reparation depend
de la technique de suture.

From the Division o f General Surgery, Ottawa Civic Hospital, Ottawa, Ont.
Accepted fo r publication Dec. 12, 1990
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n the repair of inguinal and inci
sional hernias when local tissues
are of poor quality or when closure
of a defect would create excess
tension, implantable prosthetic ma
terial is often needed to patch the
defect. The characteristics of an
ideal implantable prosthetic material
are shown in Table I.1 We have
found that an expanded polytetra
fluoroethylene (ePTFE) patch
(Gore-Tex soft tissue patch; W.L.
Gore and Associates, Inc., Flagstaff,
Ariz.) closely meets these require
ments. The ePTFE patch has an
advantage over implantable materi
als such as polypropylene mesh in
that it is more pliable, forms fewer
adhesions2 and can be sutured close
to the graft edge with less risk of
tearing. In addition, polypropylene
mesh has caused difficulties in the
presence of infection.3 In an experi-

I

Table I. Characteristics of an Ideal
Implantable Prosthetic Material*
1. Not be modified by body fluids but allow
host tissue infiltration
2. Not induce a foreign body response and
form limited adhesions to underlying
bowel
3. Be hypoallergenic
4. Lack carcinogenicity
5. Have adequate strength
6. Be pliable
7. Be able to withstand sterilization
8. Resist infection
9. Accept sutures close to graft margin
without tearing through
'Adapted from
30: 65-67.

J R Coll Surg Edlnb 1985;
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mental model, Brown and col
leagues3 demonstrated that ePTFE
produced less bacterial adherence
when intraoperative contamination
had occurred and that it created
fewer adhesions in sterile and con
taminated wounds than did poly
propylene mesh. In this study we
review the clinical experience of one
surgeon (S.M.) with 37 patients
who had direct inguinal and inci
sional hernias repaired with ePTFE.

Methods and Patients
From May 1986 to May 1990, 37
hernias were repaired using ePTFE.
The 32 men and 5 women ranged in
age from 26 to 80 years (mean 59.3
years). The hernia types included
direct inguinal (25 hernias) and inci
sional (12 hernias) (Table II).
Inguinal Hernias

In the inguinal group, the mean
age of the patients was 58.6 years.
Each hernia in this group had a
direct component, but four also had
an indirect component. Eight pa
tients had previously undergone
hernia repair. Recurrence was due
to tissue failure in six, steroid use
in one and postoperative hematoma
formation in a patient known to
have hemophilia A. In each case,
1.0 g of cefazolin was given preoperatively. For inguinal hernias, an
ePTFE patch, 1 mm thick, was
used. The indications for its use
included poor local tissues (19
hernias), presence of a large defect
for which direct closure would have
resulted in excessive tension (2
hernias) and recurrent hernia (4
hernias).
The hernia was repaired by excis
ing the direct hernia sac. The peri
toneum was then closed with a
running absorbable suture and the
transversalis fascia repaired with
2-0 Novofil (Davis & Geek, Mark

ham, Ont.), either in a continuous
or interrupted manner. The ePTFE
patch was shaped to fill the defect
between the lower margin of the
conjoined tendon and transversus
abdominis tendon and the inguinal
ligament. To secure the patch, a
continuous monofilament suture
(Gore-Tex or Novofil)4 was used.
Inferiorly this anchored the patch
to the inguinal ligament and superi
orly to the lower margin of the
conjoined tendon and transversus
abdominis tendon. The patch was
not extended lateral to the internal
ring. The running suture was tied
at the medial aspect of the internal
ring — a bite of the deep repair was
picked up at this point. This rein
forced the medial margin of the ring
(Fig. 1). None of the wounds was
drained at the time of surgery.
Postoperatively the wound was ex
amined before the patient was dis
charged, after 1 to 2 weeks and
again at 3 months.
Incisional Hernias

With respect to incisional hernias
(12), the mean age of the patients
was 63.2 years. Only 1 of the 12
was operated on for recurrent inci
sional hernia, and the recurrence
was thought to be secondary to the
patient’s marked obesity and to
poor local tissues. The dimensions
of the incisional hernias varied be
tween 15 X 10 cm to 4 X 4 cm for
total area of the patch. A 2-mm

thick ePTFE patch was used in
each case of incisional hernia. Indi
cations for its use included poor
local tissues (two hernias), to avoid
excessive tension when closing a
large defect (nine hernias) and re
current hernia (one hernia).
In incisional hernias the hernial
sac was excised, and the margins of
the defect in the abdominal wall
were identified. When a good layer
of peritoneum was present, it was
closed with absorbable suture in
one layer. Otherwise the resulting
repair had the 2-mm ePTFE patch
coming in direct contact with bowel
or omentum.
The technique of repair included
the use of both interrupted and
continuous nonabsorbable suture
(Gore-Tex or Novofil). Wounds
were drained at the time of surgery
with either a Jackson-Pratt drain
or a Hemovac drain in 9 of the 12
patients. Perioperative antibiotic
coverage and postoperative wound
examination was the same as in the
inguinal hernia group.

Results
Inguinal Hernias

Follow-up in this group ranged
from 4 to 48 months (mean 28.3
months). Early postoperative com
plications included a hematoma in

Table II. Epidemiologic Characteristics of
37 Patients Who Underwent Hernia Repair
With an Expanded Polytetrafluoroethylene
Patch
Mean age, yr (range)
No. of men/women
Types of hernia, no.
Inguinal
Incisional
Previous attempts at
repair, no.
None
1
2

59.3 (26 - 80)
32/5
25
12
28
8
1

FIG. 1 . Operative view of inguinal
hernia repair. Expanded polytetra
fluoroethylene patch in place secured
by continuous running suture.
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the patient with hemophilia A. The
hematoma was drained 2 days postoperatively. This patient had inade
quate correction of clotting factors
at the time of surgery. There were
no cases of late seroma formation
or postoperative wound infection
and no cases of recurrent hernia.
Incisional Hernias
The follow-up ranged from 3 to
42 months (mean 15.5 months).
Complications included seroma for
mation in 5 of 12 patients. Recur
rent herniation occurred in one pa
tient 9.1 months after operation.
The patient was operated on 1 year
after his initial hernia repair and
was found to have a defect between
two sutures at the lateral edge of
the graft. There was good vasculari
zation over the graft, and there
were no adhesions between the
bowel and the patch. A biopsy of
the edge of the ePTFE patch was
done. Histologic examination
showed a layer of granulomatous
inflammatory reaction made up of
histiocytes and foreign-body giant
cells at the junction of the ePTFE
with native fibrous tissue. There
was poor collagen ingrowth into the
patch and no vascularization or
fibrosis of the graft (Fig. 2). There
were areas of separation of the
ePTFE from the fibrous tissue at
the graft margin. Six months after
the second repair, the wound was
well healed, and there was no evi
dence of recurrent herniation.

logic evidence of poor collagen in
growth suggests that there is poor
anchorage of the graft with tissue
reaction alone.
The technique of expanding
PTFE into a sheet of nodes inter
connected by tiny fibrils allows fi
broblasts to infiltrate these spaces
and synthesize collagen.5'6 Howev
er, when the ePTFE is not strongly
secured to the adjacent fascia this
process appears not to take place.
Van der Lei and colleagues7 showed
that when the patch is sutured to
the fascial margin with no overlap,
there is an increased incidence of
buttonhole hernia between sutures
at the patch-fascia interface. They
advocated a double row of sutures
with an overlap technique to pre
vent recurrence. Biopsy analysis of
their patches also showed poor fibrocollagenous infiltration. Their
explanation was that the internodal
space of the ePTFE patches (i.e.,
fibril length 10 to 20 pm) was not
enough to allow good ingrowth.
However, Bauer and associates8
showed that biopsy of graft material
from their single recurrence demon

strated fibroblasts within the inter
stices of the material and collagen
penetration to 200 ^m. Their con
clusion was that good healing had
occurred with a minimal inflamma
tory response.
Our study supports the hypothe
sis that a poorly secured patch
prevents collagen ingrowth. The
technique should at least include a
running suture along the edge of
the graft to prevent herniation be
tween interrupted sutures or double
suturing and overlap as suggested
by van der Lei and colleagues.7 A
2-mm patch seems adequate8 since
no herniation occurred through the
ePTFE itself. The high incidence of
seroma formation in this group
shows the importance of operative
drainage and may suggest a need
for prolonged drainage in selected
cases.
The results in the inguinal hernia
group indicate that a 1-mm patch is
adequate for repair and that drain
age use of a Jackson-Pratt or Hemovac drain is unnecessary.
The use of ePTFE in patients
with poor local tissues, recurrent

Discussion
This series of 37 patients shows
the clinical efficacy of an ePTFE
patch in hernia repair. Expanded
PTFE closely meets the criteria for
the ideal prosthetic material.
In the one patient with recur
rence, the patch was secured using
interrupted sutures only. The histo
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FIG. 2. Histologic appearance of edge of patch in patient with recurrent herniation
shows absence of collagen ingrowth into patch; p = ePTFE (hematoxylin-eosin
stain, original magnification X 50).
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hernia and large defects and to
avoid excessive tension on the clo
sure has shown good results.
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the past 2 years. Both devices, the
gamma knife and linear accelerator, are
discussed well, although more detail
might have been presented on the com
parative technologies, accuracies and
dosimetry of the cobalt-60-based
gamma unit and the linear accelerator.
Some discussion of alignment error,
with attention to machine and localiza
tion errors, might have supplemented
the chapter further. In the end the
author leaves the impression, quite cor
rectly, that the technology matters less
than the team of individuals responsible
for the proper execution of this treat
ment modality.
The stereotactic resection of brain
tumours is a treatment for which the
author has been most noted during the
past decade. His large caseload is nicely
presented with subsequent discussions
in chapter form of the management of
glial and nonglial tumours. This is
much appreciated. In the case of highgrade gliomas, the survival after stereo
tactic resection and radiotherapy is
much better than that after biopsy and
radiotherapy, although the results of
the latter method seem much the same
as those achieved by generous open
debulking of such tumours without the
application of stereotaxy. Simply stated,
the biology of the tumour still works
against us whatever the method of
tumour removal. Where there is a more
obvious beneficial application for ste
reotactic resection is in the case of
well-circumscribed, deeply seated, low-

grade gliomas (i.e., pilocytic as
trocytomas), mixed gliomas and nongli
al tumours. Complete removal of such
radiographically identifiable tumours
may well spell the difference between
symptomatic recurrence and symptomfree survival.
In the last chapter mention is made
of the potential of surgical stereotaxy
as it applies to neuro-oncology. There is
much to be read into the passages of
this final chapter regarding the therapy
of intra- and extracranial disease. Much
opportunity for innovation exists in the
diagnosis and radiosurgical treatment of
tumours. The technical advances of
stereotaxy need not necessarily be con
fined to neurosurgery.

BOOK REVIEWS
continued from page 493

This technique is not often addressed in
the stereotactic literature and is given
recognition here as an adjunct to ste
reotactic planning.
The simplest application of the ste
reotactic method is in the biopsy of
brain lesions. With few exceptions and
with proper planning, virtually any por
tion of the brain may be approached
safely and accurately through a twist
drill or burr hole. This aspect of stereo
taxy is addressed in detail with an
honest appraisal of its benefits (positive
diagnostic yield over 98%) and compli
cations, both permanent (1%) and tran
sient (0.7%). Stereotactic third ven
triculostomy is addressed in a short but
informative chapter. It is not a common
procedure but has some relevance in
light of renewed interest in the options
available for the surgical treatment of
hydrocephalus.
Stereotactic irradiation is discussed
with more emphasis on interstitial treat
ment or brachytherapy than on external
beam therapy. The author summarizes
the experience with brachytherapy, pre
senting pertinent data regarding its ap
plication, procedural considerations,
hazards and long-term effects. It is
difficult to remain up to date on this
topic, particularly in text form, because
of its present rapid growth. This is
perhaps most apparent in the field of
external beam therapy and the use of
linear accelerators in stereotactic radi
osurgery. Their application in this form
of treatment has risen appreciably in

Host Elisevich, MD, PhD, FRCSC, DABNS
Victoria Hospital
375 South St.
London, ON
N6A 4G5
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Prescribing Information
ACTION
ERGAMISOL (levamisole hydrochloride) is capable of
restoring impaired immune responses preferentially of
the cell mediated type in compromised hosts. Therapeutic
doses of levamisole restore to normal the functions of
monocytes (phagocytes) and T lymphocytes but do not
directly influence B cells.
Levamisole is rapidly absorbed from the gastrointestinal
tract following a single oral ingestion of 150 mg. In
patients with neoplastic disease, a mean peak blood level
of 0.86 mcg/mL is attained within 2 hours of intake.
The half-life of elimination of levamisole alone is between
3-4 hours. The metabolites are eliminated more slowly
w ith a term inal half-life of approximately 16 hours.
Levamisole is extensively metabolized by the liver in man
and excreted mainly by the kidneys (70% over 3 days).
Approximately 5% is excreted in the feces. Less than 5%
of the unchanged dose is excreted in the urine and less
than 0.2% in the feces.
INDICATIONS
ERGAMISOL (levamisole hydrochloride) is indicated as
adjuvant therapy in poor prognosis malignant melanoma
following complete surgical excision and exclusion of
metastatic disease. In such patients, levamisole has been
shown to produce an improvement in relapse free survival
and overall survival when compared to observation alone,
particularly in patients aged 55 years or older.
ERGAMISOL is also indicated as adjuvant therapy, in com
bination with 5-fluorouracil, in patients with completely
resected Dukes’ stage C colon cancer. Evidence of
metastatic disease must be excluded before initiating
therapy. In patients with Dukes’ stage C carcinoma of the
colon, a regimen of levamisole plus 5-fluorouracil has
been shown to produce significant reductions in both
cancer recurrence and overall death rate.
CONTRAINDICATIONS
Levamisole is contraindicated in patients with a known
hypersensitivity to the drug.
WARNINGS
ERGAMISOL (levamisole hydrochloride) has been asso
ciated with reversible leukopenia and agranulocytosis,
therefore it is essential that appropriate hematological
m o n ito rin g be done routinely during therapy w ith
ERGAMISOL.
Patients should be instructed to report immediately any
sudden change in their state of health which may be man
ifested by influenza-like symptoms (fever, lassitude, sore
throat, shivering or sweating) so that appropriate hema
tological testing can be done.
Leukopenia (total WBC below 3000/m nf) is not neces
sarily a sign of impending agranulocytosis; recovery is
possible without withdrawal of the drug. However, with
a reduced neutrophil count (less than 20% of the total
white blood cell count) levamisole should be discontinued
permanently. (Agranulocytosis is attributed to antibody
form ation and absorption of immune complexes. This
process initiates complement activation and cell lysis; lev
amisole itself does not directly damage granulopoiesis.)
The HLA genotype B27 predisposes to the development
of agranulocytosis, particularly in females with concomi
tant rheumatoid arthritis. The onset is frequently sudden
and may be asymptomatic. Following discontinuation of
levamisole, neutrophil counts normalize within a week to
10 days. There is no evidence that steroids or WBC trans
fusions are of significant therapeutic value; prophylaxis
of infection during the acute phase of agranulocytosis
should be an important consideration.

PRECAUTIONS
Drug Interactions; The therapeutic effect of levamisole
may be antagonized by concomitant administration of cor
ticosteroids.
Additional caution is necessary when levamisole is used
in combination with other drugs potentially affecting
hemopoiesis.
Levamisole has been reported to produce “ANTABUSE™"like side effects when given concomitantly with alcohol.
ADVERSE REACTIONS
Approximately half of all patients treated with ERGAMISOL
(levamisole hydrochloride) experience adverse effects of
the medication. Due to the interm ittent nature of the
dosage schedule, drug discontinuation may not be nec
essary for successful resolution.
The adverse reactions observed when levamisole is used
in combination with 5-fluorouracil are consistent with
those anticipated if 5-fluorouracil is given alone in a com
parable dose and schedule.
The incidence of adverse reactions for levamisole alone
in malignant melanoma patients and fo r levamisole plus
5-fluorouracil in colonic cancer patients is presented in
Table I.
An encephalopathy-like syndrome has been reported.
TABLE I: INCIDENCE OF ADVERSE REACTIONS
IN PATIENTS TREATED WITH LEVAMISOLE FOR
MALIGNANT MELANOMA OR COLONIC CANCER.
INCIDENCE (%)
LEVAMISOLE LEVAMIS0LE+5-FU
COLONIC
MELA INDUC MAINTE
NOMA
TION
NANCE

ADVERSE REACTIONS
GASTROINTESTINAL
nausea
vomiting
diarrhea
taste change
anorexia
MUCOCUTANEOUS
stomatitis
dermatitis
severe
alopecia
conjunctivitis
hyperpigmentation
HEMATOLOGICAL
leukopenia
2000 to 4000/mm3
less than 2000/mrrT
thrombocytopenia
50000 to 130000 /mm’
less than 50000 /mm’
agranulocytosis
MUSCULOSKELETAL
arthralgia/myalgia
NEUROLOGIC
visual change
smell change
headache
dizziness/vertigo
ataxia
anxiety/irritability
depression
insomnia
somnolence
impaired thinking
OTHER
fatigue/weakness
fever
impaired liver function

24
6
10
1
1
4

37
8
25
2

56
17
47
7

27
8
1
4
1

28
22
1
22
7
2

38
7

38
2

4
2

18
4

2

4

10

1.4
8

1

2
2
5
4
3
2
2
1
1
2

5

11

1

2

1
1
1
2
1

SYMPTOMS AND TREATMENT OF OVERDOSAGE
There is no experience of overdosage with ERGAMISOL
(levamisole hydrochloride). At high doses ERGAMISOL
exhibits positive inotropic and chronotropic properties on
heart muscle as well as convulsant properties. General
supportive measures are recommended.
DOSAGE AND ADMINISTRATION
In patients with malignant melanoma
ERGAMISOL (levamisole hydrochloride) should be admin
istered at a dose of 2.5 mg/kg given as a single daily dose,
preferably at night, on 2 consecutive days every week.
Higher doses are not recommended as they are associated
with increased toxicity and have not been shown to
provide any additional therapeutic benefit.
In patients with Dukes' stage C carcinoma of the colon
Levamisole plus 5-fluorouracil should be administered
only by or under the supervision of qualified physicians,
experienced in cancer chemotherapy, and well versed in
the use of potent antimetabolites.
Therapy with ERGAMISOL may be initiated as soon after
resection as patients are able to tolerate oral medication,
but no sooner than one week and no later than five weeks
after surgery.
ERGAMISOL should be administered orally at a dose of
50 mg t.i.d., for three consecutive days, every two weeks.
This therapy should be continued fo r at least one year.
Administration of 5-fluorouracil should be timed to begin
concomitantly with the second three day course of lev
amisole. The initial dosage of 5-fluorouracil should be 450
mg/nf/day, given intravenously, for five consecutive days.
Four weeks following the initial five day course of 5-fluorouracil, patients should begin maintenance therapy on
a once weekly basis with an intravenous injection of 5fluorouracil at a dose of 450 mg/m!. Treatment should
continue for as long as levamisole is administered.
If the patient experiences stomatitis, diarrhea or leukope
nia, the weekly 5-fluorouracil administrations should be
deferred until these side effects have subsided. If these
side effects are moderate to severe in intensity, 5-flu
orouracil should be resumed with a 20% reduction in
the dose.
Dosage Forms;
Availability: ERGAMISOL tablets 50 mg are available in
blister packages of 36 tablets.
Storage:
ERGAMISOL tablets 50 mg should be stored
at room temperature and protected from
moisture and light.
Product monograph available on request.
1. Moertel CG et al. Levamisole and fluorouracil for adju
vant therapy of resected colon carcinoma. New Engl
J Med. 1990;322:352-8.
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U se of a Urethral Splent in One-Stage
Hypospadias Repair
John G. Pike, MD; Alex Brzezinski, MD, FRCSC; George H. Kiruluta, MB, BS, FRCSC
Over a 9-month period, 28 patients with distal penile or more proximal hypospadias
underwent one-stage surgical repair. Bladder drainage was achieved in the
traditional fashion with either an indwelling Foley catheter or suprapubic catheter
or by using a modified urethral silicone stent (“splent”). Twenty-two patients had
repair with a perimeatal skin flap, and the remaining six patients had
major urethral reconstruction with a vascularized preputial island flap. Use of the
urethral splent was associated with shorter postoperative hospitalization and
minimal short-term complications. The authors’ experience has shown that use of a
urethral splent for urinary drainage is efficient and effective in postoperative
management after hypospadias repair.

Sur une periode de 9 mois, 28 patients souffrant d’un hypospadias distal au penis
ou plus proximal ont subi une operation en un temps. Le drainage de la vessie a ete
obtenu soit de fagon classique, avec une sonde Foley a demeure ou un catheter
sus-pubien, soit avec un extenseur uretral de silicone modifie («splent»). Vingt-deux
patients ont subi une reparation a l’aide d’un lambeau cutane perimeatique, alors
que les 6 autres subissaient une reconstruction uretrale majeure avec un greffon de
tissu preputial vascularise taille en ilot. L’emploi de l’extenseur uretral a ete relie a
une duree d’hospitalisation postoperatoire plus courte et a un taux minime de
complications a court terme. L’etude realisee par les auteurs a montre que
l’utilisation d’un extenseur uretral pour fin de drainage urinaire est efficace dans les
soins postoperatoires consecutifs a la reparation d’un hypospadias.

ypospadias is a fairly common
congenital anomaly with an es
timated incidence of 3.2 in 1000
live male births or about 1 in every
300 boys.1 The urethral meatus
may be located at any point along
the midline ventral shaft of the
penis, scrotum or even the perine
um. In the more severe forms of
hypospadias, reconstruction is
necessary to allow normal voiding
and fertility.

H

With the refinement of pediatric
anesthesia, use of microsurgical
techniques and a better understand
ing of tissue repair, hypospadias
surgery is being performed at a
progressively younger age, usually
between 6 and 24 months.2’3 The
majority of surgeons use some form
of urinary diversion.
Many types of urinary diversion
have been used, including an in
dwelling Foley catheter, suprapubic

From the Division o f Pediatric Urology, The Montreal Children’s Hospital. M cGill University,
Montreal, Que.
Accepted fo r publication Nov. 6, 1990
Reprint requests to: Dr. George H. Kiruluta. Division o f Pediatric Urology, Department o f
Surgery, The M ontreal Children's Hospital, 2300 Tupper St., Montreal, PQ H 3H1P3

catheter and perineal urethrostomy.
Since most surgeons believe that
some form of urinary diversion
should remain in situ until suture
lines have healed adequately, cathe
ters often remain in place for 7 to
10 days. This practice has necessi
tated long hospital stays, physical
restraint of the child and often
serious short-term morbidity.
Recently, alternative ways to fa
cilitate bladder drainage after hy
pospadias repair have been de
scribed.45 Because of a general dis
satisfaction with the traditional
means of urinary diversion, we tried
a modified silicone urethral stent, or
“splent,” after hypospadias repair
in an effort to improve patient care
and shorten hospitalization.

Patients and Methods
During the 9-month period from
August 1989 to April 1990, 28
boys with distal penile or more
proximal hypospadias underwent
repair at our centre (Fig. 1). Minor
glanular and subglanular repairs do
not usually require any form of
urinary diversion and were subse
quently not considered in this
study. All of the repairs were done
under general anesthesia with ei
ther caudal or penile nerve block.
Middle and distal penile hypos
padias were repaired with a peri
meatal skin flap or Mathieu proce
dure.6 More proximal and penoscro
tal hypospadias were repaired with
a vascularized preputial island flap
CJS, VOL. 34, NO. 5, OCTOBER 1991
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the urethral splent, and then the
neourethra is anastomosed into po
sition. The splent is secured at the
glanular meatus using two 5-0 Prolene sutures. To avoid dislodging
the splent, the sutures need to be
placed so that there is minimal play
(Fig. 2). At the end of the proce
dure, a no. 3.5 or a no. 5 French
feeding tube is passed through the
splent into the bladder to ensure
easy catheterization in case urinary
retention occurs. The feeding tube
is removed immediately.
All patients were treated with
parenteral antibiotics during their
perioperative course and switched
to oral antibiotics once intravenous
feeding was discontinued. Oral anti
biotics were continued for 1 to 2
weeks after removal of the urinary
drain.

by either the Asopa or Duckett
technique.7’8
For the initial 10 cases we used
one of the traditional forms of uri
nary diversion, either a Foley cathe
ter, a suprapubic catheter, or both.
The remaining 18 patients were
managed with a modified silicone
stent or “splent” in a fashion simi
lar to that described by Mitchell and
Kulb in 1986.5
Surgical Technique
The splent is easily made from
no. 10 French silicone tubing or a
silicone Foley catheter. It is made
long enough to provide placement 1
cm proximal to the neourethra. A
longitudinal strip corresponding to
25% of the circumference of the
tube is then cut from the tubing;
one can simply excise the balloon
port if using a Foley catheter. Both
ends are trimmed obliquely. With
the perimeatal skin-flap procedure,
the splent is lubricated and passed
through the neourethra after the
repair is complete. In the vascula
rized preputial island-flap repair,
the neourethra is tubularized over

T a b le 1.

D a ta

Age, mo (range)
Drain in place, d (range)
Hospitalization, d (range)
Follow-up, mo (range)
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Results
The average age of children ma
naged with a splent was 19 months
and of those with an indwelling
catheter was 25 months (Table I).
Fifteen of the splented group and 7

of the indwelling-catheter group un
derwent a Mathieu type of hypos
padias repair. The remaining three
patients in each group underwent
major urethral reconstruction by
either the Asopa or the Duckett
technique.
The average hospitalization was
2.5 days for the splented group and
7.7 days for the indwelling-catheter
group. An effort was made to re
move the urinary catheter or splent
at the most convenient clinic ap
pointment 7 to 10 days postoperatively. The urethral splent stayed in
place an average of 7.8 days where
as the indwelling catheter was in
place an average of 7.2 days. The
splented group had an average fol
low-up of 4.5 months compared
with 8.2 months for the indwellingcatheter group. This difference is
explained by the fact that all of the
patients in the latter group under
went repair during the first 2
months of the study.
Short-term complications in the
splented group included two urethrocutaneous fistulas and two
splent dislodgements (Table II). In

Data on Hypospadias Repair in 28 Boys
U re th ra l
“ s p le n t”

In d w e llin g
ca th e te r

(» = 1 8 )

(z» = 10)

19(7-30)
7.8 (1 -15)
2.5(1 -4 )
4.5(1 -7 )

25 (15 - 42)
7.2 (4-11)
7.7 (4-11)
8.2 (7 -9 )
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FIG. 2. Surgical result of distal penile

hypospadias repair demonstrating
urethral splent and simple Tegaderm
dressing.

URETHRAL SPLENT IN HYPOSPADIAS REPAIR

the latter case, both children voided
spontaneously and suffered no ill
effects. No attempt was made to
replace the splent. In the indwel
ling-catheter group, there was one
urethrocutaneous fistula, one case
of meatal recession, two cases of
intractable bladder spasm despite
anticholinergic medication, one uri
nary tract infection 4 days after
removal of the catheter and one
meatal stenosis.

Discussion
The ultimate goals of hypos
padias surgery are to achieve a
straight phallus with a glanular
meatus, to have a cosmetically
“normal” appearance of the penile
shaft and glans, and to allow unob
structed, uniform flow through the
neourethra. With the advent of vari
ous repairs for even the most severe
forms of hypospadias and the re
finement of microsurgical tech
niques, these goals are readily at
tained. Attention has subsequently
focussed on the postoperative man
agement, since this was the stage in
the surgical process that caused the
most stress for both patient and
family.
Most glanular or coronal hypos
padias defects are readily repaired
by the MAGPI procedure.9 These
repairs are done routinely on an
outpatient basis and do not require
any form of urinary diversion.10 On
the other hand, more serious de
fects require some form of urinary
diversion to allow suture lines in

the neourethra to heal and become
watertight. Ideally, the drain should
allow early ambulation, provide un
obstructed bladder drainage, be
painless and nonirritating to the
patient, be infection-free and easily
removed.
The use of a urethral splent in
hypospadias surgery, as demon
strated by our findings, results in
markedly shortened hospitaliza
tions. Since the child voids sponta
neously without being encumbered
by drainage collection devices, am
bulation occurs immediately postoperatively. Parents can readily hold
and comfort their child since there
is no risk of dislodging tubes. The
dressing used to cover the wound is
simpler because there is no extrane
ous tubing to tug on the repair or
be pulled apart, and it can easily be
soaked off in the bath after 3 to
4 days. We have found the use of
two Tegaderm (3M Medical-Surgical
Division, London, Ont.) dressings
around the penis in a sandwich
fashion to be perfectly adequate.
The patient is managed with diapers
in the usual manner. As soon as he
is voiding adequately and having
minimal pain, the patient is dis
charged.
Unlike the indwelling Foley or
suprapubic catheter, bladder
spasms do not occur with the ureth
ral splent, and, because it is distal
to the external sphincter, bladder
infection is less likely. Meatal reces
sion, which is commonly seen in
repairs drained with Foley cathe
ters, should also be less likely since
there is no traction on the suture

T a b le II. Complications of Hypospadias Repair
P rocedure

Urethral splent
Mathieu repair
Asopa or Duckett repair
Indwelling catheter
Mathieu repair
Asopa or Duckett repair

No.

15
3
7
3

C o m p lic a tio n s

Splent dislodgem ent
Urethrocutaneous fistula
Urethrocutaneous fistula
Serious meatal recession
Severe bladder spasms
Urinary tract infection
Meatal stenosis

No.

2
2
1
1
2
1
1

line. The splent is easily removed in
the outpatient clinic during the first
postoperative visit when glanular
swelling has resolved.
In conclusion, we believe that use
of a urethral splent is a substantial
improvement in management of
children after hypospadias repair.
Our experience has shown that
short-term complications are mini
mal, hospital stay is shorter and
patient comfort is markedly im
proved. We believe that the urethral
splent is particularly useful for
major hypospadias repair since it
allows more effective and efficient
postoperative management.
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NARCOTIC EFFICACY W ITHO UT NARCOTIC DRAWBACKS
TORADOL (ketorolac tromethamine) 10 mg tablets
TORADOt IM (ketorolac tromethamine) 15 mg/mL and 30 mg/mL intramuscular injections
THERAPEUTIC CLASSIFICATION
Analgesic Agent
ACTION
Toradol (ketorolac tromethamine) is a non-steroidal anti-inflammatory drug that exhibits analgesic activity. Its mode of
action is to inhibit the cyclo-oxygenase enzyme system, thereby inhibiting the synthesis of prostaglandins, and is consid
ered to be a peripherally acting analgesic. A t analgesic doses it has minimal anti-inflammatory and antipyretic activity.
Ketorolac tromethamine is rapidly and completely absorbed when administered by both the oral and intramuscular routes,
and pharmacokinetics are linear following single and multiple dosing.
Steady state plasma levels are attained after one day of Q.I.D. dosing. Based only on pharmacokinetic principles, a faster
attainment of the steady state plasma level might be achieved with a loading dose of about twice the maintenance
dose. This occurs when the dosing interval is approximately equal to the drug's half-life.
Following oral administration, peak plasma concentrations of 0.52 to 1.31 mcg/ml occurred 35 minutes after a single 10 mg
dose, The terminal plasma elimination half-life ranged between 4.1 and 6.1 hours in healthy adults, while in elderly sub
jects (mean age: 72 years) it ranged between 3.0 and 6.1 hours. A high fa t diet decreased the rate but not the extent
of absorption of oral ketorolac tromethamine, while antacid had no effect.
Following intramuscular administration, peak plasma concentrations of 2.2 to 3,0 mcg/m l occurred an average of 50
minutes after a single 30 mg dose. The terminal plasma half-life ranged between 3.8 and 6.3 hours in young adults and
between 4.4 and 8.6 hours in elderly subjects (mean age: 72).
The primary route of excretion of ketorolac tromethamine and its metabolites (conjugates and the p-hydroxy m etabo
lite) is in the urine (91.4%) and the remainder is excreted in the feces.
More than 99% of the ketorolac in plasma is protein bound over a wide concentration range.
INDICATIONS
Orally administered Toradol (ketorolac tromethamine) is indicated for the short-term management of mild to moderately
severe pain, including post-surgical pain (such as general, orthopedic and dental surgery), acute musculoskeletal
traum a pain and post-partum uterine cramping pain.
Intramuscular injection of Toradol is indicated for the short-term management of moderate to severe pain, including pain
following major abdominal, orthopedic and gynecological operative procedures.
CONTRAINDICATIONS
Toradol (ketorolac tromethamine) should not be used where there is a known or suspected hypersensitivity to the drug.
Because of the possibility of cross-sensitivity, ketorolac tromethamine should not be used in patients in whom acetylsalicylic acid (ASA) or other non-steroidal anti-inflammatory agents induce acute asthmatic attacks, urticaria, rhinitis or other
allergic manifestations. Fatal anaphylactoid reactions may occur in such individuals.
Toradol (ketorolac tromethamine) also should not be used in patients with peptic ulcer or active inflammatory disease
of the gastrointestinal system.
WARNINGS
Long-term administration of ketorolac tromethamine oral formulation has shown that this drug shares the risks that other
non-steroidal anti-inflammatory drugs pose to patients when taken chronically. Peptic ulceration, perforation and gas
trointestinal bleeding, sometimes severe and occasionally fatal have been reported during therapy with non-steroidal
anti-inflammatory drugs and may occur with ketorolac tromethamine, both in the presence or absence of previous symp
toms. Elderly and debilitated individuals are most susceptible to these complications, the incidence of w hich increases
with dose and duration of treatment. Close medical supervision is recommended in patients prone to gastrointestinal
tract irritation, particularly those with a history of peptic ulcer, diverticulosis or other inflammatory disease of the gastrointestinal
tract. In these cases the physician must weigh the benefits of treatment against the possible hazards.
Patients taking any non-steroidal anti-inflammatory drug including ketorolac tromethamine should be instructed to con
tact a physician immediately if they experience symptoms or signs suggestive of peptic ulceration or gastrointestinal bleeding.
These reactions can occur at any time during the treatment. If peptic ulceration issuspected or confirmed, or if gastrointestinal
bleeding occurs, ketorolac tromethamine should be discontinued and appropriate treatment instituted and the patient
closely monitored.
Ketorolac tromethamine is not recom mended f a routine use with other non-steroidal anti-inflammatory drugs because
of the potential for additive side effects.
Use in pregnancy, lactation and labour: The administration of ketorolac tromethamine is not recommended during preg
nancy or lactation.
Ketorolac tromethamine is not recom mended for use as an obstetrical preoperative medication or for obstetrical anal
gesia because of the known effects of non-steroidal anti-inflammatory drugs on uterine contraction and fetal circulation.
Use in children: Safety and efficacy in children have not been established. Therefore, Toradol is not recom m ended for
use in children under age 16.
Use in the elderly: Because ketorolac is cleared somewhat more slowly by the elderly (See PHARMACOKINETICS) who
are also more sensitive to the renal effects of non-steroidal anti-inflammatory drugs, extra caution and the lowest effec
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PRECAUTIONS
Renal effects: As with other drugs that inhibit prostaglandin biosynthesis, elevations of blood urea nitrogen (BUN) and cre
atinine have been reported in clinical trials with ketorolac tromethamine. Since ketorolac tromethamine and its metabolites
are excreted primarily by the kidney, patients with significant impairment of renal function (serum creatinine values greater
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by half in such patients. The disposition o f ketorolac in dialysis patients has not been studied.
Patients who are volume depleted because of blood loss or severe dehydration may be dependent on renal prostaglandin
production to maintain renal perfusion and therefore glomerular filtration rate. In such situations the use of drugs which
inhibit prostaglandin synthesis might be expected to further decrease renal blood flow. Caution is advised if ketorolac
tromethamine is used in such circumstances. Close monitoring of urine output, serum urea and serum creatinine is rec
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Hepatic effects: Meaningful elevations (greater than 3 times normal) of serum transaminases (glutamate pyruvate (SGPT
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Fluid and electrolyte balance: Fluid retention and edem a have been observed in patients treated with Toradol. Therefore,
as with many other non-steroidal anti-inflammatory drugs, the possibility of precipitating congestive heart failure in
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Hematologic effects: Ketorolac tromethamine inhibits platelet function and may prolong bleeding time. It does not affect
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is administered. Unlike the prolonged effects from aspirin, the inhibition of platelet function by ketorolac tromethamine
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Blood dyscrasias associated with the use of non-steroidal anti-inflammatory drugs are rare, but co u ld occu r with
severe consequences.
Infection: In common with other anti-inflammatory drugs, ketorolac tromethamine may mask the usual signs of infection.

Drug Interactions: Toradol (ketorolac tromethamine) is highly bound to human plasma protein (mean 99.2%) and bind
ing is independent of concentration.
Prothrombin time should be carefully monitored in all patients receiving oral anticoagulant therapy concomitantly with
ketorolac tromethamine.
Ketorolac tromethamine does not alter digoxin protein binding.
In vitro studies indicated that at therapeutic concentrations of salicylates (300 mcg/mL), the binding of ketorolac
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acetaminophen, phenytoin, tolbutamide and piroxicam did not alter ketorolac tromethamine protein binding, Since ketoro
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There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits the hepatic enzymes
capable of metabolizing itself or other drugs. Hence, it would not be expected to alter the pharmacokinetics of other
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Ketorolac tromethamine mildly reduces the diuretic response to furosemide in normovolemic subjects. Inhtoition of renal lithium
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on methotrexate clearance has not been studied.
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ADVERSE EFFECTS
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Toradol IM: The adverse reactions listed below were reported to be probably related to Toradol IM in clinical trials in which
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tal efficacy at this time. In a gastroscopic study of healthy subjects, daily doses of 360 mg given over an 8-hour interval
for each of five consecutive days (3 times the highest recom mended dose) caused abdominal pain and peptic ulcers
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DOSAGE AND ADMINISTRATION
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Oral: The usual oral dose of Toradol (ketorolac tromethamine) is 10 mg every 4 to 6 hours for pain as required. Doses exceed ing 40 mg per day are not recommended.
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may be employed, but the total daily dose should not exceed 120 mg. Dose above 120 mg could cause drug toxicity
(see Warnings & Precautions). If supplemental analgesia is required, a concom itant low dose of opiate can be used.
The administration of continuous multiple daily doses of Toradol IM should not exceed 5 days for Injection dosing. There
has been limited experience with dosing for more than 5 days since the vast majority of patients have transferred to oral
medication or no longer required analgesic therapy after this time.
Directions for use: Insert the plunger into the syringe barrel and thread it onto the screw. WITHOUT REMOVINGTHENEEDLE GUARD,
apply quick, firm pressure to the plunger to break the inner seal (you will feel it let go). Pull back on the plunger slightly to relieve
pressure. Remove the needle guard by twisting as you pull. Use the unit as you would a normal syringe. Dispose of properly.
CONVERSION FROM PARENTERAL TO ORAL THERAPY
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Toradol (ketorolac tromethamine) is a Schedule F drug.
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lulose, lactose and magnesium stearate. The coating suspension contains hydroxy-propyl-methylcellulose, titanium
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in sterile water. The 30 mg/mL solution contains 10% (w/v) alcohol, USP and 4.35 mg sodium chloride in sterile water. The
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H igh -Pressure Injection Injuries
Walter Peters, MD, FRCSC
High-pressure injection injuries are potentially disabling forms of trauma. Three
cases are presented of patients who sustained high-pressure injuries from paint, air
and water.
Injuries from paint require emergency surgical debridement and exploration
because of the extreme tissue toxicity of the injected material. The patient in this
study had a favourable outcome after delayed closure of his wound and extensive
physiotherapy.
High-pressure injuries resulting from air and water can be managed
conservatively, as in the two patients reported in this paper. Their treatment
included tetanus prophylaxis, irrigation, dressings, splinting, admission to hospital,
intravenous broad-spectrum antibiotics, radiologic assessment and careful
neurovascular evaluation. Surgical debridement and exploration were not necessary.

ries (50 to 300 psi .[345 to 2068
kPa]) and high-pressure water-injec
tion injuries (6000 to 8000 psi
[41 370 to 55 160 kPa]).3' 5 This
study presents the treatment proto
cols and clinical results in three
patients, each with one of the fol
lowing injection injuries: paint, air
and water.

Case Reports
Les blessures par injection a forte pression peuvent s’averer invalidantes. On decrit
trois cas ou des patients ont subi des lesions par injection a forte pression de
peinture, d’air ou d’eau.
Les lesions causees par la peinture exigent un debridement chirurgical et une
exploration d’urgence a cause de l’extreme toxicite tissulaire du materiel injecte. Le
patient, dans cette etude, s’en tira favorablement apres fermeture retardee de la plaie
et une physiotherapie extensive.
Les lesions consecutives a l’injection d’air ou d’eau sous forte pression peuvent
etre traitees de fa?on conservatrice, commme il fut fait pour les deux patients decrits
dans cet article. Leur traitement comprenait prophylaxie antitetanique, irrigation,
pansements, pose d’une attelle, hospitalisation, administration intraveineuse d’antibiotiques a large spectre, examen radiologique et evaluation neurovasculaire
poussee. Le debridement chirurgical et l’exploration ne furent pas necessaires.

injection injuries
H igh-pressure
usually occur in the fingers of
the nondominant hand in young
male workers when they attempt to
wipe the end of a blocked nozzle.1’2
The most common devices responsi
ble for these injuries are grease
guns (pressure 5000 to 10 000 psi
[34 475 to 68 950 kPa]), paint
spray guns (up to 5000 psi [34 475

kPa]) and diesel fuel injectors (2000
to 6000 psi [13 790 to 41 370
kPa]).2’3 These types of high-pres
sure injection injuries are surgical
emergencies that require immediate
exploration, decompression and
debridement.1' 3
Other types of high-pressure in
jection injuries are less common.
These include compressed-air inju-
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Case 1

Paint injection. A 22-year-old
man living in rural Ontario was
using a commercial paint spray gun
with a line pressure of 90 psi (620
kPa). The line developed a leak, and
he received an injection injury into
the radial side of the base of his left
middle finger when he accidentally
grasped the line. He was treated
initially with cloxacillin intrave
nously, tetanus toxoid and a moist
saline gauze dressing. A plaster
splint was applied. He was then
transported directly by air ambu
lance to Toronto. He arrived at our
hospital 6 hours after the injury.
On arrival, examination revealed
a small entrance site, with minor
swelling, at the base of his left
middle finger (Fig. 1). The patient
complained of pain along the length
of the digit. There was good sensa
tion and capillary refill in the digit.
He was prepared directly for sur
gery. Under general anesthesia and
tourniquet control, the palm of the
hand was explored (Fig. 2). Numer
ous pieces of semisolid paint, which
CJS, VOL. 34, NO. 5, OCTOBER 1991
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were adherent to soft tissues, were
removed. These were all localized to
an area within 3 cm of the injection
site. The radial digital artery was
thrombosed. The ulnar digital ar
tery was intact. Both digital nerves
were intact. The flexor tendon
sheath was not involved.
The wound was thoroughly irri
gated with saline solution and was
then left open and gently packed
with wet saline gauze, which was
changed every 4 hours. The patient
was given a 1-week course of cloxacillin intravenously. Three days
after the injury, the wound re
mained clean, so the patient was
taken back to the operating room
for secondary closure of the wound.
A local transposition flap was used
to cover the exposed radial digital
nerve and flexor tendon sheath, and
the flap donor site was closed with
a skin graft.
One week later, gentle physio
therapy was initiated. The patient
was discharged from hospital 15
days after the injury and received
outpatient physiotherapy for a fur
ther 3 months. He returned to his
regular work as a commercial paint
er 3.5 months after his injury, at
which time he had a full range of
motion of his left middle finger,
except that he was lacking the final

FIG. 1. Case 1 — paint injection
injury. Entrance site can be seen at
base of middle finger.
512

JCC. VOL. 34. NO 5, OCTOBRE 1991

10° of extension at the metacarpo
phalangeal joint. He had no further
problems with his left hand.
Case 2
Air injection. A 24-year-old man
was working with a compressed air
line that was used for air condition
ing. He was unaware of any specific
injury, but when he returned home
from work that evening he noticed
that the dorsum of his left hand
“ felt like air bubbles.” Physical
examination showed a tiny entrance
site on the tip of his left index
finger. There was no pain or tender
ness. There was subcutaneous em
physema across the dorsum of the
hand and wrist, which was demon
strated on radiologic assessment
(Fig. 3).
The patient was admitted to hos
pital and placed on broad-spectrum
antibiotic therapy (cloxacillin and
gentamicin), and his left hand and
wrist were splinted and elevated.
The splint was removed daily, and
the hand was carefully examined.
He remained pain-free. Three days
after the injury, there was no sub
cutaneous emphysema, so he was
discharged from hospital to com
plete a 1-week course of antibiotics
and splinting. Subsequently, he re
quired no physiotherapy and was
able to return to work 2 weeks after
the injury.

FIG. 2. Case 1. Exploration of entrance
site.

Case 3
Clean water injection. A 20year-old man was using a highpressure water jet (9000 psi
[62 055 kPa]) to wash concrete
when he accidentally directed the
jet to the dorsum of his left foot.
The water pierced his safety boot
and entered his foot through two
irregular wounds, each about 2.5
cm long (Fig. 4). There was subcu
taneous emphysema on the dorsum
of the foot extending to the medial
and lateral aspects of the ankle, and

FIG. 3. Case 2 — air injection injury.
Radiologic evaluation demonstrates
subcutaneous emphysema on dorsum
of hand and wrist.

Fig. 4. Case 3 — water injection
injury. Two irregular entrance sites of
water can be seen.

HIGH-PRESSURE INJECTION INJURIES

this was also demonstrated on radi
ologic evaluation, which showed no
evidence of foreign bodies. The pa
tient had only minimal swelling and
discomfort. The neurovascular sta
tus of the foot was fully intact.
In view of the nature of the
offending injected agent (clean wa
ter), it was elected to perform a
minimal superficial debridement
under local anesthesia and a thor
ough irrigation of the wounds with
saline. Moist gauze dressings were
then applied, the foot was elevated
and the patient was admitted to
hospital. He was given a 1-week
course of intravenous broad-spec
trum antibiotics (cefazolin and gen
tamicin). The dressing was removed
twice daily and reapplied, and the
foot was carefully inspected for any
marked increase in swelling or vas
cular compromise. Although moder
ate swelling did occur over the first
36 hours, it subsided over the next
48 hours. He was discharged from
hospital 8 days after the injury and
gradually increased his mobilization
so that he was able to return to
work 4 weeks after his injury with
out any other therapy.

Discussion

Each of the three patients report
ed in this study demonstrate impor
tant features of managing highpressure injection injuries. In all of
these injuries, there was a relatively
small entrance site. Initially, there
was only minimal discomfort. In
spite of these early innocuous find
ings, all of these injection iujuiies
are potentially very serious and dis
abling.
Injection injuries caused by paint
and grease tend to be the most
disabling. These chemicals are usu
ally widely injected under high pres
sure and are extremely irritant to
local tissues.15 With these particu
lar agents, there is total agreement

that early and aggressive extensive
decompression and debridement of
the injured tissue are mandatory. In
spite of this treatment, the ultimate
outcome not infrequently involves
contractures, ankylosis and digital
amputation.1 The patient with the
paint injection injury in this study
demonstrates that good results can
be obtained, however, by fully fol
lowing accepted surgical guide
lines. In this patient, the relative
ly low injection pressure (90 psi
[620 kPa]) may have limited the
dissemination of the injected paint.
The patients with high-pressure
air and water injection injuries ob
tained excellent results with full
function after only conservative
treatment. This resulted because of
the decreased pressure of the injury
and the relatively clean and non
irritating nature of the injected
materials. Although some authors
have advocated extensive debride
ment with certain high-pressure
water injection injuries,45 a more
conservative regimen was followed
in our patient because of the
“clean” nature of the water (city
water supply). If the water were
from a polluted source (e.g., a
pond), more aggressive surgical ex
ploration would have been warrant
ed.
Principles for treatment of air
and water high-pressure injection
injuries should include tetanus pro
phylaxis, radiologic evaluation,
careful neurovascular evaluation,
broad-spectrum antibiotic coverage,
admission to hospital and careful
re-evaluation for vascular compro
mise or a compartment syndrome,
which would require immediate sur
gical exploration.
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continued from page 505

thesia, trauma and spinal trauma. All
contain material of interest to both
anesthetists and surgical intensivists,
and the practitioners may find them
selves in a dilemma as to which text is
best suited to their practice. This book
offers chapters on the pathophysiology,
out-of-hospital management, resuscita
tion, anesthetic and intensive care, and
issues in chronic care related to spinal
cord injury.
The chapter on pathophysiology
would be improved by diagrammatic
representations of spina] injury and the
mechanisms of injury, which would
complement the text. The chapter on
accident-site management is a practical
approach to out-of-hospital manage
ment of a spine-injured patient.
The discussion of airway manage
ment in the chapter on resuscitation is
disappointing. The authors have not
reviewed much of the recent work relat
ed to airway care in neck-injured pa
tients, and the chapter suffers badly
because of this. The same criticism
could be rendered in the chapter on
anesthetic management, which again
suffers from a rather superficial discus
sion of airway management. Some of
the comments, for example avoiding the
use of succinylcholine, appear to reflect
the author’s bias rather than a careful
review of available data and trauma
practice.
The chapters on associated injuries
and intensive care have no major flaws
or strengths. The chapters on parenter
al nutrition, chronic care, nursing care
and assessment of pain in cord-injured
patients would be of interest to practi
tioners involved in the ongoing care of
such patients. The chapter on anesthe
sia for nontraumatic spinal disease at
tempts to cover a broad topic and winds
up saying too little about too much. It
could have been expanded to several
chapters or have been restricted to a
more complete discussion of fewer top
ics.
Overall, this is a practical book offer
ing some guidelines to the care, both
acute and chronic, of cord-injured pa
tients. However, the discussions are not
extensive enough to make this an au
thoritative text, and they are not fo
cused enough to make it a valuable
reference for the physician-in-training.
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It is recommended for those practition
ers specifically interested in the chap
ters relating to the chronic care of
cord-injured patients.
Edward Crosby, MD, FRCPC
Director
Watson Library of Anesthesia
Department of Anesthesia
Ottawa General Hospital
Ottawa, ON
K1H 8L6

THE BREAST. Edited by Kirby I.
Bland and Edward M. Copeland III.
1128 pp. lllust. W.B. Saunders Company/Harcourt Brace Jovanovich, Inc.,
Philadelphia. 1991. Price not stated.
ISBN 0-7216-2234-8
This multiauthored textbook is excel
lent. It begins with chapters on the
anatomy and physiology of the breast.
The section that follows about benign
diseases of the breast is concise and
occupies about 10% of the entire book.
Cancer of the breast is the dominant
area of concern in this textbook.
All chapters are well presented, with
many tables, figures and drawings.
Each chapter is followed by extensive
and up-to-date references. Even though
the book may be oriented to surgery,
the authors pay adequate attention to
all other types of modern treatment
such as radiotherapy and chemothera
pyOne of the most interesting aspects
of this book, in my opinion, is the
importance given to the history of
breast diseases and to the history of
their treatments; this permits the reader
to understand all the changes that have
taken place over the past 20 years with
respect to the understanding and treat
ment of breast cancer.
Many chapters cover subjects that
are now very important and not always
included in such a textbook: epidemiol
ogy, oncogenesis and prevention. One
chapter is about the design and conduct
of a clinical trial for breast cancer.
Chapters on breast cancer treatment
are presented according to the treat
ment of different stages of the disease.
The editors include here not only re
sults from the United States but also

from Italian and French protocols. In
deed, these countries were the first to
start conservative treatment of the
breast. There are also contributions
from Canada and England, making this
book truly international.
Another interesting aspect of this
textbook is that specific problems re
ceive specific consideration: for exam
ple, one can find chapters about the
management of local regional recur
rences, bilateral breast cancer, cancer of
the breast and pregnancy, and manage
ment of patients at high risk.
Finally, nursing care, rehabilitation
and psychological problems are also
considered in each chapter.
The Breast should be read by all
surgeons interested in this subject, and
it may also be of interest to radiothera
pists and oncologists.
Andre B. Peloquin, MD, FRCSC, FACS
Hopital Notre-Dame
Montreal, PQ
H2L 4K8

SURGERY: A COMPLETE GUIDE
FOR PATIENTS AND THEIR FAMI
LIES. Edited by Allan Gross, Penny
Gross, Bernard Langer, Linda WilsonPauwels and Margot MacKay. 288 pp.
lllust. Harper & Collins, Toronto.
1989. $45. ISBN 0-00-217905-9
This book is intended for patients who
have been told that they need surgery,
to help them understand the role of
surgery and to give them some basic
definitions of the operation itself. It
comprises 21 chapters covering the
practice of surgery, surgical research,
anesthesia and general complications of
surgery. Specific chapters include pedi
atric surgery, thoracic surgery and gy
necologic surgery, with two interesting
chapters on transplant surgery and can
cer surgery.
I found this book enjoyable because
it covers surgical specialties with the
novice in mind and yet has sufficient
detail to answer many questions regard
ing operative procedures.
Each chapter has clear illustrations,
giving the nonmedical reader a basic
understanding of various surgical pro-
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cedures. An interesting feature is the
presentation of several case studies,
written in simple language, outlining
the work-up and emotional responses of
individual patients who undergo sur
gery. Specifically, the chapter on gener
al surgery in the adult discusses gall
bladder surgery and outlines the surgi
cal operation of cholecystectomy in rea
sonable detail. It also mentions some
complications and recent advances in
cluding lithotripsy, which introduces
the patients to noninvasive surgery.
In another section groin hernias and
their surgical treatment and complica
tions are discussed. The treatment of
cancer of the colon is demonstrated and
an anatomical diagram of the abdomen
is provided as well as clear illustrations
of what a colonic tumour may look like.
Finally, carcinoma of the breast is cov
ered, and three different surgical ap
proaches are illustrated.
The chapter on obstetrics and gyne
cology is particularly well designed. It
stresses some dysfunctional problems of
the female genital tract and describes
surgery of various conditions, including
laparoscopic sterilization, tubal preg
nancy, benign and malignant ovarian
tumours and genital prolapse.
The section on neurosurgery is also
fascinating. It includes a section on
surgical access to the brain, head inju
ry, cerebrovascular disease and spinal
cord trauma. Degenerative disc disease
and peripheral nerve trauma and tu
mours are also discussed quite simply.
A section on cosmetic surgery gives
some historical background to plastic
surgery and has clear illustrations of
basic and complex plastic surgical pro
cedures. Again, a simple case study on
breast augmentation is presented in
which the patient asks the plastic sur
geon a number of questions, which are
answered clearly.
The book in general is quite compre
hensive and would be of use to patients
awaiting surgery. It could also be used
by family practitioners to explain vari
ous surgical procedures to their pa
tients. This would have to be done in
conjunction with the treating surgeon
since the latter would be in a better
position to explain which procedure
would be best suited for the individual

patient. The weakness of the book is
that there is no mention of surgical
endoscopy or any discussion on inten
sive-care treatment of patients, both
well-defined areas of surgery. It does,
however, contain a clear, readable chap
ter on general complications of surgery.
This is an innovative book, which is
affordable, written in simple language
and clearly illustrated. It can be used by
patients or their families to help them
understand and to explain the surgical
procedure they have had or will be
having, and it would be a worthwhile
addition to public as well as medical,
college and university libraries.
Paul Belliveau, MD, FRCSC
Associate professor
Department of Surgery
Royal Victoria Hospital
McGill University
687 Pine Ave. W
Montreal, PQ
H3A 1A1

THE LUMBAR SPINE. The Interna
tional Society for the Study of the
Lumbar Spine. Editorial Committee:
James N. Weinstein and Sam W. Wiesel. 1035 pp. Illust. W.B. Saunders
Company, London/Harcourt Brace Jovanovich, Inc., Phildelphia; HBJHolt-Saunders Distribution Services,
Toronto. 1990. Price not stated. ISBN
0 -7 2 1 6 -9 3 3 7 -7

As mentioned in Weinstein’s preface,
with the mandate and collaboration of
many members of the International So
ciety for the Study of the Lumbar
Spine, a multidisciplinary book for the
multidimensional problem has been pro
duced.
The 87 contributors of medical and
nonmedical disciplines together pool
over 4000 references in this book. It
provides very comprehensive coverage
of all problems affecting the lumbar
spine with emphasis placed on newer
techniques and advances as well on
important research carried on in each
field.
The first section on epidemiology,
written by four collaborators, presents
an extensive overview of back pain from

a historical perspective to the future.
Anecdotally this is the most extensive
section, including the largest number of
references, 200 to 500 in each chapter,
on the following subjects: diagnosis and
neuromechanisms, biomechanics, bio
chemistry, radiology, clinical entities,
spondylolisthesis, spinal stenosis, reha
bilitation and industrial low back pain.
Interestingly, and perhaps as expected,
the most concrete chapter on anatomy
of low back pain has the fewest refer
ences, only 14.
I found this an interesting book to
review, perhaps because of its combina
tion of well-established knowledge and
facts, with associated updated review of
research and humble, frequent recogni
tion of the lack of knowledge concern
ing many of the most fundamental
questions.
Some chapters are well organized for
quick review. I particularly like the
structure of the chapters on facet syn
drome by Mooney, cauda equina syn
drome by McNeill and low back pain in
pregnancy by Andersson. Each has an
introduction that briefly summarizes
what is presented in the chapter, and in
what sequence, and ends with conclu
sions containing the most important
concepts and ideas. Throughout the
chapter, clear titles permit easy location
of the various parts. This is not always
the case; for example, there is a chapter
on osteoporosis by Kahanovitz that is
one continuous writing, without any
introduction, conclusion or division of
its content.
In any new edition of this book,
improvement of the structure of some
chapters will be needed, especially for
busy readers who don't have the time to
read every line to find the information
they want.
I would certainly recommend this
volume as a main reference book for
hospital libraries and for physicians
involved with the care of low back
problems.

G.R. Viviani, MD, FRCSC
Professor
Department of Surgery, Orthopedics
McMaster University Medical Centre
Hamilton, ON
L8N 3Z5
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ANNONCES CLASSEES
The Canadian Journal o f Surgery is pleased to accept classified advertisements. The deadline is 1 month before issue date. Classified rates: $55
for the first 40 words or less, additional words 704 each (additional $21 for frame). Special Display under 100 words, 55 X 55 mm, $125. $15
charge (first insertion only) for CJS reply box numbers. Display rates available on request. VISA, MASTERCARD AND AMERICAN EXPRESS
ACCEPTED.
Copy should be mailed to: Beverley Kirkpatrick, Manager, Classified Advertising, Canadian Journal o f Surgery, PO Box 8650, Ottawa, ON
K1G 0G8. Tel: (613) 731-9331. Fax: (613) 523-0937.
Send all box number replies to: Box . . . , Canadian Journal o f Surgery, PO Box 8650, Ottawa, ON K1G 0G8.
Le Journal canadien de chirurgie accepte volontiers les annonces classees. Celles-ci doivent etre refues au Journal au plus tard 1 mois avant la
date de parution. Tarifs des annonces classees 55 $ jusqu’a 40 mots et 70 4 par mot supplementaire (21 $ pour encadrement au trait). Encadre
special jusqu’a 100 mots, 55 X 55 mm, 125 $. L’emploi d’une bolte-reponse au Journal donne lieu a la perception d’un supplement de 15 $
(pour la premiere insertion seulement). Tarifs des encadres grand format disponibles sur demande. VISA, MASTERCARD ET AMERICAN
EXPRESS ACCEPTES.
La texte des annonces doit etre adresse a : Beverley Kirkpatrick, Gestionnaire des annonces classees, Journal canadien de chirurgie, CP 8650,
Ottawa, ON K1G 0G8. T e l: (613) 731-9331. Fax : (613) 523-0937.
Veuillez faire parvenir les reponses aux numeros de boites a l’adresse suivante : Boite . . . , Journal canadien de chirurgie, CP 8650, Ottawa,
ON K1G0G8.
THORACIC VASCULAR AND CARDIAC
SURGEON AVAILABLE: - FRCSC, U S. and
Canada trained, with 10 years of clinical
practice. Extensive experience in cancer of
the esophagus and portal hypertension. Direc
tor of vascular laboratory for past 7 years.
Extensive scientific publications. Wishes to
relocate. Thoracic and vascular or cardiovas
cular positions will be considered. CV avail
able upon request. Reply: Box 177, CJS.
-S91-65

GENERAL SURGEON: ON - A sixth general
surgeon is required for a 500-bed acute care
community hospital in a rapidly growing city
on the outskirts of metropolitan Toronto.
Please send curriculum vitae and enquiries to:
Dr. T. Varga, Chief of Surgery, c/o Pro
gram Administration Office, Peel Memori
al Hospital, 20 Lynch St., Brampton, ON
L 6W 2Z 8.
-S 91-84

TRANSPLANT FELLOWSHIP: ON - Univer
sity Hospital, London, Ontario has openings
for fellows in multi-organ transplantation
starting July 1, 1992. Our 2-year fellowship
program includes experience in clinical and
experimental transplantation. We expect to
perform 4 0 -5 0 heart, heart-lung and lung
transplants: 70 liver transplants; 80 kidney
transplants and 5 bowel transplants in 1992.

Candidates who have completed their training
in anesthesia, internal medicine, general sur
gery or pediatrics, and are eligible for educa
tional or general licensure in Ontario will be
given priority. Submit resumes to: Dr. David
Grant, Director, Transplant Unit, PO Box
5339, University Hospital, London. ON
N6A 5A5.
-S91-82
ACADEMIC APPOINTMENT, ORTHOPE
DIC SURGEON: SK - A full-time academic
appointment is available in the Division of
Orthopaedics, Department of Surgery, Univer
sity of Saskatchewan, Saskatoon. The suc
cessful candidate will develop an area of
subspecialty interest and pursue an active
commitment to teaching and research. Salary
and rank will be commensurate with qualifica
tions. Candidates must have certification in
orthopedic surgery from the Royal College of
Physicians and Surgeons of Canada, and be
eligible to practise in the province of Sas
katchewan. In accordance with Canadian im
migration requirements, this advertisement is
directed to Canadian citizens and permanent
residents. The University of Saskatchewan is
committed to the principles of employment
equity. Interested candidates should submit
curriculum vitae and three references, by Oct.
31, 1991, to: Dr. Roger G. Keith, Chair
man, Department of Surgery, University of
Saskatchewan, SK, Canada S7N 0X0.

GENERAL SURGICAL ONCOLOGY, CLINI
CAL FELLOWSHIP: ON - The Division of
General Surgery, University of Toronto is
offering a 1-year clinical fellowship beginning
July 1, 1992. Candidates must be board-eligi
ble or certified. Preference will be given to
individuals eligible for Canadian licensure. For
additional information, please contact: Lome
E. Rotstein, M D, Division of General Sur
gery, Eaton Wing, 7 -2 3 9 , Toronto General
Hospital, 2 00 Elizabeth St., Toronto, ON
M5G 2C4.
-S91-81

RESIDENCY IN
CARDIOVASCULAR AND
THORACIC SURGERY
Opening available in July 1992 for 3-year
training program in busy adult (600) and
pediatric (150) cardiac surgery program in
cluding arrhythmia surgery, heart and heart/
lung transplantation, and vascular and tho
racic surgery. Outstanding facilities and fully
accredited program at a major Canadian
university. ABS certification or eligibility re
quired.
Please reply to:
Patricia A. Penkoske, MD
Department of Surgery
Room 2D 2.09 W alter Mackenzie Center
University of Alberta
Edmonton, AB T6G 2R7
Tel: (403) 4 9 2 -8 0 5 7
. _66

-S 91-80

H E A D , D IV IS IO N O F V A S C U L A R S U R G ER Y
W E L L E S L E Y H O S P ITA L

H E A D , D IV IS IO N O F G E N E R A L S U R G E R Y
W E L L E S L E Y H O S P IT A L

A search committee has been formed to appoint a Head of the Division of Vascular
Surgery at the Wellesley Hospital. This position will include clinical activity,
research, undergraduate and postgraduate education, and long range planning.
The individual selected will be working closely with the Surgeon-in-Chief of the
Wellesley Hospital and the University Chairman of Vascular Surgery.

A search committee has been formed to appoint a Head of the Division of General
Surgery at the Wellesley Hospital. This position will include clinical activity, research,
undergraduate and postgraduate education, and long range planning. The individual
selected will be working closely with the Surgeon-in-Chief of the Wellesley Hospital
and the University Chairman of General Surgery.

The individual should have obtained a Royal College fellowship, and a licence to
practise in Ontario. The individual will be expected to have an excellent reputation
in clinical surgery, research and education, and have given evidence of leadership
ability.

The individual should have obtained a Royal College fellowship, and a licence to
practise in Ontario. The individual will be expected to have an excellent reputation in
clinical surgery, research and education, and have given evidence of leadership ability.

In accordance with Canadian im m igration requirements, this advertisement
is directed primarily to Canadian citizens or permanent residents. Applicants should
send a letter and accompanying curriculum vitae by Oct. 31, 1991 to:

In accordance with Canadian immigration requirements, this advertisement is directed
primarily to Canadian citizens or permanent residents. Applicants should send a letter
and accompanying curriculum vitae by Oct. 31, 1991 to:

Dr. D.E. Hastings
Surgeon-In-Chief
Wellesley Hospital
160 Wellesley St. E.
Suite 217, E.K. Jones Building
Toronto, ON
M4Y 1J3
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Dr. D.E. Hastings
Surgeon-in-Chief
Wellesley Hospital
160 Wellesley St. E.
Suite 217, E.K. Jones Building
Toronto, ON
M4Y 1J3

— S 91-74

university
o f Liberia

hospitals

VASCULAR SURGEONS
The Position:
The Division of General Surgery at the University of
Alberta Hospitals invites applications from vascular
surgeons for a position in the division. The position
carries a part-time clinical appointment in the Faculty of
Medicine and m em bership in a General Surgical
Practice Plan which includes full and part-time faculty
members.

The Candidate:
Candidates should be certified in vascular surgery by the
Royal College of Physicians and Surgeons of Canada.
A strong commitment to academic endeavors is required
of all prospective candidates.
The University of Alberta Hospitals is committed to
providing exemplary patient care and education in an
atmosphere of compassion and scholarly inquiry while
preserving the dignity and rights of patients and their
families.

Apply to: Dr. Bryce K.A. Weir, Professor and
Chairman, Department of Surgery, University of
Alberta Hospitals, 2D2.44, Walter C. Mackenzie
Health Sciences Centre, 8440 - 112th Street,
Edmonton, Alberta T6G 2B7

ORTHOPEDIC SURGEON

University of Alberta
Edmonton

Gastrointestinal
Surgeon
The University of Alberta, jointly with the
University of Alberta Hospitals, is
accepting applications for the position of
Gastrointestinal Surgeon, Division of
General Surgery, Department of Surgery,
University of Alberta Hospitals.
The successful applicant must have
fulfilled the fellowship qualifications of
the Royal College of Physicians and
Surgeons of Canada in Surgery. Special
training and expertise in gastrointestinal
surgery including endoscopy and E.R.C.P.
is required. An interest in teaching and
research is expected.
In accordance with Canadian immigration
requirements, this advertisement is
directed to Canadian citizens and
permanent residents.

Sunnybrook Health Science Centre, a
1200-bed acute and chronic fully affiliated
hospital of the University of Toronto, and
the major Level One Regional Trauma Unit
for Metropolitan Toronto and the University
of Toronto, has initiated a search for a fully
qualified orthopedic surgeon, specializing
in the area of spinal disorders.

The rank and salary o f this appointment
will be commensurate with qualifications
and experience (minimum $39,000 to
$60,000 per annum depending on rank).
Applicants should reply by October 31,
1991, enclosing a recent curriculum vitae
and the names of three referees to:

With our Spinal Injuries Unit, the candidate
should have expertise and experience in
the area of spinal trauma. The candidate
should also have the skills required to
participate in the academic undergraduate
and postgraduate teaching programs
attached to the Division of Orthopaedic
Surgery, University of Toronto, with some
percentage of time spent in research.

Dr. B.K.A. Weir
Walter Stirling Anderson
Professor and Chairman
Department of Surgery
2D2.24, Walter Mackenzie
Health Sciences Centre
8440 - 112 Street
Edmonton, Alberta
T6G 2B7

All interested candidates please reply to:
Dr. Joseph Schatzker
Head, Division of Orthopaedic Surgery
Sunnybrook Health Science Centre
Room A315, 2075 Bayview Ave.
Toronto, ON
M4N 3M5
—S91-79

The University o f Alberta is committed to
the principle o f equity in employment.
The University encourages applications
from aboriginal persons, disabled persons,
members o f visible minorities, and
women.
-ssn-77
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CHIEF OF SURGERY
HOSPITAL FOR SICK CHILDREN
In accordance with the by-laws of the Hospital for Sick Children, a search for the position of Chief, Department of
Surgery is being conducted. Applications or nominations are invited for this position which would start July 1, 1992 for
a term of up to 5 years, renewable upon recommendation of a board-appointed review committee. In accordance
with the hospital’s by-laws the current incumbent may stand for nomination in this search process.
The Hospital for Sick Children is the largest pediatric teaching and research hospital in North America. Located in
downtown Toronto, this 520-bed hospital is in close proximity to the University of Toronto and other major teaching
hospitals. Our affiliation with the University of Toronto has facilitated our development as a major pediatric service,
teaching and research centre with internationally-recognized expertise in a wide range of specialties.
The Hospital for Sick Children’s Department of Surgery is organized into six divisions, each of which is highly
productive in clinical, teaching and research activities. The hospital is completing major redevelopment that will replace
all patient rooms, emergency, and operating room facilities.
The successful candidate’s qualifications will include excellence in patient care, leadership in teaching, effective
administrative skills, and demonstrated achievements which would further research. The applicant must have
C anadian sp e c ia lity c e rtific a tio n or e qu iva len t and be e lig ib le to hold an O ntario m e d i c a l l i c e n c e . T h e
s u c c e s s fu l c a n d i d a t e will be e l i gi bl e for cross-appointment to the University of Toronto, Faculty of Medicine.
Both women and men are encouraged to apply. In accordance with Canadian immigration requirements, priority
will be given to Canadian citizens and permanent residents of Canada.
Applications or nominations should be submitted by Oct. 31, 1991, with curriculum vitae to:
Chair, Chief of Surgery Search Committee
c /o Terry McBurney, V-P Patient Programs
The Hospital for Sick Children
555 University Avenue
Toronto, Ontario
M5G 1X8

ADVERTISERS’ INDEX
INDEX DES ANNONCEURS

Berlex Canada Inc.
Androcur 414,446
Davis & Geek
Dexon II Outside Back Cover
Ethicon Ltd. Inside Front Cover
Hoffmann-La Roche Limited
Rocephin 430,484
Janssen Pharmaceutica
Ergamisol 435,506
Johnson & Johnson 468
Instat 413,460
Lederle
Leucovorin 486 A,B,C,D
Long Island Jewish Medical Center
440
Merck Sharp & Dohme Canada
Mefoxin 452, 453, 480, 481
Pepcid 494, 495, Inside Back Cover
Parke-Davis
Anusol-HC 441
Pfizer Canada Inc.
Diflucan 408, 500, 501
Ross Laboratories
Jevity 436
Roussel Canada Inc.
Claforan 470 A,B
Syntex Inc.
Toradol 419,420,421,422,423,510
Wyeth Ltd.
Enercal 410
518

JCC, VOL. 34, N° 5, OCTOBRE 1991

SCOTT & WHITE
The Division of Neurological Surgery of Scott &
White Clinic and Texas A&M University College
of Medicine is seeking a Neurosurgeon to fill a
clinical/faculty position as Director of the
Division of Neurological Surgery.
Scott & White is located in Temple, Texas,
approximately 60 miles north of Austin and 120
miles south of Dallas/Ft. Worth. Temple is a
family oriented city of 50,000 with numerous
nearby lakes and outdoor activities.
Scott & White provides an exceptionally
attractive salary and benefits package to include
4 weeks vacation and 3 weeks C.M.E.
For more information, please call Barry Harper
at 1-800-725-3627 or send curriculum vitae to:
Dennis J. Lynch, M.D.
Chairman, Department of Surgery
Scott & White Clinic, Texas A&M
University College of Medicine
2401 South 31st Street
Temple, TX 76508
S91-83
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The

Burning

Question

Does Your I nj ectabl e H 2 Ant agoni st Provi de Prompt, Persi st ent Gastri c pH Cont rol ?

The on set o f a n tisecreto ry e ffe ct o f PEPCID® 20 m g I.V. w as n o ted as e a r ly as o n e h ou r a fter
adm inistration in a study of hypersecretor individuals.1 Mean gastric pH values were maintained above
4.0 for up to 12 hours. The convenient ql2h dosage of PEPCID® I.V. may mean significant cost savings
and a reduction in time needed to prepare medication. So for prompt, persistent pH control: PEPCID®.
For many patients with pathological hypersecretory conditions or intractable
ulcers, or for short term use in patients unable to take oral medication.
__
/ q 12 fl

MSP

PAAB

MERCK

For Complete Prescribing Information Please See Page 494
(©Trademark Merck & Co., Inc./Merck Frosst Canada Inc., R.U.

Ca n a d a

PCD-90-CDN-3103-JA

Pepcid

O

(famotidine injection)

A nsw ers th e b u r n in g q u estio n

Taking suture technology
to new heights
NEW

D
(BRAIDED SYNTHETIC ABSORBABLE SUTURE)

DEXON@n
3.5 Metric

BI-COLOR" Braided Bolyfllycolic

_

Acid Suture wltti PolytaproSate"
. _
Coating System

T -1 2
37 mm

CX10
DAVttHIECX CYAKAMtD CANADA INC. MONTREAL, QUE.H9X3N7

DAVIS+GECK
Cyanam id Canada Inc.
Markham
®/™ Registered User: Cyanamid Canada Inc.

DEXONII, the newest generation
in the evolution of synthetic
absorbable sutures, offers markedly j
different performance in handling,
tying and knot snug-in.
The unique new Polycaprolate™
Coating System...
•Allows the sutures to pass through
tissue smoothly with little or no
chatter or drag
• Provides superior suppleness and
silk-like feel
• Ensures minimal out-of-package •
memory
In addition, DEXON II offers un
equalled out-of-package tensile
strength* and excellent knotsecurity.

There is a difference.,
See it.. .feel it.. .try it!
•DEXON compared to Vicryl.t Data on file.
tTrade m ark of Ethicon.
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